View Filing Data

Print Document View Excel Document

Document and Entity Information - USD ($) $ in Billions	12 Months Ended
Document and Entity Information - USD ($) $ in Billions	Dec. 31, 2017	Feb. 13, 2018	Jun. 30, 2017
Document And Entity Information [Abstract]
Entity Registrant Name	Chemours Co
Entity Central Index Key	0001627223
Current Fiscal Year End Date	--12-31
Entity Filer Category	Large Accelerated Filer
Document Type	10-K
Trading Symbol	CC
Document Period End Date	Dec. 31, 2017
Document Fiscal Year Focus	2017
Document Fiscal Period Focus	FY
Amendment Flag	false
Entity Common Stock, Shares Outstanding		182,524,068
Entity Well-known Seasoned Issuer	Yes
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Public Float			$ 7.0

Consolidated Statements of Operations - USD ($)	12 Months Ended
Consolidated Statements of Operations - USD ($)	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Income Statement [Abstract]
Net sales	$ 6,183,000,000	$ 5,400,000,000	$ 5,717,000,000
Cost of goods sold	4,429,000,000	4,290,000,000	4,762,000,000
Gross profit	1,754,000,000	1,110,000,000	955,000,000
Selling, general, and administrative expense	602,000,000	934,000,000	632,000,000
Research and development expense	80,000,000	80,000,000	97,000,000
Restructuring and asset-related charges, net	57,000,000	170,000,000	333,000,000
Goodwill impairment	0	0	25,000,000
Total expenses	739,000,000	1,184,000,000	1,087,000,000
Equity in earnings of affiliates	33,000,000	29,000,000	22,000,000
Interest expense, net	(215,000,000)	(213,000,000)	(132,000,000)
Other income, net	79,000,000	247,000,000	54,000,000
Income (loss) before income taxes	912,000,000	(11,000,000)	(188,000,000)
Provision for (benefit from) income taxes	165,000,000	(18,000,000)	(98,000,000)
Net income (loss)	747,000,000	7,000,000	(90,000,000)
Less: Net income attributable to non-controlling interests	1,000,000	0	0
Net income (loss) attributable to Chemours	$ 746,000,000	$ 7,000,000	$ (90,000,000)
Per share data
Basic earnings (loss) per share of common stock	$ 4.04	$ 0.04	$ (0.50)
Diluted earnings (loss) per share of common stock	3.91	0.04	(0.50)
Dividends per share of common stock	$ 0.29	$ 0.12	$ 0.58

Consolidated Statements of Comprehensive Income (Loss) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Statement Of Income And Comprehensive Income [Abstract]
Net income (loss), pre-tax	$ 912	$ (11)	$ (188)
Net Income (loss), tax	(165)	18	98
Net income (loss)	747	7	(90)
Other comprehensive income (loss):
Unrealized (loss) gain on net investment hedge, pre tax	(86)	14	8
Unrealized (loss) gain on net investment hedge, tax	24	0	0
Unrealized (loss) gain on net investment hedge, after-tax	(62)	14	8
Cumulative translation adjustments, pre-tax	200	(73)	(304)
Cumulative translation adjustments, tax	0	0	0
Cumulative translation adjustments, after-tax	200	(73)	(304)
Defined benefit plans:
Net gain (loss), pre tax	24	(17)	(11)
Net gain (loss), tax	(5)	5	1
Net gain (loss), after-tax	19	(12)	(10)
Prior service credit, pre-tax	0	0	24
Prior service credit, tax	0	0	(4)
Prior service credit, after-tax	0	0	20
Effect of foreign exchange rates, pre-tax	(38)	15	33
Effect of foreign exchange rates, tax	0	(3)	(8)
Effect of foreign exchange rates, after-tax	(38)	12	25
Amortization of prior service (gain) loss	(2)	(1)	4
Amortization of prior service (gain) loss, tax	0	0	0
Amortization of prior service (gain) loss, after-tax	(2)	(1)	4
Amortization of actuarial loss, pre-tax	24	23	16
Amortization of actuarial loss, tax	(6)	(6)	(3)
Amortization of actuarial loss, after-tax	18	17	13
Settlement loss, pre-tax	0	5	0
Settlement loss, tax	0	(1)	0
Settlement loss, after-tax	0	4	0
Curtailment gain, pre-tax	0	(2)	0
Curtailment gain, tax	0	0	0
Curtailment gain, after-tax	0	(2)	0
Defined benefit plans, net, pre-tax	8	23	66
Defined benefit plans, net, tax	(11)	(5)	(14)
Defined benefit plans, net, after-tax	(3)	18	52
Other comprehensive income (loss),pre tax	122	(36)	(230)
Other comprehensive income (loss), tax	13	(5)	(14)
Other comprehensive income (loss), after tax	135	(41)	(244)
Comprehensive income (loss), pre-tax	1,034	(47)	(418)
Comprehensive income (loss), tax	(152)	13	84
Comprehensive income (loss) , after-tax	882	(34)	(334)
Less: Comprehensive income attributable to non-controlling interests, pre-tax	1	0	0
Less: Comprehensive income attributable to non-controlling interests, tax	0	0	0
Less: Comprehensive income attributable to non-controlling interests, after-tax	1	0	0
Comprehensive income (loss) attributable to Chemours,pre tax	1,033	(47)	(418)
Comprehensive income (loss) attributable to Chemours, tax	(152)	13	84
Comprehensive income (loss) attributable to Chemours, after-tax	$ 881	$ (34)	$ (334)

Consolidated Balance Sheets - USD ($) $ in Millions	Dec. 31, 2017	Dec. 31, 2016
Current assets:
Cash and cash equivalents	$ 1,556	$ 902
Accounts and notes receivable, net	919	807
Inventories	935	767
Prepaid expenses and other	83	77
Total current assets	3,493	2,553
Property, plant, and equipment	8,511	7,997
Less: Accumulated depreciation	(5,503)	(5,213)
Property, plant, and equipment, net	3,008	2,784
Goodwill and other intangible assets, net	166	170
Investments in affiliates	173	136
Other assets	453	417
Total assets	7,293	6,060
Current liabilities:
Accounts payable	1,075	884
Current maturities of long-term debt	15	15
Other accrued liabilities	558	872
Total current liabilities	1,648	1,771
Long-term debt, net	4,097	3,529
Deferred income taxes	208	132
Other liabilities	475	524
Total liabilities	6,428	5,956
Commitments and contingent liabilities
Equity
Common stock (par value $0.01 per share; 810,000,000 shares authorized; 185,343,034 shares issued and 182,956,628 shares outstanding at December 31, 2017; 182,600,533 shares issued and outstanding at December 31, 2016)	2	2
Treasury stock at cost (2,386,406 shares at December 31, 2017; nil at December 31, 2016)	116
Additional paid-in capital	837	789
Retained earnings (accumulated deficit)	579	(114)
Accumulated other comprehensive loss	(442)	(577)
Total Chemours stockholders’ equity	860	100
Non-controlling interests	5	4
Total equity	865	104
Total liabilities and equity	$ 7,293	$ 6,060

Consolidated Balance Sheets (Parenthetical) - $ / shares	Dec. 31, 2017	Dec. 31, 2016
Statement Of Financial Position [Abstract]
Common stock, shares authorized (in shares)	810,000,000	810,000,000
Common stock , par value (USD per share)	$ 0.01	$ 0.01
Common stock, shares Issued (in shares)	185,343,034	182,600,533
Common stock, shares outstanding (in shares)	182,956,628	182,600,533
Treasury stock (in shares)	2,386,406	0

Consolidated Statements of Stockholders' Equity - USD ($) $ in Millions	Total	Common Stock [Member]	Treasury Stock [Member]	DuPont Company Net Investment [Member]	Additional Paid-In Capital [Member]	(Accumulated Deficit) Retained Earnings [Member]	Accumulated Other Comprehensive (Loss) Income [Member]	Noncontrolling Interests [Member]
Total stockholders' equity, beginning balance at Dec. 31, 2014	$ 3,673			$ 3,650			$ 19	$ 4
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Issuance of common stock at Separation		$ 2			$ (2)
Issuance of common stock at separation (in shares)		180,966,833
Common stock issued - compensation plans (in shares)		102,918
Cash provided at Separation by DuPont	247			247
Non-cash exchange of long-term debt	(507)			(507)
Net transfers to DuPont	(2,814)			(3,583)	769
Dividends paid or accrued	(105)			(100)	(5)
Net income (loss)	(90)			25		$ (115)
Establishment of pension plans, net and related other comprehensive loss	(43)			$ 268			(311)
Stock-based compensation expense	13				13
Other comprehensive loss	(244)						(244)
Total stockholders' equity, ending balance at Dec. 31, 2015	130	$ 2			775	(115)	(536)	4
Shares, ending balance at Dec. 31, 2015		181,069,751
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Common stock issued - compensation plans (in shares)		583,859
Exercise of stock options, net	11				11
Exercise of stock options, net (in shares)		946,923
Dividends paid or accrued	(22)				(16)	(6)
Net income (loss)	7					7
Stock-based compensation expense	19				19
Other comprehensive loss	(41)						(41)
Total stockholders' equity, ending balance at Dec. 31, 2016	104	$ 2			789	(114)	(577)	4
Shares, ending balance at Dec. 31, 2016		182,600,533
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Common stock issued - compensation plans (in shares)		569,263
Exercise of stock options, net	31				31
Exercise of stock options, net (in shares)		2,173,238
Purchases of treasury stock at cost	(116)		$ (116)
Purchases of treasury stock at cost (in shares)		(2,386,406)	2,386,406
Cancellation of unissued stock awards withheld to cover taxes	(12)				(12)
Dividends paid or accrued	(53)					(53)
Net income (loss)	747					746		1
Stock-based compensation expense	29				29
Other comprehensive loss	135						135
Total stockholders' equity, ending balance at Dec. 31, 2017	$ 865	$ 2	$ (116)		$ 837	$ 579	$ (442)	$ 5
Shares, ending balance at Dec. 31, 2017		182,956,628	2,386,406

Consolidated Statements of Cash Flows - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Cash flows from operating activities
Net income (loss)	$ 747	$ 7	$ (90)
Adjustments to reconcile net income (loss) to cash provided by operating activities:
Depreciation and amortization	273	284	267
Asset-related charges	3	124	206
(Gain) loss on sale of assets and businesses	(22)	(254)	9
Equity in earnings of affiliates, net	(33)	(12)
Amortization of deferred financing costs and issuance discount	13	20	8
Deferred tax provision (benefit)	83	(111)	(198)
Other operating charges and credits, net	41	52	7
Decrease (increase) in operating assets:
Accounts and notes receivable, net	(88)	5	(64)
Inventories and other operating assets	(208)	147	19
(Decrease) increase in operating liabilities:
Accounts payable and other operating liabilities	(170)	332	18
Cash provided by operating activities	639	594	182
Cash flows from investing activities
Purchases of property, plant, and equipment	(411)	(338)	(519)
Proceeds from sales of assets and businesses, net	39	708	12
Investments in affiliates		(1)	(32)
Foreign exchange contract settlements, net	2	(12)	42
Cash (used for) provided by investing activities	(370)	357	(497)
Cash flows from financing activities
Proceeds from issuance of debt, net	495		3,491
Debt repayments	(27)	(381)	(10)
Payment of deferred financing fees	(6)	(4)	(79)
Purchases of treasury stock at cost	(106)
Cash provided at Separation by DuPont			247
Net transfers to DuPont			(2,857)
Proceeds from exercised stock options, net	31	11
Tax payments related to withholdings on vested restricted stock units	(12)
Payment of dividends	(22)	(22)	(105)
Cash provided by (used for) financing activities	353	(396)	687
Effect of exchange rate changes on cash and cash equivalents	32	(19)	(6)
Increase in cash and cash equivalents	654	536	366
Cash and cash equivalents at January 1,	902	366	0
Cash and cash equivalents at December 31,	1,556	902	366
Cash paid during the year for:
Interest, net of amounts capitalized	208	208	103
Income taxes, net of refunds	79	50	53
Non-cash investing and financing activities:
Changes in property, plant, and equipment included in accounts payable	(14)	$ (12)	$ 45
Obligations incurred under build-to-suit lease arrangement	8
Purchases of treasury stock not settled by year-end	10
Dividends accrued but not yet paid	$ 31

Background and Description of the Business	12 Months Ended
Background and Description of the Business	Dec. 31, 2017
Organization Consolidation And Presentation Of Financial Statements [Abstract]
Background and Description of the Business	Note 1. Background and Description of the Business The Chemours Company (Chemours, or the Company) is a leading, global provider of performance chemicals that are key inputs in end-products and processes in a variety of industries. The Company delivers customized solutions with a wide range of industrial and specialty chemicals products for markets, including plastics and coatings, refrigeration and air conditioning, general industrial, electronics, mining, and oil refining. The Company’s principal products include titanium dioxide (TiO₂), refrigerants, industrial fluoropolymer resins, sodium cyanide, and performance chemicals and intermediates. Chemours’ business consists of three reportable segments: Titanium Technologies, Fluoroproducts, and Chemical Solutions. The Titanium Technologies segment is a leading, global producer of TiO₂ pigment, a premium white pigment used to deliver whiteness, brightness, opacity, and protections in a variety of applications. The Fluoroproducts segment is a leading, global provider of fluoroproducts, including refrigerants and industrial fluoropolymer resins. The Chemical Solutions segment is a leading, North American provider of industrial chemicals used in gold production, industrials, and consumer applications. Chemours has manufacturing facilities, sales centers, administrative offices, and warehouses located throughout the world. Chemours’ operations are primarily located in the United States (U.S.), Canada, Mexico, Brazil, the Netherlands, Belgium, China, Taiwan, Japan, Switzerland, Singapore, Hong Kong, India, and France. At December 31, 2017, the Company operated 26 production facilities globally, of which, five were dedicated to Titanium Technologies, 18 were dedicated to Fluoroproducts, two were dedicated to Chemical Solutions, and one supported multiple segments. Chemours began operating as an independent company on July 1, 2015 (Separation Date) after separating from E.I. DuPont de Nemours and Company (DuPont) (Separation). Effective prior to the opening of trading on the New York Stock Exchange (NYSE) on the Separation Date, DuPont completed the Separation of the businesses comprising its Performance Chemicals reporting segment, and certain other assets and liabilities, into Chemours, a separate and distinct public company. The Separation was completed by way of a distribution of all of the then-outstanding shares of Chemours’ common stock through a dividend-in-kind of Chemours’ common stock (par value $0.01) to holders of DuPont’s common stock (par value $0.30) as of the close of business on June 23, 2015 (Record Date). On the Separation Date, each holder of DuPont’s common stock received one share of Chemours’ common stock for every five shares of DuPont’s common stock held on the Record Date. The Separation was completed pursuant to a separation agreement and other agreements with DuPont, including an employee matters agreement, a tax matters agreement, a transition services agreement, and an intellectual property cross-license agreement. These agreements govern the relationship between Chemours and DuPont following the Separation and provided for the allocation of various assets, liabilities, rights, and obligations at the Separation Date. These agreements also include arrangements for transition services to be provided to Chemours by DuPont, which were substantially completed during 2016. Unless the context otherwise requires, references herein to “The Chemours Company,” “Chemours,” “the Company,” “our company,” “we,” “us,” and “our,” refer to The Chemours Company and its consolidated subsidiaries after giving effect to the Separation. References herein to “DuPont” refer to E.I. du Pont de Nemours and Company, a Delaware corporation, and its consolidated subsidiaries (other than Chemours and its consolidated subsidiaries), unless the context otherwise requires.

Basis of Presentation	12 Months Ended
Basis of Presentation	Dec. 31, 2017
Organization Consolidation And Presentation Of Financial Statements [Abstract]
Basis of Presentation	Note 2. Basis of Presentation The accompanying consolidated financial statements have been prepared in accordance with generally accepted accounting principles (GAAP) in the United States (U.S.). The notes that follow are an integral part of the consolidated financial statements. Chemours did not operate as a separate, stand-alone entity for all periods included within these consolidated financial statements. Prior to the Separation on July 1, 2015, Chemours’ operations were included in DuPont’s financial results in different legal forms, including, but not limited to, wholly-owned subsidiaries for which Chemours was the sole business, components of legal entities in which Chemours operated in conjunction with other DuPont businesses, and a majority-owned joint venture. For periods prior to the Separation Date, the accompanying consolidated financial statements have been prepared from DuPont’s historical accounting records and are presented on a stand-alone basis as if Chemours’ operations had been conducted independently from DuPont. Prior to January 1, 2015, aside from a Japanese entity that is a dual-resident for U.S. federal income tax purposes, there was no direct ownership relationship among all of the other various legal entities comprising Chemours. Prior to the Separation Date, DuPont and its subsidiaries’ net investments in these operations are shown in lieu of stockholders’ equity in the consolidated financial statements. The consolidated financial statements include the historical operations, assets, and liabilities of the legal entities that are considered to comprise Chemours’ business, including certain environmental remediation and litigation obligations of DuPont and its subsidiaries that Chemours may be required to indemnify pursuant to the Separation-related agreements executed prior to the Separation. All of the allocations and estimates in the consolidated financial statements prior to the Separation Date are based on assumptions that management believes are reasonable. Therefore, Chemours’ financial position, results of operations, and cash flows prior to the Separation Date may not be indicative of Chemours’ financial position, results of operations, and cash flows in the future, or if Chemours had been a separate, stand-alone entity during the periods presented. The net transfers to DuPont in the consolidated statements of stockholders’ equity include a non-cash contribution from DuPont of $109 for the year ended December 31, 2015. This non-cash contribution occurred during the physical separation of certain activities at shared production facilities in the U.S. prior to the Separation, and for certain assets identified at the Separation Date. It was determined that assets previously managed by other DuPont businesses would be transferred to and managed by Chemours. Certain prior period amounts have been reclassified to conform to the current period presentation, the effect of which was not material to the Company’s consolidated financial statements taken as a whole. Comprehensive income as of December 31, 2016 includes an out of period adjustment of $31 related to 2015 cumulative translation adjustments with a corresponding adjustment to other current assets. This adjustment is not material to the Company’s consolidated financial statements taken as a whole.

Summary of Significant Accounting Policies	12 Months Ended
Summary of Significant Accounting Policies	Dec. 31, 2017
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	Note 3. Summary of Significant Accounting Policies Preparation of Financial Statements The consolidated financial statements have been prepared in conformity with GAAP, which requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the consolidated financial statements, and the reported amounts of revenues and expenses, including the allocations of costs as discussed above, during the reporting period. Management’s estimates are based on historical experiences, facts, and circumstances available at the time and various other assumptions that management believes are reasonable. Actual results could differ from those estimates. Principles of Consolidation and Combination The consolidated financial statements include the accounts of Chemours and its subsidiaries, as well as entities in which a controlling interest is maintained. For those consolidated subsidiaries in which the Company’s ownership is less than 100%, the outside shareholders’ interests are shown as non-controlling interests. Investments in companies in which Chemours, directly or indirectly, owns 20% to 50% of the voting stock, or has the ability to exercise significant influence over the operating and financial policies of the investee, are accounted for using the equity method of accounting. As a result, Chemours’ share of the earnings or losses of such equity affiliates is included in the consolidated statements of operations, and Chemours’ share of such equity affiliates’ equity is included in the consolidated balance sheets. The financial statements for the periods prior to the Separation Date include the combined assets, liabilities, revenues, and expenses of Chemours. All intercompany accounts and transactions were eliminated in the preparation of the accompanying consolidated financial statements. Revenue Recognition Revenue is recognized when the earnings process is complete. Revenue for product sales is recognized when products are shipped to the customer in accordance with the terms of the agreement, title and risk of loss have been transferred, collectability is reasonably assured, and pricing is fixed or determinable. Revenue associated with advance payments are recorded as deferred revenue and are recognized as shipments are made and title, ownership, and risk of loss pass to the customer. Accruals are made for sales returns and other allowances based on historical experience. Cash sales incentives are accounted for as a reduction in sales, and non-cash sales incentives are recorded as a charge to cost of goods sold at the time that the revenue or selling expense, depending on the nature of the incentive, is recorded. Amounts billed to customers for shipping and handling fees are included in net sales, and costs incurred by Chemours for the delivery of goods are classified as cost of goods sold in the consolidated statements of operations. Taxes on revenue-producing transactions are excluded from net sales. Licensing and royalty income is recognized in accordance with agreed upon terms, when performance obligations are satisfied, the amount is fixed or determinable, and collectability is reasonably assured. Research and Development Expense Research and development (R&D) costs are expensed as incurred. R&D expenses include costs (primarily consisting of employee costs, materials, contract services, research agreements, and other external spend) relating to the discovery and development of new products, enhancement of existing products, and regulatory approval of new and existing products. Provision for (Benefit from) Income Taxes The provision for (benefit from) income taxes is determined using the asset and liability approach of accounting for income taxes. Under this approach, deferred taxes represent the future tax consequences expected to occur when the reported amounts of assets and liabilities are recovered or paid. The provision for (benefit from) income taxes represents income taxes paid or payable for the current year, plus the change in deferred taxes during the year. Deferred taxes result from differences between the financial and tax bases of Chemours’ assets and liabilities and are adjusted for changes in tax rates and tax laws when changes are enacted. Valuation allowances are recorded to reduce deferred tax assets when it is more-likely-than-not that a tax benefit will not be realized. Chemours recognizes income tax positions that meet the more-likely-than-not threshold and accrues any interest related to unrecognized income tax positions as a component of other income, net in the consolidated statements of operations. Income tax-related penalties are included in the provision for (benefit from) income taxes. Chemours does not provide for income taxes on the undistributed earnings of all of its foreign subsidiaries that are intended to be indefinitely reinvested. Prior to the Separation, the amounts recorded for income taxes attributed certain current and deferred income taxes of DuPont to Chemours’ stand-alone financial statements in a manner that is systematic, rational, and consistent with the asset and liability method prescribed by Accounting Standards Codification Topic 740, Income Taxes (Topic 740). Accordingly, Chemours’ income tax provision was prepared following the separate return method. The separate return method applies Topic 740 to the stand-alone financial statements of each member of the consolidated group as if the group member were a separate taxpayer and a stand-alone enterprise. Earnings Per Share Chemours presents both basic earnings per share and diluted earnings per share. Basic earnings per share excludes dilution and is computed by dividing the total net income (loss) attributable to Chemours by the weighted-average number of shares outstanding for the period. Diluted earnings per share reflects the dilution that could occur if the Company’s outstanding stock-based compensation awards, including any unvested restricted shares, were vested and exercised, thereby resulting in the issuance of common stock as determined under the treasury stock method. In periods where the Company incurs a net loss, stock-based compensation awards are excluded from the calculation of earnings per share as their inclusion would have an anti-dilutive effect. Cash and Cash Equivalents Cash and cash equivalents generally include cash, time deposits, or highly liquid investments with original maturities of three months or less. Receivables and Allowance for Doubtful Accounts Receivables are recognized net of an allowance for doubtful accounts. The allowance for doubtful accounts reflects the best estimate of losses inherent in Chemours’ receivables portfolio, which is determined on the basis of historical experience, specific allowances for known troubled accounts, and other available evidence. Receivables are written-off when management determines that they are uncollectible. Inventories Chemours’ U.S. inventories are valued at the lower of cost or market, as inventories held at substantially all U.S. locations are valued using the last-in, first-out (LIFO) method. Chemours’ non-U.S. inventories are valued at the lower of cost or net realizable value, as inventories held outside the U.S. are valued using the average cost method. The elements of cost in inventories include raw materials, direct labor, and manufacturing overhead. Stores and supplies are valued at the lower of cost or net realizable value. Cost is generally determined by the average cost method. Property, Plant, and Equipment Property, plant, and equipment is carried at cost and is depreciated using the straight-line method. Property, plant, and equipment placed in service prior to 1995 is depreciated under the sum-of-the-years’ digits method, or other substantially-similar methods. Substantially all equipment and buildings are depreciated over useful lives ranging from 15 to 25 years. Capitalizable costs associated with computer software for internal use are amortized on a straight-line basis over five to seven years. When assets are surrendered, retired, sold, or otherwise disposed of, their gross carrying values and related accumulated depreciation are removed from the consolidated balance sheets and are included in the determination of any gain or loss on such disposals. Repair and maintenance costs that materially add to the value of the asset or prolong its useful life are capitalized and depreciated based on their extension to the asset’s useful life. Capitalized repair and maintenance costs are recorded on the consolidated balance sheets as a component of other assets. Impairment of Long-lived Assets Chemours evaluates the carrying value of its long-lived assets to be held and used when events or changes in circumstances indicate the carrying value may not be recoverable. For the purposes of recognition or measurement of an impairment charge, the assessment is performed on the asset or asset group at the lowest level for which identifiable cash flows are largely independent of the cash flows of other groups of assets and liabilities. To determine the level at which the assessment is performed, Chemours considers factors such as revenue dependency, shared costs, and the extent of vertical integration. The carrying value of a long-lived asset is considered impaired when the total projected undiscounted cash flows from the use and eventual disposition of the asset or asset group are separately identifiable and are less than its carrying value. In that event, a loss is recognized based on the amount by which the carrying value exceeds the fair value of the long-lived asset. The fair value methodology used is an estimate of fair market value, which is made based on prices of similar assets or other valuation methodologies, including present value techniques. Long-lived assets to be disposed of by means other than sale are classified as held for use until their disposal. Long-lived assets to be disposed of by sale are classified as held for sale and are reported at the lower of carrying amount or fair market value, less the estimated cost to sell. Depreciation is discontinued for any long-lived assets classified as held for sale. Goodwill and Other Intangible Assets The excess of the purchase price over the estimated fair value of the net assets acquired in a business combination, including any identified intangible assets, is recorded as goodwill. Chemours tests its goodwill for impairment at least annually on October 1; however, these tests are performed more frequently when events or changes in circumstances indicate that the asset may be impaired. Goodwill is evaluated for impairment at the reporting unit level, which is defined as an operating segment, or one level below an operating segment. A reporting unit is the level at which discrete financial information is available and reviewed by business management on a regular basis. An impairment exists when the carrying value of a reporting unit exceeds its fair value. Chemours has the option to first qualitatively assess whether it is more-likely-than-not that an impairment exists for a reporting unit. Such qualitative factors include, among other things, prevailing macroeconomic conditions, industry and market conditions, changes in costs associated with raw materials, labor, or other inputs, the Company’s overall financial performance, and certain other entity-specific events that impact Chemours’ reporting units. When performing a quantitative assessment, the Company weights the results of an income-based valuation technique, the discounted cash flows method, and a market-based valuation technique, the guideline public companies method, to determine its reporting units’ fair value. Definite-lived intangible assets, such as purchased and licensed technology, patents, trademarks, and customer lists, are amortized over their estimated useful lives, generally for periods ranging from five to 20 years. The reasonableness of the useful lives of these assets is continually evaluated. Defined Benefit Plans Due to local regulations outside the U.S., Chemours has defined benefit plans covering certain of its employees. The benefits of these plans, which primarily relate to pension, are accrued over the employees’ service periods. The Company uses actuarial methods and assumptions in the valuation of its defined benefit obligations and the determination of any net periodic pension income or expense. Any differences between actual and expected results, or changes in the value of defined benefit obligations and plan assets, if any, are not recognized in earnings as they occur. Rather, they are systematically recognized over subsequent periods. Derivatives Chemours enters into forward currency exchange contracts to minimize its volatility in earnings related to foreign exchange gains and losses, which result from remeasuring any net monetary assets denominated in non-functional currencies held by Chemours. Chemours does not hold or issue financial instruments for speculative or trading purposes. Derivative assets and liabilities are reported on a gross basis on the consolidated balance sheets. All gains and losses resulting from the revaluation of the Company’s derivative assets and liabilities are recognized in other income, net in the consolidated statements of operations during the period in which they occur. Asset Retirement Obligations Chemours records its asset retirement obligations at their fair value at the time the liability is incurred. Fair value is measured using the expected future cash outflows discounted at Chemours’ credit-adjusted, risk-free interest rate, which is considered to be a Level 3 input within the fair value hierarchy. Accretion expense is recognized as an operating expense classified within cost of goods sold in the consolidated statements of operations using the credit-adjusted, risk-free interest rate in effect when the liability was recognized. The associated asset retirement obligations are capitalized as part of the carrying amount of the long-lived asset and depreciated over the estimated remaining useful life of the asset, generally for periods ranging from two to 30 years. Insurance Chemours insures for certain risks where permitted by law or regulation, including workers’ compensation, vehicle liability, and employee-related benefits. Liabilities associated with these risks are estimated in part by considering any historical claims experience, demographic factors, and other actuarial assumptions. For certain other risks, the Company uses a combination of third-party insurance and self-insurance, reflecting its comprehensive reviews of relevant risks. A receivable for an insurance recovery is generally recognized when the loss has occurred and collection is considered probable. Prior to the Separation, Chemours was a participant in DuPont’s self-insurance program where permitted by law or regulation, including workers’ compensation, vehicle liability, and employee-related benefits. Liabilities associated with these risks were estimated in part by considering any historical claims experience, demographic factors, and other actuarial assumptions. For other risks, a combination of third-party insurance and self-insurance was used, reflecting DuPont’s comprehensive reviews of relevant risks. The annual cost was allocated to all of the participating businesses using methodologies deemed reasonable by management. All obligations pursuant to these plans had historically been obligations of DuPont. As such, these obligations were not included in the consolidated balance sheets, with the exception of self-insurance liabilities related to workers’ compensation, vehicle liability, and employee-related benefits. Litigation Chemours accrues for legal matters when it is probable that a liability has been incurred and the amount of the liability can be reasonably estimated. Litigation-related liabilities and expenditures included in the consolidated financial statements represent legal matters that are liabilities of DuPont and its subsidiaries, which Chemours may be required to indemnify pursuant to the Separation-related agreements executed prior to the Separation. Legal costs, such as outside counsel fees and expenses, are charged to expense in the period that services are rendered. Environmental Liabilities and Expenditures Chemours accrues for remediation activities when it is probable that a liability has been incurred and a reasonable estimate of the liability can be made. Where the available information is sufficient to estimate the amount of liability, that estimate has been used. Where the available information is only sufficient to establish a range of probable liability, and no point within the range is more likely than any other, the lower end of the range has been used. Estimated liabilities are determined based on existing remediation laws and technologies. Inherent uncertainties exist in such evaluations, primarily due to unknown environmental conditions, changing governmental regulations and legal standards regarding liability, and emerging remediation technologies. These accruals are adjusted periodically as remediation efforts progress and as additional technological, regulatory, and legal information become available. Environmental liabilities and expenditures include claims for matters that are liabilities of DuPont and its subsidiaries, which Chemours may be required to indemnify pursuant to the Separation-related agreements executed prior to the Separation. Accrued liabilities are undiscounted and do not include claims against third-parties, and are included in other accrued liabilities and other liabilities on the consolidated balance sheets. Costs related to environmental remediation are charged to expense in the period incurred, within cost of goods sold in the consolidated statements of operations. Other environmental costs are also charged to expense in the period incurred, unless they increase the value of the property or reduce or prevent contamination from future operations, in which case they are capitalized and amortized. Treasury Stock Chemours accounts for repurchases of the Company’s common stock as treasury stock using the cost method, whereby the entire cost of the acquired common stock is recorded as treasury stock. Stock-based Compensation Chemours’ stock-based compensation consists of stock options, restricted stock units (RSUs), and performance share units (PSUs) awarded to employees and non-employee directors. Stock options and PSUs are measured at their fair value on the grant date or date of modification, as applicable. RSUs are measured at the stock price on the grant date or date of modification, as applicable. The Company recognizes compensation expense on a straight-line basis over the requisite service and/or performance period, as applicable. Forfeitures of awards are accounted as a reduction in stock-based compensation expense in the period such awards are forfeited. Foreign Currency Translation Chemours identifies its separate and distinct foreign entities and groups them into two categories: (i) extensions of the parent (U.S. dollar functional currency); and, (ii) self-contained (local functional currency). If a foreign entity does not align with either category, factors are evaluated, and a judgment is made to determine the functional currency. Chemours changes the functional currency of its separate and distinct foreign entities only when significant changes in economic facts and circumstances clearly indicate that the functional currency has changed. During the periods covered by the consolidated financial statements, part of Chemours’ business operated within foreign entities. For foreign entities where the U.S. dollar is the functional currency, all foreign currency-denominated asset and liability amounts are remeasured into U.S. dollars at end-of-period exchange rates, with the exception of inventories, prepaid expenses, property, plant, and equipment, goodwill, and other intangible assets. These aforementioned assets are remeasured at historical rates. Foreign currency-denominated revenue and expense amounts are remeasured at average exchange rates in effect during the period, with the exception of expenses related to any balance sheet amounts remeasured at historical exchange rates. Exchange gains and losses arising from remeasurement of foreign currency-denominated monetary assets and liabilities are included in other income, net in the period in which they occur. For foreign entities where the local currency is the functional currency, assets and liabilities denominated in local currencies are translated into U.S. dollars at end-of-period exchange rates, and the resulting translation adjustments are reported as a component of accumulated other comprehensive loss within equity. Assets and liabilities denominated in currencies other than the functional currency are remeasured into the functional currency prior to translation into U.S. dollars, and the resulting exchange gains or losses are included in income in the period in which they occur. Revenues and expenses are translated into U.S. dollars at average exchange rates in effect during the period. During 2015, when Chemours’ operations were legally and operationally separated within DuPont in anticipation of the Separation, certain of Chemours’ foreign entities set their respective local currencies as the functional currency. Fair Value Measurement Fair value is defined as the exit price, the price that would be received to sell an asset or transfer a liability in an orderly transaction between market participants at the measurement date. Under the accounting for fair value measurements and disclosures, a fair value hierarchy was established to prioritize the valuation inputs used to measure fair value. The hierarchy gives highest priority to unadjusted, quoted prices in active markets for identical assets and liabilities (Level 1 measurements) and lowest priority to unobservable inputs (Level 3 measurements). A financial instrument’s level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement. Chemours applies the following valuation hierarchy in measuring the fair values of its assets and liabilities: Level 1 – Quoted prices in active markets for identical assets and liabilities; Level 2 – Significant other observable inputs (e.g., quoted prices for similar items in active markets, quoted prices for identical or similar items in markets that are not active, inputs other than quoted prices that are observable, such as interest rate and yield curves, and market-corroborated inputs); and, Level 3 – Unobservable inputs for the asset or liability, which are valued based on management’s estimates of assumptions that market participants would use in pricing the asset or liability. Recent Accounting Pronouncements Accounting Guidance Issued and Not Yet Adopted In May 2014, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) No. 2014-09, Revenue from Contracts with Customers (Topic 606) (ASU No. 2014-09). The objective of this standard is to remove inconsistent practices regarding revenue recognition between GAAP and International Financial Reporting Standards. The standard intends to improve the comparability of revenue recognition practices across entities, industries, jurisdictions, and capital markets. Subsequent to the issuance of ASU No. 2014-09, the FASB issued multiple clarifying updates in connection with the standard. The provisions of ASU No. 2014-09 and its related updates will be adopted by the Company in the first quarter of 2018 under the modified retrospective transition method. The Company believes that the adoption of the standard will not have a material impact on its consolidated financial statements. Substantially all of the Company’s revenue consists of sales of products that represent a single performance obligation where control transfers at the point in time title and risk of loss pass to the customer. The Company continues to evaluate the impact of the standard update on its consolidated financial statements and related disclosures, and additional differences may be identified as new or amended contracts with customers that will impact future periods are executed. The Company expects that its disclosure in the notes to the consolidated financial statements related to revenue recognition will be expanded in the first quarter of 2018 in line with the requirements of the standard to further describe the nature, timing, and uncertainty of revenue and cash flows arising from contracts with customers. In February 2016, the FASB issued ASU No. 2016-02, Leases (Topic 842) (ASU No. 2016-02), which supersedes the leases requirements in Topic 840. The core principle of ASU No. 2016-02 is that a lessee should recognize on the balance sheet the lease assets and lease liabilities that arise from all lease arrangements with terms greater than 12 months. Recognition of these lease assets and lease liabilities represents a change from previous GAAP, which did not require lease assets and lease liabilities to be recognized for operating leases. Qualitative disclosures along with specific quantitative disclosures will be required to provide enough information to supplement the amounts recorded in the financial statements so that users can understand more about the nature of an entity’s leasing activities. The Company will be required to recognize and measure leases at the beginning of the earliest period presented using a modified retrospective approach, which includes a number of optional practical expedients that the Company may elect to apply. The provisions of ASU No. 2016-02 are effective for the Company’s fiscal year beginning January 1, 2019, including interim periods within that fiscal year. At adoption, the Company will recognize a right-of-use asset and a lease liability initially measured at the present value of its operating lease payments. The Company is currently evaluating the impacts of adopting this guidance on its financial position, results of operations, and cash flows. In August 2016, the FASB issued various updates to ASU No. 2016-15, Statement of Cash Flows (Topic 230): Classification of Certain Cash Receipts and Cash Payments (ASU No. 2016-15), which clarifies and amends the presentation and classification of certain cash receipts and cash payments in the statement of cash flows. The provisions of ASU No. 2016-15 are effective for the Company’s fiscal year beginning January 1, 2018, including interim periods within that fiscal year, and will be applied using a retrospective transition method. The Company is currently evaluating the impacts of adopting this guidance on its cash flows. In March 2017, the FASB issued ASU No. 2017-07, Compensation - Retirement Benefits (Topic 715) (ASU No. 2017-07), which requires that employers offering their employees defined benefit pension plans disaggregate the service cost component from the other components of net benefit cost. The amendments also provide explicit guidance on how to present the service cost component and the other components of net benefit cost in the income statement and allow only the service cost component of net benefit cost to be eligible for capitalization. The provisions of ASU No. 2017-07 are effective for the Company’s fiscal year beginning January 1, 2018, including interim periods within that fiscal year, and should be applied retrospectively for the presentation of the service cost component and the other components of net periodic pension cost and net periodic post-retirement benefit cost in the income statement, and prospectively for the capitalization of the service cost component of net periodic pension cost and net periodic post-retirement benefit in assets. Upon adoption in 2018, Chemours will reclassify $34 and $20 of non-operating pension income from the operating expense captions of the consolidated statements of operations to other income, net for the years ended December 31, 2017 and 2016, respectively. In August 2017, the FASB issued ASU No. 2017-12, Derivatives and Hedging (Topic 815) (ASU No. 2017-12), which simplifies financial statement reporting for qualifying hedging relationships by eliminating the requirement to separately measure and report hedge ineffectiveness. For net investment hedges, the entire change in fair value of the hedging instruments is recorded in the currency translation adjustment section of other comprehensive income or loss. Pursuant to the amendments, these amounts are required to be subsequently reclassified to earnings in the same income statement line item in which the earnings effect of the hedged item is presented when the hedged item affects earnings. The provisions of ASU No. 2017-12 are effective for the Company’s fiscal year beginning January 1, 2019, including interim periods within that fiscal year. Early adoption is permitted in any interim period. The amendments in this update will be applied to hedging relationships existing on the date of adoption, which includes a cumulative-effect adjustment to eliminate any ineffectiveness recorded to accumulated other comprehensive income or loss with a corresponding adjustment to the opening balance of retained earnings as of the beginning of the fiscal year in which adoption occurred. Presentation and disclosure amendments are required to be applied prospectively. Chemours is currently evaluating the timing of adoption and does not expect the adoption of this guidance to have a significant impact on its financial position, results of operations, and cash flows. Recently Adopted Accounting Guidance In March 2016, the FASB issued ASU No. 2016-09, Compensation - Stock Compensation (Topic 718) (ASU No. 2016-09). ASU No. 2016-09 sets forth areas for simplification within several aspects of the accounting for shared-based payment transactions, including the income tax consequences, classification of awards as either equity or liabilities, and classification on the statement of cash flows. The amendments in ASU No. 2016-09 are effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2016. Chemours adopted this guidance effective January 1, 2017, and the adoption did not have a significant impact on the Company’s financial position, results of operations, or cash flows, except for the impact of windfall income tax benefits on share-based payments and the classification of employee withholding tax payments on vested RSUs as a financing activity on the statements of cash flows. Specific to the impact of windfall tax benefits, the Company expects the guidance will cause volatility in its income tax rates going forward. As of the adoption date, there were no windfall tax benefits from prior periods recognized; therefore, prior period adjustments were not required under a modified retrospective basis. For the year ended December 31, 2017, Chemours recognized $22 of federal and state windfall income tax benefits, primarily from options exercised and RSUs vested, which were included in the provision for income taxes in the consolidated statements of operations. In January 2017, the FASB issued ASU No. 2017-04, Intangibles - Goodwill and Other (Topic 350): Simplifying the Test for Goodwill Impairment (ASU No. 2017-04), which eliminates the requirement to determine the fair value of the individual assets and liabilities of a reporting unit to measure goodwill impairment. Under the amendments, goodwill impairment testing will be performed by comparing the fair value of the reporting unit with its carrying amount and recognizing an impairment charge for the amount by which the carrying amount exceeds the reporting unit’s fair value. Any impairment charges recognized would not exceed the total amount of goodwill allocated to the reporting unit. The provisions of ASU No. 2017-04 are effective for annual and interim goodwill impairment tests performed in fiscal years beginning after December 15, 2019. Early adoption is permitted for annual or interim goodwill impairment testing performed after January 1, 2017. The Company adopted this guidance and implemented its provisions for the annual goodwill impairment testing performed on October 1, 2017. Pursuant to the amendment, the Company will implement the provisions of ASU No. 2017-04 for interim and annual goodwill impairment tests performed prospectively. The adoption of this guidance did not have a significant impact on the Company’s financial position, results of operations, or cash flows. In May 2017, the FASB issued ASU No. 2017-09, Compensation - Stock Compensation (Topic 718): Scope of Modification Accounting (ASU No. 2017-09), which provides clarity and reduces both diversity in practice and the cost and complexity of applying the guidance in Topic 718 to a change in the terms or conditions of a share-based payment award. Pursuant to this update, modification accounting is required to be applied to changes in the terms and conditions of a share-based payment award unless all of the following criteria remain unchanged before and after the award is modified: (i) the fair value of the award; (ii) the vesting conditions of the award; and, (iii) the classification of the award as an equity instrument or a liability instrument. The provisions of ASU No. 2017-09 are effective for annual periods, and interim periods within those annual periods, beginning after December 15, 2017, and are to be applied prospectively to an award modified on or after the adoption date. Early adoption, including adoption in any interim period, is permitted for public business entities in reporting periods for which financial statements have not yet been issued. The Company has adopted this guidance and will implement its provisions prospectively for changes in the terms and conditions of share-based payment awards. The Company does not expect that the adoption of this guidance will have a significant impact on its financial position, results of operations, or cash flows.

Relationship with DuPont and Related Entities	12 Months Ended
Relationship with DuPont and Related Entities	Dec. 31, 2017
Related Party Transactions [Abstract]
Relationship with DuPont and Related Entities	Note 4. Relationship with DuPont and Related Entities Prior to the Separation, Chemours sold finished goods to DuPont and its non-Chemours businesses. Related party sales to DuPont recorded by Titanium Technologies, Fluoroproducts, and Chemical Solutions for the year ended December 31, 2015 were $2, $34, and $21, respectively. Following the Separation, beginning on July 1, 2015, transactions with DuPont’s businesses were not considered related party transactions. Also, prior to the Separation, DuPont incurred significant corporate costs for services provided to Chemours, as well as other DuPont businesses. These costs included expenses for information systems, accounting, other financial services such as treasury and audit, purchasing, human resources, legal, facilities, engineering, corporate R&D, corporate stewardship, marketing, and business analysis support. A portion of these costs benefited multiple or all DuPont businesses, including Chemours, and were allocated to Chemours and its reportable segments using methods based on proportionate formulas involving total costs or other various allocation methods that management considered consistent and reasonable. Chemours’ corporate costs are not allocated to the reportable segments and are reported in Corporate and Other. The total allocated leveraged functional service and general corporate expenses included in the consolidated statements of operations amounted to $238 for the year ended December 31, 2015. These expenses were recorded within cost of goods sold, selling, general, and administrative expense, and R&D expense for $23, $205, and $10, respectively. Subsequent to the Separation on July 1, 2015, transactions with DuPont’s businesses were not considered related party transactions. Accordingly, no costs from DuPont were allocated to Chemours after the Separation Date. Cash Management and Financing The separation agreement set forth a process to true-up cash and working capital amounts transferred to Chemours from DuPont at the Separation. In January 2016, Chemours and DuPont entered into an agreement, contingent upon entry into the credit agreement amendment (described further in Note 18), which provided for the extinguishment of payment obligations of cash and working capital true-ups previously contemplated in the separation agreement. As a result, Chemours is no longer required to make any payments to DuPont, nor will DuPont make any payments to Chemours. The agreement also set forth a $190 prepayment to be made by DuPont in advance of certain specified goods and services that, under existing agreements, Chemours was to provide to DuPont through mid-2017. The prepayment was received by Chemours in February 2016 and was recorded as deferred revenue. As of December 31, 2017, the entire $190 prepayment from DuPont has been earned by Chemours. Tax Matters Agreement The tax matters agreement between Chemours and DuPont governs the parties’ respective rights, responsibilities, and obligations with respect to tax liabilities and benefits, tax attributes, the preparation and filing of tax returns, the control of audits and other tax proceedings, and other matters regarding taxes. In general, under the agreement, DuPont is responsible for any U.S. federal, state, and local taxes (and any related interest, penalties, or audit adjustments) reportable on a consolidated, combined, or unitary return that includes DuPont or any of its subsidiaries and Chemours and/or any of its subsidiaries for any periods or portions thereof ending on or prior to the Separation Date. Chemours is responsible for any U.S. federal, state, local, and foreign taxes (and any related interest, penalties, or audit adjustments) that are imposed on Chemours and/or any of its subsidiaries for all tax periods, whether before or after the Separation Date.

Research and Development Expense	12 Months Ended
Research and Development Expense	Dec. 31, 2017
Research And Development [Abstract]
Research and Development Expense	Note 5. Research and Development Expense R&D expense incurred by Chemours was $80, $80, and $97 for the years ended December 31, 2017, 2016, and 2015, respectively. R&D expense for the year ended December 31, 2015 includes $10 of assigned costs, which are attributable to DuPont’s Corporate Central Research and Development (Central R&D) function’s long-term research activities. This assignment was based on the cost of research projects for which Chemours was determined to be the sponsor or co-sponsor. All research services previously provided to Chemours by DuPont’s Central R&D function were specifically requested by Chemours, covered by service-level agreements, and billed based on usage. DuPont’s R&D services were no longer used after the Separation Date.

Restructuring and Asset-Related Charges, Net

12 Months Ended

Dec. 31, 2017

Restructuring And Related Activities [Abstract]

Restructuring and Asset-Related Charges, Net

Note 6. Restructuring and Asset-related Charges, Net

The following table sets forth the components of the Company’s restructuring and asset-related charges, net for the years ended December 31, 2017, 2016, and 2015.

	Year Ended December 31,
	2017		2016		2015
Restructuring-related charges:
Employee separation charges	$	23	$	4	$	137
Decommissioning and other charges, net		33		47		18
Asset-related charges - restructuring		—		—		133
Total restructuring-related charges, net		56		51		288
Asset-related charges - impairment (1)		1		119		45
Total restructuring and asset-related charges, net	$	57	$	170	$	333

(1)

Impairment charges for the year ended December 31, 2016 include $13 and $58 in pre-tax impairment charges related to the sales of the Company’s corporate headquarters building located in Wilmington, Delaware and its Sulfur business, respectively, and $48 in pre-tax impairment charges related to the Company’s aniline facility in Pascagoula, Mississippi. Impairment charges for the year ended December 31, 2015 include $45 in pre-tax impairment charges related to the Company’s Reactive Metals Solutions (RMS) manufacturing facility in Niagara Falls, New York.

The impacts of the Company’s restructuring programs to segment earnings for the years ended December 31, 2017, 2016, and 2015 are set forth in the following table.

	Year Ended December 31,
	2017		2016		2015
Plant and product line closures (1) :
Titanium Technologies	$	4	$	30	$	140
Fluoroproducts		3		7		24
Chemical Solutions		17		8		12
Total plant and product line closures		24		45		176
2015 Global Restructuring Program (2) :
Titanium Technologies		—		2		33
Fluoroproducts		—		4		54
Chemical Solutions		—		—		25
Total 2015 Global Restructuring Program		—		6		112
2017 Restructuring Program		32		—		—
Total restructuring-related charges, net	$	56	$	51	$	288

(1)

Includes charges related to employee separation, decommissioning and dismantling costs, and asset-related charges in connection with the restructuring activities.

(2)

Includes $24 related to corporate support functions that were allocated to the segments for the year ended December 31, 2015.

Plant and Product Line Closures

Titanium Technologies

In August 2015, the Company announced the closure of its Edge Moor, Delaware manufacturing plant. The Edge Moor plant produced TiO₂ for use in the paper industry and certain other applications where demand had steadily declined, resulting in under-used capacity at the plant. In addition, the Company permanently shut down one under-used TiO₂ production line at its New Johnsonville, Tennessee plant. The Company stopped production at its Edge Moor plant in September 2015, and immediately began decommissioning the plant. These actions resulted in the write-off of substantially all of the Edge Moor plant’s assets’ carrying values in 2015.

As a result, the Company recorded restructuring charges of $140 for the year ended December 31, 2015, which consist of employee separation costs of $11, property, plant, and equipment and other asset-related, pre-tax impairment charges of $115, and decommissioning costs and other charges of $14. For the years ended December 31, 2017 and 2016, the Company recorded additional restructuring charges of $4 and $30, respectively, which relate to decommissioning, dismantling, and removal activities. The Company substantially completed these activities in 2017, and sold the land where the plant was located for $10 in the first quarter of 2017.

Fluoroproducts

In August 2015, in an effort to improve the profitability of the Company’s Fluoroproducts segment, management approved the shutdown of certain production lines in the segment’s U.S. manufacturing plants. As a result, the Company recorded restructuring charges of $21 for the year ended December 31, 2015, which consist of accelerated depreciation on property, plant, and equipment of $18, employee separation costs of $2, and decommissioning and other costs of $1. For the years ended December 31, 2017 and 2016, the Company recorded additional restructuring charges of $3 and $7, respectively, which relate to decommissioning, dismantling, and removal activities. At December 31, 2017, the Company has substantially completed all actions related to the restructuring activities for certain of its production lines.

Chemical Solutions

In the fourth quarter of 2015, the Company announced the completion of the strategic review of its RMS business and the decision to stop production at its Niagara Falls, New York manufacturing plant. The RMS plant had approximately 200 employees and contractors impacted by this action, and production stopped at the plant in September 2016, when the Company immediately began actions to decommission the plant.

As a result, the Company recorded restructuring charges of $12 for the year ended December 31, 2015, which represent employee separation costs. For the year ended December 31, 2016, the Company recorded additional restructuring charges of $8, which consist of contract termination charges of $2 and decommissioning and other related charges of $6. Additional restructuring charges of $17 for decommissioning and site redevelopment activities were recorded for the year ended December 31, 2017, and the Company expects to incur approximately $4 in additional restructuring charges for similar activities in 2018, which will be expensed as incurred.

2015 Global Restructuring Program

In November 2015, Chemours announced a global workforce reduction impacting approximately 430 positions. This action was part of the Company’s ongoing efforts to streamline and simplify the structure of the organization worldwide, and to reduce costs. As a result, the Company recorded $48 of pre-tax employee separation costs during the fourth quarter of 2015. The associated headcount reductions were completed as of December 31, 2016, and all related payments are expected to be completed by early 2018.

In June 2015, in light of the then-weakness in the global TiO₂ market cycle and continued foreign currency impacts due to a strengthening of the U.S. dollar, Chemours implemented a restructuring plan to reduce and simplify its cost structure. This plan resulted in a global workforce reduction of more than 430 positions. As a result, the Company recorded a pre-tax charge of $64 for employee separation costs in the year ended December 31, 2015. All actions associated with this charge were completed by December 31, 2016.

2017 Restructuring Program

In 2017, the Company initiated certain restructuring activities designed to further the cost savings and productivity improvements outlined under management’s transformation plan. These activities include, among other efforts: (i) outsourcing and further centralizing certain business process activities; (ii) consolidating existing, outsourced third-party information technology (IT) providers; and, (iii) implementing various upgrades to the Company’s current IT infrastructure. In connection with these corporate function efforts, the Company recorded $14 in restructuring-related charges for year ended December 31, 2017.

In October 2017, the Company announced a voluntary separation program (VSP) for certain eligible U.S. employees in an effort to better manage the anticipated future changes to its workforce. Employees who volunteered for, and were accepted under the VSP will receive certain financial incentives above the Company’s customary involuntary termination benefits to end their employment with Chemours after providing a mutually agreed-upon service period. Approximately 300 employees will separate from the Company by the end of 2018. An accrual representing the majority of these termination benefits, amounting to $18, was recognized in the fourth quarter of 2017. The remaining incremental, one-time financial incentives under the VSP will be recognized over the period each participating employee continues to provide service to Chemours.

As a result of its 2017 program, the Company expects to incur charges for restructuring-related activities and termination benefits ranging from $20 to $25 through December 31, 2018, which will be expensed as incurred.

The following table sets forth the change in the Company’s employee separation-related liabilities associated with its restructuring programs for the years ended December 31, 2017, 2016, and 2015.

	Titanium Technologies Site Closures			Fluoroproducts Lines Shutdown			Chemical Solutions Site Closures			2015 Global Restructuring Program			2017 Restructuring Program		Total
Balance at December 31, 2015	$	11		$	2		$	12		$	73		$	—	$	98
Charges (credits) to income (1)		—			—			(2	)		6			—		4
Payments		(7	)		(1	)		(1	)		(59	)		—		(68	)
Currency translation and other adjustments (2)		—			—			(1	)		1			—		—
Balance at December 31, 2016		4			1			8			21			—		34
Charges to income		—			—			—			1			23		24
Payments		(3	)		(1	)		(6	)		(21	)		—		(31	)
Currency translation and other adjustments (2)		—			—			—			—			—		—
Balance at December 31, 2017	$	1		$	—		$	2		$	1		$	23	$	27

(1)

Due to the unexpected resignations of certain employees at the Company’s RMS manufacturing facility during 2016, $2 of employee separation charges were reversed to income during the year ended December 31, 2016.

(2)

Amounts include net currency translation adjustments of $1 or less for the periods presented and/or immaterial rounding differences.

There are no significant outstanding liabilities related to the Company’s decommissioning and other restructuring-related charges for the periods presented.

Sales of Assets and Businesses

12 Months Ended

Dec. 31, 2017

Discontinued Operations And Disposal Groups [Abstract]

Sales of Assets and Businesses

Note 7. Sales of Assets and Businesses

Sale of Corporate Headquarters

In December 2016, in connection with a sale agreement entered in January 2017 to sell Chemours’ corporate headquarters building located in Wilmington, Delaware, the Company recorded a $13 pre-tax impairment charge and classified the net book value of the building as an asset held for sale within other assets on the consolidated balance sheets at December 31, 2016. The Company completed the sale in April 2017 for net proceeds of $29, of which, $13 was used to repay a portion of Chemours’ senior secured term loans. Contemporaneous with the sale, Chemours entered into lease agreements to leaseback a portion of the building. A gain of $2 was deferred in connection with the sale and leaseback transaction.

Chemical Solutions Portfolio Optimization

In June 2016, the Company entered into an asset purchase agreement with Veolia North America, Inc. (Veolia), whereby Veolia agreed to acquire the Sulfur business of Chemours’ Chemical Solutions segment for a purchase price of $325 in cash, subject to customary working capital and other adjustments. $10 of the proceeds were received in May 2016. The Company completed the sale and, in July 2016, received the remaining proceeds of $311, net of working capital adjustments. Prior to the completion of the sale, in the second quarter of 2016, the Company recorded a pre-tax impairment loss of $58 as a component of restructuring and asset-related charges, net in the consolidated statements of operations. Upon completion of the sale, the Company also recorded an additional pre-tax loss on sale of $4, net of a benefit from contractual adjustments in other income, net in the consolidated statements of operations. The net book value of the assets and liabilities disposed of in this sale amounted to $342 and $11, respectively.

In April 2016, the Company entered into a stock and asset purchase agreement with LANXESS Corporation (Lanxess), whereby Lanxess agreed to acquire the Clean & Disinfect (C&D) business of Chemours’ Chemical Solutions segment by acquiring certain of Chemours’ subsidiaries and assets for a purchase price of $230 in cash, subject to customary working capital and other adjustments. The Company completed the sale and, in August 2016, received proceeds of $223, net of working capital adjustments and $2 of cash transferred. For the year ended December 31, 2016, in connection with this sale, the Company recorded a pre-tax gain of $169 in other income, net in the consolidated statements of operations. The net book values of the assets and liabilities disposed of in this sale amounted to $48 (including goodwill of $13) and $6, respectively, and the Company incurred $9 of transaction and other charges in connection therewith.

In November 2015, the Company signed a definitive agreement to sell its aniline facility in Beaumont, Texas to The Dow Chemical Company (Dow). The net book value of the related asset group (including goodwill) was classified as an asset held for sale at December 31, 2015, which was included in prepaid expenses and other on the consolidated balance sheets. The transaction closed in March 2016, and Chemours received $140 in cash from Dow. The net book value of the assets disposed of in this sale amounted to $41 (including goodwill of $4), and the Company incurred $11 of transaction and other charges in connection therewith. As a result of the transaction, Chemours recognized a pre-tax gain of $89 for the year ended December 31, 2016, which was recorded in other income, net in the consolidated statements of operations.

The aggregate amounts and major components of the assets and liabilities disposed of in connection with the portfolio optimization activities for Chemours’ Chemical Solutions segment during the year ended December 31, 2016 are set forth in the following table.

	Chemical Solutions Portfolio Optimization
Current assets:
Accounts receivable - trade	$	22
Inventories		17
Total current assets		39
Non-current assets:
Property, plant, and equipment, net		298
Goodwill		17
Other assets		136
Less: Impairment loss		(58	)
Total non-current assets, net		393
Total assets		432
Accounts payable and accrued liabilities		17
Total liabilities		17
Total net assets disposed	$	415

Other Income, Net

12 Months Ended

Dec. 31, 2017

Other Income And Expenses [Abstract]

Other Income, Net

Note 8. Other Income, Net

The following table sets forth the components of the Company’s other income, net for the years ended December 31, 2017, 2016, and 2015.

	Year Ended December 31,
	2017		2016			2015
Leasing, contract services, and miscellaneous income	$	30	$	35		$	25
Royalty income (1)		24		15			19
Gain (loss) on sale of assets and businesses (2)		22		254			(9	)
Exchange gains (losses), net (3)		3		(57	)		19
Total other income, net	$	79	$	247		$	54

(1)

Royalty income is primarily from technology and trademark licensing.

(2)

For the year ended December 31, 2017, gain on sale includes a gain of $13 associated with the sale of the Company’s land in Repauno, New Jersey that was previously deferred and realized upon meeting certain milestones, and a $12 gain associated with the sale of the Company’s Edge Moor, Delaware plant site, net of certain losses on other disposals. For the year ended December 31, 2016, gain on sale includes gains of $169 and $89 associated with the sales of the Company’s C&D business and its aniline facility in Beaumont, Texas, respectively.

(3)

Exchange gains (losses), net includes gains and losses on foreign currency forward contracts.

Income Taxes

12 Months Ended

Dec. 31, 2017

Income Tax Disclosure [Abstract]

Income Taxes

Note 9. Income Taxes

U.S. Income Tax Reform

On December 22, 2017, the U.S. government enacted comprehensive tax legislation, commonly referred to as the Tax Cuts and Jobs Act (Tax Act). The Tax Act makes broad and complex changes to the U.S. tax code, including, but not limited to: (i) reducing the U.S. federal corporate tax rate from 35% to 21%; (ii) requiring companies to pay a one-time transition tax on certain unrepatriated earnings of foreign subsidiaries; (iii) generally eliminating U.S. federal income taxes on dividends from foreign subsidiaries; (iv) requiring a current inclusion in U.S. federal taxable income of certain earnings of controlled foreign corporations; (v) eliminating the corporate alternative minimum tax (AMT) and changing how existing AMT credits can be realized; (vi) creating the base erosion anti-abuse tax, a new minimum tax; (vii) creating a new limitation on deductible interest expense; (viii) changing rules related to uses and limitations of net operating loss carryforwards created in tax years beginning after December 31, 2017; and, (ix) creating the global intangibles low-tax income (GILTI) inclusions.

The Company’s accounting for the following elements of the Tax Act is incomplete; however, management was able to make reasonable estimates of certain effects and, therefore, recorded the provisional adjustments set forth below.

Reduction of U.S. Federal Corporate Tax Rate

The Tax Act reduces the corporate tax rate to 21%, effective January 1, 2018. For certain of the Company’s U.S. deferred tax assets and liabilities, it has recorded a provisional tax benefit of $68, with a corresponding net adjustment to deferred tax benefit. While the Company is able to make a reasonable estimate of the impact of the reduction in its corporate rate, it may be affected by other analyses related to the Tax Act, including, but not limited to, the Company’s calculation of deemed repatriation of deferred foreign earnings and profits (E&P) and the state tax effect of adjustments made to federal temporary differences.

Deemed Repatriation Transition Tax

The Deemed Repatriation Transition Tax (Transition Tax) is a tax on previously untaxed accumulated and current E&P of certain of the Company’s foreign subsidiaries. To determine the amount of the Transition Tax, the Company must determine, in addition to other factors, the amount of post-1986 E&P of the relevant subsidiaries, as well as the amount of non-U.S. income taxes paid on such earnings. The Company is able to make a reasonable estimate of the Transition Tax and recorded a provisional Transition Tax obligation of $322, which was partially offset by $202 of foreign tax credits, on $2,400 of historic unremitted foreign E&P. The Company continues to gather additional information to more-precisely compute the amount of the Transition Tax. The Company continues to believe that its foreign earnings are permanently reinvested; however, as the Company continues to evaluate the impacts of the Tax Act, the Company may change this assertion in a future period.

Valuation Allowance

During the fourth quarter of 2017, the Company released $33 of valuation allowance related to its foreign tax credits that were utilized against the provisional amount of Transition Tax recorded in income tax expense. The Company continues to assess whether its valuation allowance analyses are affected by various aspects of the Tax Act, for example, as it relates to the deemed repatriation of deferred foreign income, GILTI inclusions, new categories of foreign tax credits, the immediate full-expensing of certain capital expenditures, and interest expense limitations. Since, as discussed herein, the Company has recorded provisional amounts related to certain portions of the Tax Act, any corresponding determination of the need for or change in a valuation allowance is also provisional.

Global Intangibles Low-tax Income

The Tax Act creates a new requirement that certain income (i.e., GILTI) earned by controlled foreign corporations (CFCs) must be included currently in the gross income of the CFCs’ U.S. shareholder. GILTI is the excess of the shareholder’s net CFC-tested income over the net deemed tangible income return, which is currently defined as the excess of (i) 10% of the aggregate of the U.S. shareholder’s pro rata share of the qualified business asset investment of each CFC with respect to which it is a U.S. shareholder over, (ii) the amount of certain interest expense taken into account in the determination of net CFC-tested income. Because of the complexity of the new GILTI tax rules, the Company continues to evaluate this provision of the Tax Act and the application of Topic 740.

Under GAAP, the Company is allowed to make an accounting policy choice of either (i) treating taxes due on future U.S. inclusions in taxable income related to GILTI as a current period expense when incurred (i.e., the period cost method), or (ii) factoring such amounts into the Company’s measurement of its deferred taxes (i.e., the deferred method). The Company’s selection of an accounting policy with respect to the new GILTI tax rules will depend, in part, on analyzing its global income to determine whether it expects to have future U.S. inclusions in taxable income related to GILTI and, if so, what the impact is expected to be. Because whether the Company expects to have future U.S. inclusions in taxable income related to GILTI depends on not only its current structure and estimated future results of global operations, but also its intent and ability to modify its structure and/or its business, management is not yet able to reasonably estimate the effect of this provision of the Tax Act. Therefore, the Company has not made any adjustments related to potential GILTI tax in its consolidated financial statements, and has not made a policy decision regarding whether to record deferred taxes on GILTI.

Income Taxes

The following table sets forth the components of the Company’s provision for (benefit from) income taxes for the years ended December 31, 2017, 2016, and 2015.

	Year Ended December 31,
	2017			2016			2015
Current tax expense:
U.S. federal (1)	$	(8	)	$	—		$	37
U.S. state and local (1)		1			—			1
International		89			93			62
Total current tax expense		82			93			100
Deferred tax expense (benefit):
U.S. federal		60			(101	)		(187	)
U.S. state and local		6			(17	)		(14	)
International		17			7			3
Total deferred tax expense (benefit)		83			(111	)		(198	)
Total provision for (benefit from) income taxes	$	165		$	(18	)	$	(98	)

(1)

Amounts for the year ended December 31, 2015 were recorded pursuant to the Separation-related tax matters agreement.

The following table sets forth the components of the Company’s deferred tax assets and liabilities at December 31, 2017 and 2016.

	December 31,
	2017			2016
Deferred tax assets:
Environmental and other reserves	$	89		$	150
Litigation reserves		14			149
Stock-based compensation and accrued employee benefits		26			35
Other assets and other accrued liabilities		8			27
Tax loss carryforwards		27			45
Foreign tax credit carryforwards		17			50
Total deferred tax assets		181			456
Less: Valuation allowance		(17	)		(50	)
Total deferred tax assets, net		164			406
Deferred tax liabilities:
Pension and other liabilities		(55	)		(16	)
Property, plant, and equipment		(274	)		(441	)
Inventories and other assets		(4	)		(40	)
Total deferred tax liabilities		(333	)		(497	)
Deferred tax liability, net	$	(169	)	$	(91	)

The following table sets forth an analysis of the Company’s effective tax rate for the years ended December 31, 2017, 2016, and 2015.

	Year Ended December 31,
	2017						2016						2015
	$			%			$			%			$			%
Statutory U.S. federal income tax rate	$	319			35.0	%	$	(4	)		35.0	%	$	(66	)		35.0	%
State income taxes, net of federal benefit (1)		7			0.7	%		(16	)		150.4	%		(10	)		5.1	%
Lower effective tax rate on international operations, net		(149	)		(16.3	)%		(61	)		552.5	%		(23	)		12.0	%
Depletion		(8	)		(0.9	)%		(6	)		51.2	%		(6	)		3.4	%
Goodwill		—			—	%		5			(47.9	)%		6			(3.2	)%
Exchange losses (gains)		5			0.6	%		4			(39.1	)%		(1	)		0.5	%
Provision to return and other adjustments		6			0.6	%		6			(57.9	)%		—			—	%
Permanent items		9			1.0	%		3			(27.3	)%		1			(0.5	)%
Valuation allowance (2)		(33	)		(3.6	)%		50			(451.6	)%		—			—	%
Net impact of U.S. tax reform		39			4.3	%		—			(—	)%		—			—	%
Stock-based compensation (1)		(20	)		(2.2	)%		—			(—	)%		—			—	%
Other, net		(10	)		(1.2	)%		1			(1.7	)%		1			(0.2	)%
Total effective tax rate	$	165			18.1	%	$	(18	)		163.6	%	$	(98	)		52.1	%

(1)

Total windfall benefits on stock-based compensation amounted to $22 for the year ended December 31, 2017, which is inclusive of $20 in federal income tax benefit and $2 in state income tax benefit.

(2)

Release of the valuation allowance during 2015 was related to a tax loss carryforward incurred prior to July 1, 2015 that is attributable to DuPont’s tax periods pursuant to the tax matters agreement and did not impact the effective tax rate as the adjustment was recorded in DuPont’s net investment in the consolidated statements of stockholders’ equity for the year ended December 31, 2015.

The following table sets forth the Company’s income (loss) before income taxes for its U.S. and international operations for the years ended December 31, 2017, 2016, and 2015.

	Year Ended December 31,
	2017			2016			2015
U.S. operations (including exports)	$	(306	)	$	(481	)	$	(492	)
International operations		1,218			470			304
Total income (loss) before income taxes	$	912		$	(11	)	$	(188	)

For the year ended December 31, 2017, the Company released $33 of valuation allowance on its foreign tax credits. The valuation allowance release represents the amount of foreign tax credit carryforward that was used to offset the provisional Transition Tax recorded in the period.

Under the tax laws of various jurisdictions in which the Company operates, deductions or credits that cannot be fully utilized for tax purposes during the current year may be carried forward or back, subject to statutory limitations, to reduce taxable income or taxes payable in the future or prior years. At December 31, 2017, the U.S federal and state tax losses are $24, which substantially expire between 2035 and 2037. The Company also has U.S. foreign tax credit carryforwards of $17, which expire in 2026 and are fully offset by a valuation allowance. Lastly, the Company has foreign net operating losses of $1, which substantially expire between 2025 and 2026.

The Company has maintained a valuation allowance of $17 on its remaining foreign tax credit carryforward. The amount of the foreign tax credits that are considered realizable could be adjusted in the future as the Company continues to evaluate the impact of U.S. tax reform on its ability to utilize these credits.

Each year, Chemours and/or its subsidiaries file income tax returns in the U.S. federal jurisdiction and various states and non-U.S. jurisdictions.

The following table sets forth the Company’s significant jurisdictions’ tax returns that are subject to examination by their respective taxing authorities for the open years listed.


Jurisdiction	Open Years
China		2011 through 2017
Mexico		2012 through 2017
Netherlands		2014 through 2017
Taiwan		2014 through 2017
U.S.		2015 through 2017

Positions challenged by the taxing authorities may be settled or appealed by Chemours and/or DuPont in accordance with the tax matters agreement. As a result, income tax uncertainties are recognized in the Company’s consolidated financial statements in accordance with accounting for income taxes, when applicable. During 2017, the Company received approval from the Internal Revenue Service for an accounting method change; therefore, $6 of unrecognized tax benefits were released. Chemours is not aware of any other matters that would result in significant changes to the amount of unrecognized income tax benefits reflected in the consolidated balance sheets at December 31, 2017.

Prior to the Separation, Chemours was included in DuPont’s consolidated income tax returns, and Chemours’ income taxes for those periods are computed and reported herein under the separate return method. Use of the separate return method may result in differences when the sum of the amounts allocated to stand-alone tax provisions are compared with amounts presented in the consolidated financial statements. In that event, the related deferred tax assets and liabilities could be significantly different from those presented herein for these periods. Certain tax attributes that were reflected in DuPont’s consolidated financial statements, such as net operating loss carryforwards, may or may not exist at the stand-alone Chemours level. As it is assumed that all amounts due to DuPont prior to the Separation were settled on December 31 of each year, Chemours’ consolidated financial statements do not reflect any amounts due to DuPont for income tax-related matters.

The following table sets forth the change in the Company’s unrecognized tax benefit for the years ended December 31, 2017, 2016, and 2015.

	Year Ended December 31,
	2017			2016			2015
Balance at January 1,	$	6		$	7		$	39
Gross amounts of decreases in unrecognized tax benefits as a result of adjustments to tax provisions taken during the prior period		(6	)		(1	)		—
Gross amounts of increases in unrecognized tax benefits as a result of tax positions taken during the current period		—			—			—
Reduction to unrecognized tax benefits as a result of a lapse of the applicable statute of limitations (1)		—			—			(32	)
Balance at December 31,	$	—		$	6		$	7

Total unrecognized tax benefits, if recognized, that would impact the effective tax rate	$	—		$	—		$	—
Total amount of interest and penalties recognized in the consolidated statements of operations (1)		—			—			1
Total amount of interest and penalties recognized in the consolidated balance sheets		—			—			—

(1)

Reduction to the unrecognized tax benefits represents DuPont’s responsibilities for uncertain income tax positions recorded prior to July 1, 2015 pursuant to the tax matters agreement. The reduction was recorded in DuPont’s net investment in the consolidated statements of stockholders’ equity for the year ended December 31, 2015.

The following table sets forth a rollforward of the Company’s deferred tax asset valuation allowance for the years ended December 31, 2017, 2016, and 2015.

	Year Ended December 31,
	2017			2016		2015
Balance at January 1,	$	50		$	—	$	36
Net charges to income tax expense		—			50		—
Release of valuation allowance (1)		(33	)		—		(36	)
Balance at December 31,	$	17		$	50	$	—

(1)

The valuation allowance released during 2015 was related to tax loss carryforwards incurred prior to July 1, 2015, which were attributable to DuPont’s tax periods pursuant to the tax matters agreement. The adjustment was recorded in DuPont’s net investment in the consolidated statements of stockholders’ equity for the year ended December 31, 2015.

Earnings Per Share of Common Stock

12 Months Ended

Dec. 31, 2017

Earnings Per Share [Abstract]

Earnings Per Share of Common Stock

Note 10. Earnings Per Share of Common Stock

Reconciliations of the numerators and denominators for the Company’s basic and diluted earnings per share calculations for the years ended December 31, 2017, 2016, and 2015 are set forth in the following table.

	Year Ended December 31,
	2017		2016		2015
Numerator:
Net income (loss) attributable to Chemours	$	746	$	7	$	(90	)
Denominator:
Weighted-average number of common shares outstanding - basic		184,844,106		181,621,422		180,993,623
Dilutive effect of the Company’s employee compensation plans		6,139,885		1,795,078		—
Weighted-average number of common shares outstanding - diluted		190,983,991		183,416,500		180,993,623

The following table sets forth the average number of stock options that were anti-dilutive and, therefore, were not included in the Company’s diluted earnings per share calculations for the years ended December 31, 2017, 2016, and 2015.

	Year Ended December 31,
	2017		2016		2015
Average number of stock options		43,072		5,820,499		8,358,894

Accounts and Notes Receivable, Net

12 Months Ended

Dec. 31, 2017

Receivables [Abstract]

Accounts and Notes Receivable, Net

Note 11. Accounts and Notes Receivable, Net

The following table sets forth the components of the Company’s accounts and notes receivable, net at December 31, 2017 and 2016.

	December 31,
	2017		2016
Accounts receivable - trade, net (1)	$	847	$	742
VAT, GST, and other taxes (2)		54		46
Other receivables (3)		18		19
Total accounts and notes receivable, net	$	919	$	807

(1)

Accounts receivable - trade, net includes trade notes receivable and is net of allowances for doubtful accounts of $5 at December 31, 2017 and 2016. Such allowances are equal to the estimated uncollectible amounts.

(2)

Value added tax (VAT) and goods and services tax (GST) for various jurisdictions.

(3)

Other receivables consist of notes receivable, advances, and other deposits.

Accounts and notes receivable are carried at amounts that approximate fair value. Bad debt expense amounted to $1, $7, and $1 for the years ended December 31, 2017, 2016, and 2015, respectively.

- Definition

The entire disclosure for claims held for amounts due a entity, excluding financing receivables. Examples include, but are not limited to, trade accounts receivables, notes receivables, loans receivables. Includes disclosure for allowance for credit losses.

+ References + Details

Inventories

12 Months Ended

Dec. 31, 2017

Inventory Net [Abstract]

Inventories

Note 12. Inventories

The following table sets forth the components of the Company’s inventories at December 31, 2017 and 2016.

	December 31,
	2017			2016
Finished products	$	648		$	532
Semi-finished products		164			150
Raw materials, stores, and supplies		313			285
Inventories before LIFO adjustment		1,125			967
Adjustment of inventories to LIFO basis		(190	)		(200	)
Total inventories	$	935		$	767

Inventory values, before LIFO adjustment, are generally determined by the average cost method, which approximates current cost. Inventories are valued under the LIFO method at substantially all U.S. locations, which comprised $509 and $465, or 45% and 48%, of inventories before the LIFO adjustments at December 31, 2017 and 2016, respectively. The remainder of inventory held in international locations and certain U.S. locations is valued under the average cost method.

Property, Plant, and Equipment, Net

12 Months Ended

Dec. 31, 2017

Property Plant And Equipment [Abstract]

Property, Plant, and Equipment, Net

Note 13. Property, Plant, and Equipment, Net

The following table sets forth the components of the Company’s property, plant, and equipment, net at December 31, 2017 and 2016.

	December 31,
	2017			2016
Equipment	$	6,961		$	6,748
Buildings		875			814
Construction-in-progress		520			293
Land		119			106
Mineral rights		36			36
Property, plant, and equipment		8,511			7,997
Less: Accumulated depreciation		(5,503	)		(5,213	)
Total property, plant, and equipment, net	$	3,008		$	2,784

Depreciation expense amounted to $269, $281, and $264 for the years ended December 31, 2017, 2016, and 2015, respectively. Property, plant, and equipment, net includes gross assets under capital leases of $7 and $5 at December 31, 2017 and 2016, respectively, and a build-to-suit lease asset of $8 at December 31, 2017. Interest expense capitalized as part of property, plant, and equipment, net amounted to $9, $18, and $21 for the years ended December 31, 2017, 2016, and 2015, respectively.

See Note 18 for further discussion regarding the Company’s build-to-suit lease arrangement.

Goodwill and Other Intangible Assets, Net

12 Months Ended

Dec. 31, 2017

Goodwill And Intangible Assets Disclosure [Abstract]

Goodwill and Other Intangible Assets, Net

Note 14. Goodwill and Other Intangible Assets, Net

Goodwill

The following table sets forth the changes in the carrying amount of the Company’s goodwill by reportable segment for the years ended December 31, 2017 and 2016.

	Titanium Technologies		Fluoroproducts		Chemical Solutions			Total
Balance at January 1, 2016	$	13	$	85	$	68		$	166
Sale of business (1)		—		—		(13	)		(13	)
Balance at December 31, 2016		13		85		55			153
Balance at December 31, 2017	$	13	$	85	$	55		$	153

(1)

Represents goodwill disposed of in connection with the sale of the Company’s C&D business.

Chemours consists of three operating segments: Titanium Technologies, Fluoroproducts, and Chemical Solutions. The Company defines its reporting units as one level below these operating segments, with the exception of Titanium Technologies, which is both an operating segment and a reporting unit. The Company tested the goodwill balances attributable to each of its reporting units for potential impairment on October 1, 2017 and 2016, the date of Chemours’ annual goodwill assessment, and concluded that the fair value of each reporting unit that carries goodwill substantially exceeded the respective reporting unit’s carrying amount. As a result, no impairment charges related to goodwill were recognized by the Company for the years ended December 31, 2017 and 2016.

In 2015, the Company performed a strategic evaluation of its Chemical Solutions portfolio. As a result of subsequent changes to the segment’s reporting units in the third quarter of 2015, the Company recorded a $25 pre-tax impairment charge related to its Sulfur reporting unit. The Sulfur reporting unit was disposed of through the sale of its assets and business during 2016.

Accordingly, there are no accumulated impairment losses included in the Company’s goodwill at December 31, 2017 and 2016.

Other Intangible Assets, Net

The following table sets forth the gross carrying amounts and accumulated amortization of the Company’s other intangible assets by major class at December 31, 2017 and 2016.

	December 31, 2017							December 31, 2016
	Cost		Accumulated Amortization			Net		Cost		Accumulated Amortization			Net
Customer lists	$	9	$	(8	)	$	1	$	9	$	(7	)	$	2
Patents		19		(18	)		1		19		(18	)		1
Purchased trademarks		5		(2	)		3		5		(2	)		3
Purchased and licensed technology		3		(2	)		1		3		(2	)		1
Other (1)		10		(3	)		7		10		—			10
Total other intangible assets, net	$	46	$	(33	)	$	13	$	46	$	(29	)	$	17

(1)

Represents non-cash favorable supply contracts acquired in connection with the sale of the Sulfur business and recognized during the third quarter of 2016 based on the present value of the difference between their contractual cash flows and estimated cash flows had the contracts been executed at a determinable market price. These contract intangibles will be amortized to cost of goods sold over the remaining life of the supply contracts through 2021.

The aggregate pre-tax amortization expense for definite-lived intangible assets was $4, $3, and $3 for the years ended December 31, 2017, 2016, and 2015, respectively. The estimated aggregate pre-tax amortization expense for 2018, 2019, 2020, 2021, and 2022 is $3, $3, $3, $2, and $1, respectively. Definite-lived intangible assets are amortized over their estimated useful lives, generally for periods ranging from five to 20 years. The reasonableness of the useful lives of these assets is continually evaluated. The Company does not have any indefinite-lived intangible assets.

- Definition

The entire disclosure for the aggregate amount of goodwill and a description of intangible assets, which may include (a) for amortizable intangible assets (also referred to as finite-lived intangible assets), the carrying amount, the amount of any significant residual value, and the weighted-average amortization period, (b) for intangible assets not subject to amortization (also referred to as indefinite-lived intangible assets), the carrying amount, and (c) the amount of research and development assets acquired and written off in the period, including the line item in the income statement in which the amounts written off are aggregated, if not readily apparent from the income statement. Also discloses (a) for amortizable intangibles assets in total and by major class, the gross carrying amount and accumulated amortization, the total amortization expense for the period, and the estimated aggregate amortization expense for each of the five succeeding fiscal years, (b) for intangible assets not subject to amortization the carrying amount in total and by major class, and (c) for goodwill, in total and for each reportable segment, the changes in the carrying amount of goodwill during the period (including the aggregate amount of goodwill acquired, the aggregate amount of impairment losses recognized, and the amount of goodwill included in the gain (loss) on disposal of a reporting unit). If any part of goodwill has not been allocated to a reportable segment, discloses the unallocated amount and the reasons for not allocating. For each impairment loss recognized related to an intangible asset (excluding goodwill), discloses: (a) a description of the impaired intangible asset and the facts and circumstances leading to the impairment, (b) the amount of the impairment loss and the method for determining fair value, (c) the caption in the income statement or the statement of activities in which the impairment loss is aggregated, and (d) the segment in which the impaired intangible asset is reported. For each goodwill impairment loss recognized, discloses: (a) a description of the facts and circumstances leading to the impairment, (b) the amount of the impairment loss and the method of determining the fair value of the associated reporting unit, and (c) if a recognized impairment loss is an estimate not finalized and the reasons why the estimate is not final. May also disclose the nature and amount of any significant adjustments made to a previous estimate of an impairment loss.

+ References + Details

Other Assets

12 Months Ended

Dec. 31, 2017

Deferred Costs Capitalized Prepaid And Other Assets Disclosure [Abstract]

Other Assets

Note 15. Other Assets

The following table sets forth the components of the Company’s other assets at December 31, 2017 and 2016.

	December 31,
	2017		2016
Capitalized repair and maintenance costs	$	117	$	145
Pension assets (1)		260		159
Deferred income taxes		40		41
Asset held for sale (2)		—		29
Miscellaneous (3)		36		43
Total other assets	$	453	$	417

(1)

Pension assets represent the funded status of certain of the Company’s long-term employee benefit plans.

(2)

Asset held for sale at December 31, 2016 represents the Company’s corporate headquarters building located in Wilmington, Delaware, which was sold in 2017.

(3)

Miscellaneous includes deferred financing fees related to the Company’s senior secured revolving credit facility of $9 and $13 at December 31, 2017 and 2016, respectively.

Accounts Payable

12 Months Ended

Dec. 31, 2017

Payables And Accruals [Abstract]

Accounts Payable

Note 16. Accounts Payable

The following table sets forth the components of the Company’s accounts payable at December 31, 2017 and 2016.

	December 31,
	2017		2016
Trade payables	$	1,008	$	858
Dividends payable (1)		31		—
VAT and other payables		36		26
Total accounts payable	$	1,075	$	884

(1)

Represents a $0.17 per share dividend declared in December 2017, which will be paid on March 15, 2018 to the Company’s shareholders of record as of the close of business on February 15, 2018.

Other Accrued Liabilities

12 Months Ended

Dec. 31, 2017

Payables And Accruals [Abstract]

Other Accrued Liabilities

Note 17. Other Accrued Liabilities

The following table sets forth the components of the Company’s other accrued liabilities at December 31, 2017 and 2016.

	December 31,
	2017		2016
Compensation and other employee-related costs	$	174	$	154
Employee separation costs (1)		27		31
Accrued litigation (2)		13		344
Environmental remediation (3)		66		71
Income taxes		58		39
Customer rebates		83		53
Deferred revenue (4)		8		76
Accrued interest		24		21
Miscellaneous (5)		105		83
Total other accrued liabilities	$	558	$	872

(1)

Represents the current portion of accrued employee separation costs related to the Company’s restructuring activities.

(2)

Accrued litigation includes a $335 litigation accrual related to Company’s PFOA MDL Settlement at December 31, 2016, which is discussed further in Note 20. The Company made payments of $15 and $320 during the second and third quarters of 2017 for a full release of all claims by the settling plaintiffs.

(3)

Represents the current portion of accrued environmental remediation, which is discussed further in Note 20.

(4)

Deferred revenue includes a $58 prepayment from DuPont for specified goods and services at December 31, 2016, which were fulfilled and/or delivered during 2017.

(5)

Miscellaneous primarily includes accrued utility expenses, property taxes, an accrued indemnification liability, the current portion of the Company’s asset retirement obligations, and other miscellaneous expenses.

Debt

12 Months Ended

Dec. 31, 2017

Debt Disclosure [Abstract]

Debt

Note 18. Debt

The following table sets forth the components of the Company’s total debt at December 31, 2017 and 2016.

	December 31,
	2017			2016
Senior secured term loans:
Tranche B term loan due May 2022	$	—		$	1,372
Tranche B-1 Dollar Term Loan due May 2022		923			—
Tranche B-1 Euro Term Loan due May 2022 (€394 at December 31, 2017)		469			—
Senior unsecured notes:
6.625% due May 2023		1,158			1,158
7.000% due May 2025		750			750
6.125% due May 2023 (€295 at December 31, 2017 and 2016)		350			308
5.375% due May 2027		500			—
Capital lease obligations		3			3
Build-to-suit lease obligation		8			—
Total debt		4,161			3,591
Less: Unamortized issue discounts		(8	)		(5	)
Less: Unamortized debt issuance costs		(41	)		(42	)
Less: Current maturities of long-term debt		(15	)		(15	)
Total long-term debt, net	$	4,097		$	3,529

Senior Secured Credit Facilities

On May 12, 2015, Chemours entered into a credit agreement that provides for a seven-year senior secured term loan in an aggregate principal amount of $1,500, which is repayable in equal quarterly installments at a rate of 1% of the original principal amount per annum, with the balance payable at maturity (Prior Term Loan). The Prior Term Loan was issued with a $7 original issue discount and bore interest at a rate of LIBOR plus 3.0%, subject to a LIBOR floor of 0.75%. The proceeds from the Prior Term Loan were used to fund a portion of the distribution to DuPont, along with certain related fees and expenses.

The credit agreement, as amended, also provides for a five-year, $750 senior secured revolving credit facility (Revolving Credit Facility). The proceeds of any loans made under the Revolving Credit Facility can be used for capital expenditures, acquisitions, working capital needs, and other general corporate purposes. No borrowings were outstanding under the Revolving Credit Facility at December 31, 2017 and 2016; however, Chemours had $101 and $132 in letters of credit issued and outstanding under this facility at December 31, 2017 and 2016, respectively. The Revolving Credit Facility bears variable interest of a range based on Chemours’ total net leverage ratio between (i) a 0.50% and 1.25% spread for base rate loans and (ii) a 1.50% and 2.25% spread for LIBOR loans. The applicable margins were 0.50% for base rate loans and 1.50% for LIBOR loans at December 31, 2017. In addition, the Company is required to pay a commitment fee on the average daily unused amount of the Revolving Credit Facility at a rate based on its total net leverage ratio, between 0.20% and 0.35%. At December 31, 2017, commitment fees were assessed at a rate of 0.20% per annum.

On April 3, 2017, the Company completed an amendment (April Amendment) to its credit agreement which provides for a new class of term loans, denominated in euros, in an aggregate principal amount of €400 (Euro Term Loan), and a new class of term loans, denominated in U.S. dollars, in an aggregate principal amount of $940 (Dollar Term Loan, and, collectively with the Euro Term Loan, the New Term Loans). The New Term Loans replaced in full the Prior Term Loan outstanding as of March 31, 2017. The New Term Loans mature on May 12, 2022, which is the same maturity date of the Prior Term Loan. The Euro Term Loan bears a variable interest rate equal to EURIBOR plus 2.25%, subject to a EURIBOR floor of 0.75%, and the Dollar Term Loan bears a variable interest rate equal to LIBOR plus 2.50%, subject to a LIBOR floor of 0.00%. The April Amendment also modified certain provisions of the credit agreement, including increased certain incurrence limits to allow further flexibility for the Company. All other provisions, including financial covenants, remained unchanged. No incremental debt was issued as a result of the April Amendment, although the Euro Term Loan is subject to remeasurement gains or losses. The Company recorded a $3 loss on debt extinguishment and related amendment fees in the second quarter of 2017. The effective interest rates on the Dollar Term Loan and the Euro Term Loan were approximately 3.85% and 3.00%, respectively, for the year ended December 31, 2017.

The credit agreement contains financial covenants which, solely with respect to the Revolving Credit Facility, as amended, require Chemours not to exceed a maximum senior secured net leverage ratio of: (i) 3.50 to 1.00 each quarter through December 31, 2016; (ii) 3.00 to 1.00 through June 30, 2017; and (iii) further decreasing by 0.25 to 1.00 every subsequent six months to 2.00 to 1.00 by January 1, 2019 and thereafter. Chemours is also required to maintain a minimum interest coverage ratio of 1.75 to 1.00 each quarter through June 30, 2017 and further increasing by 0.25 to 1.00 every subsequent six months to 3.00 to 1.00 by January 1, 2019 and thereafter. In addition, the credit agreement contains customary affirmative and negative covenants that, among other things, limit or restrict Chemours’ and its subsidiaries’ ability, subject to certain exceptions, to incur liens, merge, consolidate or sell, transfer or lease assets, make investments, pay dividends, transact with subsidiaries, and incur indebtedness. The credit agreement also contains customary representations and warranties and events of default. Chemours was in compliance with its debt covenants at December 31, 2017.

Chemours’ obligations under the Revolving Credit Facility and the New Term Loans (collectively, the Senior Secured Credit Facilities) are guaranteed on a senior secured basis by all of its material domestic subsidiaries, subject to certain agreed upon exceptions. The obligations under the Senior Secured Credit Facilities are also, subject to certain agreed upon exceptions, secured by a first lien on substantially all of Chemours’ and its material, wholly-owned domestic subsidiaries’ assets, including 100% of the stock of certain of its domestic subsidiaries and 65% of the stock of certain of its foreign subsidiaries.

Senior Unsecured Notes

On May 12, 2015, Chemours issued an aggregate principal amount of $2,503 in senior unsecured notes in a private placement (collectively, the Notes). The 2023 Notes, with an aggregate principal amount of $1,350, bear interest at a rate of 6.625% per annum and will mature on May 15, 2023, with all outstanding principal payable at maturity (2023 Notes). The 2025 Notes, with an aggregate principal amount of $750, bear interest at a rate of 7.000% per annum and will mature on May 15, 2025, with all outstanding principal payable at maturity (2025 Notes). The 2023 Notes, denominated in euros, with an aggregate principal amount of €360, bear interest at a rate of 6.125% per annum and will mature on May 15, 2023, with all outstanding principal payable at maturity (Euro Notes). Interest on the Notes is payable semi-annually in cash in arrears on May 15 and November 15 of each year. The proceeds from the Notes were used to fund the cash and in-kind distributions to DuPont and to pay any related fees and expenses. The in-kind distribution to DuPont in an aggregate principal amount of $507 of Chemours’ 2025 Notes were exchanged by DuPont with third-parties for certain of DuPont’s notes.

The Notes are fully and unconditionally guaranteed, jointly and severally, by Chemours’ existing and future subsidiaries that guarantee the Senior Secured Credit Facilities or that guarantee the Company’s other indebtedness or any of its guarantors’ indebtedness in an aggregate principal amount in excess of $75 million. The Notes are unsecured and unsubordinated by Chemours and its guarantor subsidiaries. The Notes rank equally in right of payment to all of Chemours’ existing and future unsecured unsubordinated debt and senior in right of payment to all of its existing and future debt that is by its terms expressly subordinated in right of payment to the Notes. The Notes are subordinated to indebtedness under the Senior Secured Credit Facilities as well as any future secured debt to the extent of the value of the assets securing such debt. The Company is obligated to offer to purchase the Notes at a price of (i) 101% of their principal amount, together with accrued and unpaid interest, if any, up to, but not including, the date of purchase, upon the occurrence of certain change of control events, and (ii) 100% of their principal amount, together with accrued and unpaid interest, if any, up to, but not including, the date of purchase, with the proceeds from certain asset dispositions. These restrictions and prohibitions are subject to certain qualifications and exceptions set forth in the indenture, including without limitation, reinvestment rights with respect to the proceeds of asset dispositions. Chemours is permitted to redeem some or all of the 2023 Notes and Euro Notes by paying a “make-whole” premium prior to May 15, 2018, and on or after May 15, 2018 and thereafter at specified redemption prices. Chemours may redeem some or all of the 2025 Notes on or after May 15, 2020 at specified redemption prices. Chemours may also redeem some or all of the Notes by means other than a redemption, including tender offer or open market purchases. Pursuant to the terms of the tax matters agreement entered into at the time of the Separation, the Company’s ability to pre-pay, pay down, redeem, retire, or otherwise acquire the 2025 Notes is limited in the absence of obtaining certain tax opinions.

In connection with the issuance of the Notes, Chemours entered into a registration rights agreement, in which Chemours agreed to file a registration statement with the U.S. Securities and Exchange Commission (SEC) for the exchange of the Notes for newly-registered notes with identical terms. On March 18, 2016, the Company filed a registration statement on Form S-4 with respect to the exchange offer, and the registration statement was declared effective on April 12, 2016. The exchange offer was completed on May 19, 2016. In addition, the Euro Notes were listed for trading on the Global Exchange Market of the Irish Stock Exchange on May 5, 2016.

On May 23, 2017, Chemours issued a $500 aggregate principal amount of 5.375% senior unsecured notes due May 2027 (2027 Notes). The 2027 Notes require payment of principal at maturity and interest semi-annually in cash and in arrears on May 15 and November 15 of each year. The Company received proceeds of $489, net of an original issue discount of $5 and underwriting fees and other related expenses of $6, which are deferred and amortized to interest expense using the effective interest method over the term of the 2027 Notes. A portion of the net proceeds from the 2027 Notes was used to pay the $335 accrued for the global settlement of the multi-district PFOA MDL Settlement, as discussed in Note 20. The remaining proceeds from the 2027 Notes were available for general corporate purposes. The offering of the 2027 Notes was registered under the Securities Act of 1933, as amended, under a registration statement on Form S-3 filed with the SEC on May, 4, 2017.

The 2027 Notes are fully and unconditionally guaranteed, jointly and severally, on a senior unsecured unsubordinated basis by each of Chemours’ existing and future domestic subsidiaries that (i) incurs or guarantees indebtedness under the Senior Secured Credit Facilities or (ii) guarantees other indebtedness of Chemours or any guarantor in an aggregate principal amount in excess of $100. The guarantees of the 2027 Notes will rank equally with all other senior indebtedness of the guarantors. The 2027 Notes rank equally in right of payment to all of Chemours’ existing and future unsecured unsubordinated debt and are senior in right of payment to all of its existing and future debt that is by its terms expressly subordinated in right of payment to the 2027 Notes. The 2027 Notes are subordinated to indebtedness under the Senior Secured Credit Facilities as well as any future secured debt to the extent of the value of the assets securing such debt, and structurally subordinated to the liabilities of any non-guarantor subsidiaries.

Chemours may redeem the 2027 Notes, in whole or in part, at an amount equal to 100% of the aggregate principal amount plus a specified “make-whole” premium and accrued and unpaid interest, if any, to the date of purchase prior to February 15, 2027. Chemours may also redeem some or all of the 2027 Notes by means other than a redemption, including tender offer and open market repurchases. Chemours is obligated to offer to purchase the 2027 Notes at a price of 101% of the principal amount, together with accrued and unpaid interest, if any, up to, but not including, the date of purchase, upon the occurrence of certain change of control events.

Build-to-suit Lease Obligation

In October 2017, Chemours executed a build-to-suit lease agreement to construct a new 312,000-square-foot R&D facility on the Science, Technology, and Advanced Research campus of the University of Delaware (UD) in Newark, Delaware (The Chemours Discovery Hub). The land on which The Chemours Discovery Hub will be located is leased to a third-party owner-lessor by UD, and Chemours will act as the construction agent and ultimate lessee of the facility based on the Company’s agreement with the owner-lessor. Project costs paid by the owner-lessor are reflected in the Company’s consolidated balance sheets as construction-in-progress within property, plant, and equipment, and a corresponding build-to-suit lease liability within long-term debt. Through December 31, 2017, project costs paid by the owner-lessor amounted to $8. Construction of The Chemours Discovery Hub is expected to be completed by early 2020.

Term Loans and Notes Repayments

During the year ended December 31, 2016, the Company repurchased or repaid portions of its Prior Term Loan, 2023 Notes, and Euro Notes with the aggregate principal and cash payment amounts set forth in the following table.

	Year Ended December 31, 2016
	Aggregate Principal		Cash Payments
Prior Term Loan (1)	$	105	$	104
2023 Notes		192		182
Euro Notes		73		68
	$	370	$	354

(1)

The Prior Term Loan’s aggregate principal amounts exclude the required quarterly installment repayments, which are equivalent to $15 per year.

For the years ended December 31, 2017, 2016, and 2015, Chemours recognized interest expense, net of $215, $213, and $132, respectively. Interest expense, net for the year ended December 31, 2016 includes a gain on extinguishment of debt of $10, net of $5 in charges related to the write-off of deferred financing costs associated with the extinguished debt.

Maturities

Chemours has required quarterly principal payments related to the New Term Loans equivalent to 1.00% per annum through March 2022, with the balance due at maturity. Principal maturities on the New Term Loans, as amended, over the next five years are approximately $14 in each year from 2018 to 2021, with the remaining principal of $1,336 due in 2022. Debt maturities related to the Notes in 2023 and beyond will be $2,758.

Following the end of each fiscal year commencing on the year ended December 31, 2016, on an annual basis, the Company is also required to make additional principal repayments, depending on leverage levels as defined in the credit agreement, equivalent to up to 50% of excess cash flows based on certain leverage targets with step-downs to 25% and 0% as actual leverage decreases to below a 3.00 to 1.00 leverage target. No principal repayments were required to be made in 2017 based upon the December 31, 2016 excess cash flows determined under the credit agreement.

Debt Fair Value

The fair values of the Dollar Term Loan, the Euro Term Loan, the 2023 Notes, the 2025 Notes, the Euro Notes, and the 2027 Notes at December 31, 2017 were approximately $928, $471, $1,228, $816, $373, and $521, respectively. The estimated fair values of the New Term Loans and the Notes are based on quotes received from third-party brokers, and are classified as Level 2 financial instruments in the fair value hierarchy.

Other Liabilities

12 Months Ended

Dec. 31, 2017

Other Liabilities Disclosure [Abstract]

Other Liabilities

Note 19. Other Liabilities

The following table sets forth the components of the Company’s other liabilities at December 31, 2017 and 2016.

	December 31,
	2017		2016
Environmental remediation (1)	$	187	$	208
Employee-related costs (2)		123		113
Employee separation costs		—		3
Accrued litigation (1)		48		53
Asset retirement obligations (1)		43		41
Deferred revenue		6		5
Miscellaneous (3)		68		101
Total other liabilities	$	475	$	524

(1)

The Company’s accrued environmental remediation, accrued litigation, and asset retirement obligations liabilities are discussed further in Note 20.

(2)

Employee-related costs primarily represent liabilities associated with the Company’s long-term employee benefits plans.

(3)

Miscellaneous primarily includes an accrued indemnification liability of $52 and $78 at December 31, 2017 and 2016, respectively.

Commitments and Contingent Liabilities

12 Months Ended

Dec. 31, 2017

Commitments And Contingencies Disclosure [Abstract]

Commitments and Contingent Liabilities

Note 20. Commitments and Contingent Liabilities

Guarantees

Obligations of Equity Affiliates and Others

Chemours has directly guaranteed certain obligations of its equity affiliates and customers. At December 31, 2017 and 2016, Chemours had directly guaranteed $2 and less than $1 of such obligations, respectively. These guarantees represent the maximum potential amount of future undiscounted payments that Chemours could be required to make under the guarantees in the event of default by the guaranteed parties. No amounts were accrued at December 31, 2017 and 2016.

Chemours assesses payment and performance risk by assigning default rates based on the duration of the guarantees. These default rates are assigned either (i) based on the external credit rating of the counterparty, or (ii) through internal credit analysis and historical default history for counterparties that do not have published credit ratings. For counterparties without an external rating or available credit history, a cumulative average default rate is used.

Operating Leases

Chemours uses various leased facilities and equipment in its operations. The terms for these leased assets vary depending on the lease agreement. Future minimum lease payments (including residual value guarantee amounts) under non-cancelable operating leases are $59, $52, $38, $33, and $37 for the years ended December 31, 2018, 2019, 2020, 2021, and 2022, respectively, and $268 for the years thereafter. Net rental expense under the Company’s operating leases was $76, $68, and $83 for the years ended December 31, 2017, 2016, and 2015, respectively.

Asset Retirement Obligations

Chemours has recorded asset retirement obligations, which are inclusive of costs related to closure, reclamation, and removal for mining operations in the production of TiO₂ in the Titanium Technologies segment; cap, cover, and post-closure maintenance of landfills in all segments; and shipment and disposal of stored waste in all segments.

The following table sets forth the activity in the Company’s asset retirement obligations for the years ended December 31, 2017 and 2016.

	Year Ended December 31,
	2017			2016
Balance at January 1,	$	43		$	42
Accretion expense		6			2
Settlements and payments		(1	)		(1	)
Balance at December 31,	$	48		$	43

Current portion	$	5		$	2
Non-current portion		43			41

Litigation

In addition to the matters discussed below, Chemours, by virtue of its status as a subsidiary of DuPont prior to the Separation, is subject to or required under the Separation-related agreements executed prior to the Separation to indemnify DuPont against various pending legal proceedings arising out of the normal course of Chemours’ business including product liability, intellectual property, commercial, environmental, and antitrust lawsuits. It is not possible to predict the outcomes of these various proceedings. Except for the litigation specific to PFOA (collectively, perfluorooctanoic acids and its salts, including the ammonium salt) and GenX and other perfluorinated and polyfluorinated compounds for which separate assessments are provided below, while management believes it is reasonably possible that Chemours could incur losses in excess of the amounts accrued, if any, for the aforementioned proceedings, it does not believe any such loss would have a material impact on Chemours’ consolidated financial position, results of operations, or liquidity. Disputes between Chemours and DuPont may also arise with respect to indemnification matters, including disputes based on matters of law or contract interpretation. If and to the extent these disputes arise, they could materially adversely affect Chemours.

Asbestos

In the Separation, DuPont assigned its asbestos docket to Chemours. At December 31, 2017 and 2016, there were approximately 1,600 and 1,900 lawsuits pending, respectively, against DuPont alleging personal injury from exposure to asbestos. These cases are pending in state and federal court in numerous jurisdictions in the U.S. and are individually set for trial. A small number of cases are pending outside the U.S. Most of the actions were brought by contractors who worked at sites between 1950 and the 1990s. A small number of cases involve similar allegations by DuPont employees or household members of contractors or DuPont employees. Finally, certain lawsuits allege personal injury as a result of exposure to DuPont products.

At December 31, 2017 and 2016, Chemours had an accrual of $38 and $41 related to this matter, respectively. Chemours reviews this estimate and related assumptions quarterly.

Benzene

In the Separation, DuPont assigned its benzene docket to Chemours. As of December 31, 2017 and 2016, there were 17 and 27 cases pending against DuPont alleging benzene-related illnesses, respectively. These cases consist of premises matters involving contractors and deceased former employees who claim exposure to benzene while working at DuPont sites primarily in the 1960s through the 1980s, and product liability claims based on alleged exposure to benzene found in trace amounts in aromatic hydrocarbon solvents used to manufacture DuPont products such as paints, thinners, and reducers.

A benzene case (Hood v. DuPont) was tried to a verdict in Texas state court on October 20, 2015. Plaintiffs alleged that Mr. Hood’s Acute Myelogenous Leukemia was the result of 24 years of occupational exposure to trace benzene found in DuPont automotive paint products and that DuPont negligently failed to warn him that its paints, reducers, and thinners contained benzene that could cause cancer or leukemia. The jury found in the plaintiffs’ favor, awarding $6.9 in compensatory damages and $1.5 in punitive damages. In March 2016, acting on the Company’s motion, the court struck the punitive award. Through DuPont, Chemours has filed an appeal on the remaining award based upon substantial errors made at the trial court level. Plaintiffs filed a cross appeal.

Management believes that a loss is reasonably possible related to these matters; however, given the evaluation of each benzene matter is highly fact-driven and impacted by disease, exposure, and other factors, a range of such losses cannot be reasonably estimated at this time.

PFOA

Prior to the fourth quarter of 2014, the performance chemicals segment of DuPont made PFOA at its Fayetteville, North Carolina plant and used PFOA as a processing aid in the manufacture of fluoropolymers and fluoroelastomers at certain sites including: Washington Works, Parkersburg, West Virginia; Chambers Works, Deepwater, New Jersey; Dordrecht Works, Netherlands; Changshu Works, China; and Shimizu, Japan. These sites are now owned and/or operated by Chemours.

Chemours recorded accruals of $14 and $349 related to the PFOA matters discussed below at December 31, 2017 and 2016, respectively. Specific to the PFOA MDL Settlement (also discussed below), the Company recorded an accrual of $335 at December 31, 2016, which was paid in installments of $15 and $320 during the second and third quarters of 2017, respectively.

These accruals also include charges related to DuPont’s obligations under agreements with the U.S. Environmental Protection Agency (EPA) and voluntary commitments to the New Jersey Department of Environmental Protection. These obligations and voluntary commitments include surveying, sampling, and testing drinking water in and around certain Company sites offering treatment or an alternative supply of drinking water if tests indicate the presence of PFOA in drinking water at or greater than the national health advisory. A provisional health advisory level was set by the EPA in 2009 at 0.4 parts per billion (ppb) that includes PFOA in drinking water. In May 2016, the EPA announced a health advisory level of 0.07 ppb that includes PFOA in drinking water. As a result, Chemours recorded an additional $4 in the second quarter of 2016 based on management’s best estimate of the impact of the new health advisory level on the Company’s obligations to the EPA, which have expanded the testing and water supply commitments previously established. Based on prior testing, the Company has initiated additional testing and treatment in certain additional locations in and around the Chambers Works and Washington Works plants. The Company will continue to work with the EPA regarding the extent of work that may be required with respect to these matters.

In February 2018, the State of Ohio initiated litigation against DuPont regarding historical PFOA emissions from the Washington Works site. Chemours is an additional named defendant. Ohio alleges damage to natural resources and seeks damages including remediation and other costs and punitive damages. This action is in its early stages and it is not possible at this point to predict the timing, course, or outcome.

Drinking Water Actions

In August 2001, a class action, captioned Leach v. DuPont, was filed in West Virginia state court alleging that residents living near the Washington Works facility had suffered, or may suffer, deleterious health effects from exposure to PFOA in drinking water.

DuPont and attorneys for the class reached a settlement in 2004 that binds about 80,000 residents. In 2005, DuPont paid the plaintiffs’ attorneys’ fees and expenses of $23 and made a payment of $70, which class counsel designated to fund a community health project. DuPont funded a series of health studies which were completed in October 2012 by an independent science panel of experts (C8 Science Panel). The studies were conducted in communities exposed to PFOA to evaluate available scientific evidence on whether any probable link exists, as defined in the settlement agreement, between exposure to PFOA and human disease. The C8 Science Panel found probable links, as defined in the settlement agreement, between exposure to PFOA and pregnancy-induced hypertension, including preeclampsia, kidney cancer, testicular cancer, thyroid disease, ulcerative colitis, and diagnosed high cholesterol.

In May 2013, a panel of three independent medical doctors released its initial recommendations for screening and diagnostic testing of eligible class members. In September 2014, the medical panel recommended follow-up screening and diagnostic testing three years after initial testing, based on individual results. The medical panel has not communicated its anticipated schedule for completion of its protocol. DuPont is obligated to fund up to $235 for a medical monitoring program for eligible class members and, in addition, administrative cost associated with the program, including class counsel fees. In January 2012, DuPont put $1 in an escrow account to fund medical monitoring as required by the settlement agreement. The court-appointed Director of Medical Monitoring established the program to implement the medical panel’s recommendations and the registration process, as well as eligibility screening, is ongoing. Diagnostic screening and testing is ongoing and associated payments to service providers are being disbursed from the escrow account. As of December 31, 2017, less than $1 has been disbursed from the escrow account related to medical monitoring. While it is probable that the Company will incur costs related to the medical monitoring program discussed above, such costs cannot be reasonably estimated due to uncertainties surrounding the level of participation by eligible class members and the scope of testing.

In addition, under the Leach settlement agreement, DuPont must continue to provide water treatment designed to reduce the level of PFOA in water to six area water districts and private well users. At Separation, this obligation was assigned to Chemours, which is included in the accrual amounts recorded as of December 31, 2017.

Under the Leach settlement, class members may pursue personal injury claims against DuPont only for those human diseases for which the C8 Science Panel determined a probable link exists. Approximately 3,500 lawsuits were filed in various federal and state courts in Ohio and West Virginia and consolidated in multi-district litigation (MDL) in Ohio federal court.

Settlement of MDL between DuPont and MDL Plaintiffs

In March 2017, DuPont entered into an agreement with the MDL plaintiffs’ counsel providing for a global settlement of all cases and claims in the MDL, including all filed and unfiled personal injury cases and claims that are part of the plaintiffs’ counsel’s claim inventory, as well as cases that have been tried to a jury verdict (MDL Settlement). The total settlement amount is $670.7 in cash, with half paid by Chemours and half paid by DuPont. DuPont’s payment was not subject to indemnification or reimbursement by Chemours, and Chemours accrued $335 associated with this matter at December 31, 2016. In exchange for payment of the total settlement amount, DuPont and Chemours received a complete release of all claims by the settling plaintiffs. The MDL Settlement was entered into solely by way of compromise and settlement and is not in any way an admission of liability or fault by DuPont or Chemours. As of September 30, 2017, Chemours had paid the full $335 accrued under the MDL Settlement.

Settlement between DuPont and Chemours Related to MDL

DuPont and Chemours agreed to a limited sharing of potential future PFOA costs (indemnifiable losses, as defined in the separation agreement between DuPont and Chemours) for a period of five years. During that five-year period, Chemours will annually pay future PFOA costs up to $25 and, if such amount is exceeded, DuPont will pay any excess amount up to the next $25 (which payment will not be subject to indemnification by Chemours), with Chemours annually bearing any further excess costs under the terms of the separation agreement. After the five-year period, this limited sharing agreement will expire, and Chemours’ indemnification obligations under the separation agreement will continue unchanged. Chemours has also agreed that it will not contest its indemnification obligations to DuPont under the separation agreement for PFOA costs on the basis of ostensible defenses generally applicable to the indemnification provisions under the separation agreement, including defenses relating to punitive damages, fines or penalties, or attorneys’ fees, and waives any such defenses with respect to PFOA costs. Chemours has, however, retained other defenses, including as to whether any particular PFOA claim is within the scope of the indemnification provisions of the separation agreement.

Post-MDL Settlement Injury Matters

There are a few plaintiffs who declined to participate in the MDL Settlement. The Company expects that these matters will be dismissed.

The MDL Settlement does not resolve PFOA personal-injury claims of plaintiffs who did not have cases or claims in the MDL or personal-injury claims based on diseases first diagnosed after February 11, 2017. Since the resolution of the MDL, personal-injury cases have been filed in West Virginia, Ohio, and New York courts. The New York matters, which are not part of the Leach class, are brought by three individual plaintiffs alleging negligence and other claims in the release of perfluorinated compounds, including PFOA, into drinking water, and seeking compensatory and punitive damages against current and former owners and suppliers of a manufacturing facility in Hoosick Falls, New York.

Management believes that the probability of loss is reasonably possible but not estimable at this time due to various reasons including, among others, that the proceedings are in early stages and there are significant factual issues to be resolved.

Centre Water

In May 2017, the Water Works and Sewer Board of the Town of Centre, Alabama filed suit against numerous carpet manufacturers located in Dalton, Georgia and suppliers and former suppliers, including DuPont, in Alabama state court. The complaint alleges negligence, nuisance, and trespass in the release of perfluorinated compounds, including PFOA, into a river leading to the town’s water source, and seeks compensatory and punitive damages. Management believes that the probability of loss is remote.

PFOA Summary

Chemours accrued $335 associated with the MDL Settlement at December 31, 2016, of which all $335 had been paid as of December 31, 2017. There could be additional lawsuits filed related to DuPont’s use of PFOA, its manufacture of PFOA, or its customers’ use of DuPont products that may not be within the scope of the MDL Settlement. Any such litigation could result in Chemours incurring additional costs and liabilities. Management believes it is reasonably possible that the Company could incur losses related to other PFOA matters in excess of amounts accrued, but any such losses are not estimable at this time due to various reasons including, among others, that such matters are in early stages and have significant factual issues to be resolved.

U.S. Smelter and Lead Refinery, Inc.

Six lawsuits, including one putative class action, are pending against DuPont by area residents concerning the U.S. Smelter and Lead Refinery multi-party Superfund site in East Chicago, Indiana. Five of the lawsuits allege that Chemours is now responsible for DuPont environmental liabilities. The lawsuits include allegations for personal injury damages, property diminution, and damages under the Comprehensive Environmental Response Compensation and Liability Act (CERCLA, often referred to as Superfund). At Separation, DuPont assigned Chemours its former plant site, which is located south of the residential portion of the Superfund area, and its responsibility for the environmental remediation at the Superfund site. DuPont has requested that Chemours defend and indemnify it, and Chemours has agreed to do so under a reservation of rights. Management believes a loss is reasonably possible, but not estimable at this time due to various reasons including, among others, that such matters are in early stages and have significant factual issues to be resolved.

GenX and Other Perfluorinated and Polyfluorinated Compounds

As reported in the press and noted in public statements by the Company, governmental agencies and local community members have made inquiries and engaged in discussions with the Company with respect to the discharge of the polymerization processing aid HFPO Dimer Acid (sometimes referred to as GenX or C3 Dimer) and perfluorinated and polyfluorinated compounds from the Company’s facility in Fayetteville, North Carolina into the Cape Fear River, groundwater, and air. The Company believes that such discharges have not impacted the safety of drinking water in North Carolina. The Company has commenced capturing and separately disposing process wastewater from the Fayetteville facility and is cooperating with a variety of ongoing inquiries and investigations from federal, state, and local authorities, regulators, and other governmental entities, including responding to three federal grand jury subpoenas.

In September 2017, the North Carolina Department of Environmental Quality (NC DEQ) issued a 60-day notice of intent to suspend the permit for the Fayetteville facility and the State of North Carolina filed an action in North Carolina state court regarding the discharges seeking a temporary restraining order and preliminary injunction, as well as other relief including abatement and site correction. A partial consent order was entered partially resolving the State’s action in return for the Company’s agreement to continue and supplement the voluntary wastewater-disposal measures it had previously commenced and to provide certain information. In November 2017, NC DEQ informed the Company that it was suspending the process wastewater discharge permit for the Fayetteville facility. The Company thereafter commenced the capture and separate disposal of all process wastewater from the Fayetteville facility related to the Company’s own operations. The Company is continuing to cooperate with and discuss these matters with the State and NC DEQ, including as to issues raised by the State and NC DEQ relating to groundwater deposition and air emissions. It is possible that issues relating to groundwater deposition and/or air emissions could result in further litigation or regulatory demands with regard to the Fayetteville facility.

Civil actions have been filed against the Company and DuPont in North Carolina federal court relating to discharges from the Fayetteville site, including a consolidated action brought by water systems seeking damages and injunctive relief, and a consolidated purported class action seeking medical monitoring and property damage and/or other monetary and injunctive relief on behalf of the putative classes of property owners and residents in areas near or that draw drinking water from the Cape Fear River. It is possible that additional litigation may be filed against the Company and/or DuPont concerning the discharges. The Company believes it has valid defenses to such litigation including that the discharges did not impact the safety of drinking water or cause any damages or injury.

As these issues are in their early stages, however, it is not possible at this point to predict the timing, course, or outcome of the governmental and regulatory inquiries, the notice issued by NC DEQ, the action brought by North Carolina, and the other litigation, and it is possible that these matters could materially affect the Company’s results and operations. In addition, local communities, organizations, and federal and state regulatory agencies have raised questions concerning HFPO Dimer Acid at certain other manufacturing sites operated by the Company, and it is possible that similar developments to those described above and centering on the Fayetteville site could arise in other locations.

Environmental

Chemours, by virtue of its status as a subsidiary of DuPont prior to the Separation, is subject to contingencies pursuant to environmental laws and regulations that in the future may require further action to correct the effects on the environment of prior disposal practices or releases of chemical substances by Chemours or other parties. Much of this liability results from CERCLA, the Resource Conservation and Recovery Act and similar state and global laws. These laws require Chemours to undertake certain investigative, remediation, and restoration activities at sites where Chemours conducts or once conducted operations or at sites where Chemours-generated waste was disposed. The accrual also includes estimated costs related to a number of sites identified for which it is probable that environmental remediation will be required, but which are not currently the subject of enforcement activities.

At December 31, 2017 and 2016, the consolidated balance sheets included a liability relating to these matters of $253 and $278, respectively, which, in management’s opinion, is appropriate based on existing facts and circumstances. The time-frame for a site to go through all phases of remediation (investigation and active clean-up) may take about 15 to 20 years, followed by several years of operation, maintenance, and monitoring (OM&M) activities. Remediation activities, including OM&M activities, vary substantially in duration and cost from site to site. These activities, and their associated costs, depend on the mix of unique site characteristics, evolving remediation technologies, diverse regulatory requirements, as well as the presence or absence of other potentially responsible parties. In addition, for claims that Chemours may be required to indemnify DuPont pursuant to the Separation-related agreements, Chemours, through DuPont, has limited available information for certain sites or is in the early stages of discussions with regulators. For these sites in particular, there may be considerable variability between the clean-up activities that are currently being undertaken or planned and the ultimate actions that could be required. Therefore, considerable uncertainty exists with respect to environmental remediation costs and, under adverse changes in circumstances, although deemed remote, the potential liability may range up to approximately $510 above the amount accrued at December 31, 2017.

For the years ended December 31, 2017, 2016, and 2015, Chemours incurred environmental remediation expenses of $48, $44, and $38, respectively.

Based on existing facts and circumstances, management does not believe that any loss, in excess of amounts accrued, related to remediation activities at any individual site will have a material impact on the Company’s financial position, results of operations, or cash flows in any given year, as such obligation can be satisfied or settled over many years.

Equity	12 Months Ended
Equity	Dec. 31, 2017
Stockholders Equity Note [Abstract]
Equity	Note 21. Equity Share Repurchase Program On November 30, 2017, the Company’s board of directors approved a share repurchase program authorizing the purchase of shares of Chemours’ issued and outstanding common stock in an aggregate amount not to exceed $500, plus any associated fees or costs in connection with the Company’s share repurchase activity. Under the share repurchase program, shares of Chemours’ common stock may be purchased on the open market from time to time, subject to management’s discretion, as well as general business and market conditions. The Company’s share repurchase program became effective on November 30, 2017 and continues through its expiration on December 31, 2020. The program may be suspended or discontinued at any time. All common shares purchased under the share repurchase program are held as treasury stock and are accounted for using the cost method. As of December 31, 2017, the Company purchased 2,386,406 shares of Chemours’ issued and outstanding common stock under the share repurchase program, which amounted to $116 at an average share price of $48.81 per share. Of the 2,386,406 shares purchased by Chemours, 206,106 shares amounting to $10 settled subsequent to December 31, 2017. All common shares purchased were part of the Company’s share repurchase program, which was announced to the public on December 1, 2017. The aggregate amount of Chemours’ common stock that remains available for purchase under the share repurchase program at December 31, 2017 is $384. Dividends Payable On November 30, 2017, the Company’s board of directors declared a cash dividend of $0.17 per share, payable to the record holders of Chemours’ issued and outstanding common stock as of the close of business on February 15, 2018. This dividend will be paid on March 15, 2018, and accordingly, the Company has accrued a dividend payable amounting to $31 at December 31, 2017.

Financial Instruments

12 Months Ended

Dec. 31, 2017

Derivative Instruments And Hedging Activities Disclosure [Abstract]

Financial Instruments

Note 22. Financial Instruments

Derivative Instruments

Objectives and Strategies for Holding Derivative Instruments

In the ordinary course of business, Chemours enters into contractual arrangements (derivatives) to reduce its exposure to foreign currency risks. The Company has established a derivative program to be utilized for financial risk management. This program reflects varying levels of exposure coverage and time horizons based on an assessment of risk. The derivative program has procedures consistent with Chemours’ financial risk management policies and guidelines.

Foreign Currency Forward Contracts

Chemours uses foreign currency forward contracts to reduce its net exposure, by currency, related to the non-functional currency-denominated monetary assets and liabilities of its operations so that exchange gains and losses resulting from exchange rate changes are minimized. These derivative instruments are not part of a cash flows hedge program or a fair value hedge program, and have not been designated as a hedge. Although all of the forward contracts are subject to an enforceable master netting agreement, Chemours has elected to present the derivative assets and liabilities on a gross basis on its consolidated balance sheets. No collateral has been required for these contracts. All gains and losses resulting from the revaluation of the derivative assets and liabilities are recognized in other income, net in the consolidated statements of operations during the period in which they occurred.

At December 31, 2017, there were no forward exchange currency contracts outstanding, and at December 31, 2016, there were 45 forward exchange currency contracts outstanding with an aggregate gross notional value of $518. Chemours recognized a net gain of $4 for the year ended December 31, 2017, a net loss of $15 for the year ended December 31, 2016, and a net gain of $42 for the year ended December 31, 2015, which are recorded in other income, net in the consolidated statements of operations.

Net Investment Hedge - Foreign Currency Borrowings

Chemours designated its Euro Notes and, beginning in April 2017, also designated its new Euro Term Loan as a hedge of its net investments in certain of its international subsidiaries that use the euro as their functional currency in order to reduce the volatility in stockholders’ equity caused by the changes in foreign currency exchange rates of the euro with respect to the U.S. dollar. Chemours uses the spot method to measure the effectiveness of its net investment hedge. For each reporting period, the change in the carrying value of the Euro Notes and the Euro Term Loan due to remeasurement of the effective portion are reported in accumulated other comprehensive loss on the consolidated balance sheets, and the remaining change in the carrying value of the ineffective portion, if any, is recognized in other income, net in the consolidated statements of operations. Chemours evaluates the effectiveness of its net investment hedge quarterly. Chemours did not record any ineffectiveness for the years ended December 31, 2017, 2016, or 2015. The Company recognized pre-tax losses of $86 and pre-tax gains of $14 and $8 on its net investment hedges within accumulated other comprehensive loss for the years ended December 31, 2017, 2016, and 2015, respectively.

Fair Value of Derivative Instruments

The following table sets forth the fair value of Chemours’ derivative assets and liabilities, and their level within the fair value hierarchy, at December 31, 2017 and 2016.

		Fair Value Using Level 2 Inputs
		December 31,
	Balance Sheet Location	2017		2016
Asset derivatives:
Foreign currency forward contracts	Accounts and notes receivable - trade, net	$	—	$	2
Total asset derivatives		$	—	$	2

Liability derivatives:
Foreign currency forward contracts	Other accrued liabilities	$	—	$	4
Total liability derivatives		$	—	$	4

The Company’s foreign currency forward contracts are classified as Level 2 financial instruments within the fair value hierarchy as the valuation inputs are based on quoted prices and market observable data of similar instruments. For derivative assets and liabilities, standard industry models are used to calculate the fair value of the various financial instruments based on significant observable market inputs, such as foreign exchange rates and implied volatilities obtained from various market sources. Market inputs are obtained from well-established and recognized vendors of market data, and are subjected to tolerance and/or quality checks.

Long-term Employee Benefits

12 Months Ended

Dec. 31, 2017

General Discussion Of Pension And Other Postretirement Benefits [Abstract]

Long-term Employee Benefits

Note 23. Long-term Employee Benefits

Plans Covering Employees in the U.S.

Chemours sponsors a variety of employee benefit plans, which cover substantially all U.S. employees. Prior to July 1, 2015, U.S. employees generally participated in DuPont’s primary pension plan, the Retirement Savings Plan (RSP), and certain other long-term employee benefit plans. In conjunction with the Separation on July 1, 2015, Chemours’ employees stopped participating in DuPont’s plans and became participants in newly-established Chemours plans. DuPont retained all liabilities related to its U.S. plans following the Separation.

On July 1, 2015, Chemours established a defined contribution plan, similar in design to DuPont’s RSP, which covered all eligible U.S. employees. The purpose of the plan is to encourage employees to save for their future retirement needs. The plan is a tax-qualified contributory profit-sharing plan, with cash or deferred arrangement, and any eligible employee of Chemours may participate. Chemours matches 100% of the first 6% of the employee’s contribution election, and the plan’s matching contributions vest immediately upon contribution. Chemours may also provide an additional discretionary retirement savings contribution to eligible employees’ compensation. The amount of this contribution, if any, is at the sole discretion of the Company, and the discretionary contribution vests for employees with at least three years of service. From time to time, Chemours provides additional discretionary retirement savings contributions to eligible employees’ compensation.

In lieu of a defined benefit plan, Chemours provides an enhanced 401(k) contribution for employees who previously participated in DuPont’s pension plan. The enhanced benefits consist of an additional contribution of 1% to 7% of the employee’s eligible compensation, depending upon the employee’s length of service with DuPont at the time of separation. The plan will continue until 2019, subject to early termination.

Plans Covering Employees Outside the U.S.

Pension coverage for employees of Chemours’ non-U.S. subsidiaries is provided, to the extent deemed appropriate, through separate plans established after the Separation and comparable to the DuPont plans in those countries. Obligations under such plans are either funded by depositing funds with trustees, covered by insurance contracts, or unfunded.

Participation in the Plans

Prior to July 1, 2015, Chemours participated in DuPont’s U.S. and non-U.S. plans (excluding plans in the Netherlands and Taiwan) as though they were participants in a multi-employer plan with the other businesses of DuPont.

The following table sets forth the multi-employer pension expense allocated by DuPont to Chemours for the plans in which Chemours participated prior to the Separation. The allocation of cost was based on active employee headcount and is included in the consolidated statements of operations. These amounts do not represent cash payments to DuPont or DuPont’s plans.

	EIN / Pension	Year Ended December 31,
Plan Name	Number	2017		2016		2015
DuPont Pension and Retirement Plan (U.S.)	51-0014090/001	$	—	$	—	$	48
All other U.S. and non-U.S. Plans			—		—		5

Single and Multi-employer Plans

Beginning in the first quarter of 2015, Chemours has accounted for the plans covering its employees in the Netherlands and Taiwan as a multi-employer plan and a single-employer plan, respectively. In the third quarter of 2015, in connection with the Separation, additional plans in Germany, Belgium, Japan, Korea, Mexico, and Switzerland were established. As of December 31, 2015, these plans were all accounted for as single-employer plans. Starting in 2017, DuPont exited the Netherlands plan, and the Company began accounting for the Netherlands plan as a single-employer plan.

The following table sets forth the Company’s net periodic pension income and amounts recognized in other comprehensive income (loss) for the years ended December 31, 2017, 2016, and 2015.

	Year Ended December 31,
	2017			2016			2015
Net periodic pension cost (income):
Service cost	$	16		$	14		$	16
Interest cost		16			19			19
Expected return on plan assets		(75	)		(63	)		(83	)
Amortization of actuarial loss		22			23			16
Amortization of prior service (credit) cost		(2	)		(1	)		4
Curtailment gain		—			(2	)		—
Settlement loss		1			5			—
Net periodic pension income		(22	)		(5	)		(28	)
Changes in plan assets and benefit obligations recognized in other comprehensive income (loss):
Net (gain) loss		(24	)		17			11
Amortization of actuarial loss		(24	)		(28	)		(16	)
Prior service credit		—			—			(24	)
Amortization of prior service credit (cost)		2			3			(4	)
Effect of foreign exchange rates		38			(15	)		(33	)
Benefit recognized in other comprehensive income (loss)		(8	)		(23	)		(66	)
Total net periodic pension income and benefit recognized in other comprehensive income (loss)	$	(30	)	$	(28	)	$	(94	)

The following table sets forth the pre-tax amounts recognized in accumulated other comprehensive loss for the years ended December 31, 2017, 2016, and 2015.

	Year Ended December 31,
	2017			2016			2015
Net loss	$	329		$	336		$	363
Prior service credit		(11	)		(11	)		(16	)
Total amount recognized in accumulated other comprehensive loss	$	318		$	325		$	347

The estimated pre-tax net loss and prior service credit for the defined benefit pension plans that will be amortized from accumulated other comprehensive loss into net periodic pension cost (income) during 2018 are $14 and $2, respectively.

The following table sets forth summarized information on the Company’s pension plans at December 31, 2017 and 2016.

	December 31,
	2017			2016
Change in benefit obligation:
Benefit obligation at beginning of year	$	1,105		$	1,103
Service cost		16			14
Interest cost		16			19
Plan participants’ contributions		2			2
Actuarial (gain) loss		(39	)		69
Benefits paid		(53	)		(36	)
Plan Amendments		(1	)		—
Curtailments		—			(3	)
Settlements and transfers		(3	)		(12	)
Other events		(4	)		(2	)
Currency translation		138			(49	)
Benefit obligation at end of year		1,177			1,105
Change in plan assets:
Fair value of plan assets at beginning of year		1,169			1,137
Actual return on plan assets		60			113
Employer contributions		38			16
Plan participants’ contributions		2			2
Benefits paid		(53	)		(36	)
Settlements and transfers		(3	)		(12	)
Other events		(3	)		—
Currency translation		153			(51	)
Fair value of plan assets at end of year		1,363			1,169
Total funded status at end of year	$	186		$	64

The following table sets forth the net amounts recognized in the Company’s consolidated balance sheets at December 31, 2017 and 2016.

	December 31,
	2017			2016
Non-current assets	$	258		$	159
Current liabilities		(1	)		(1	)
Non-current liabilities		(71	)		(94	)
Total net amount recognized	$	186		$	64

The accumulated benefit obligation for all pension plans was $1,112 and $1,042 as of December 31, 2017 and 2016, respectively.

The following tables set forth information related to the Company’s pension plans with projected and accumulated benefit obligations in excess of the fair value of plan assets at December 31, 2017 and 2016.

	December 31,
Pension plans with projected benefit obligation in excess of plan assets	2017		2016
Projected benefit obligation	$	178	$	183
Accumulated benefit obligation		149		152
Fair value of plan assets		106		87

	December 31,
Pension plans with accumulated benefit obligation in excess of plan assets	2017		2016
Projected benefit obligation	$	178	$	179
Accumulated benefit obligation		149		151
Fair value of plan assets		106		84

Assumptions

The Company generally utilizes discount rates that are developed by matching the expected cash flows of each benefit plan to various yield curves constructed from a portfolio of high quality, fixed income instruments provided by the plan’s actuary as of the measurement date. The expected rate of return on plan assets reflects economic assumptions applicable to each country.

The following tables set forth the assumptions that have been used to determine the Company’s benefit obligations and net benefit cost at December 31, 2017 and 2016.

	December 31,
Weighted average assumptions used to determine benefit obligations	2017			2016
Discount rate		1.9	%		1.8	%
Rate of compensation increase (1)		2.5	%		2.5	%

(1)

The rate of compensation increase represents the single annual effective salary increase that an average plan participant would receive during the participant’s entire career at Chemours.

	December 31,
Weighted average assumptions used to determine net benefit cost	2017			2016
Discount rate		1.8	%		2.4	%
Rate of compensation increase (1)		2.5	%		2.5	%
Expected return on plan assets		5.7	%		5.7	%

(1)

The rate of compensation increase represents the single annual effective salary increase that an average plan participant would receive during the participant’s entire career at Chemours.

Plan Assets

Each pension plan’s assets are invested through a master trust fund. The strategic asset allocation for the trust fund is selected by management, reflecting the results of comprehensive asset and liability modeling. Chemours establishes strategic asset allocation percentage targets and appropriate benchmarks for significant asset classes with the aim of achieving a prudent balance between return and risk. Strategic asset allocations in countries are selected in accordance with the laws and practices of those countries.

The following table sets forth the weighted-average allocation for the Company’s pension plan assets at December 31, 2017 and 2016.

	December 31,
	2017			2016
Cash and cash equivalents		4.8	%		2.5	%
U.S. and non-U.S. equity securities		42.6	%		41.6	%
Fixed income securities		52.6	%		55.9	%
Total weighted-average target allocation		100.0	%		100.0	%

Fixed income securities include corporate-issued, government-issued, and asset-backed securities. Corporate debt investments encompass a range of credit risk and industry diversification.

Fair value calculations may not be indicative of net realizable value or reflective of future fair values. Furthermore, although Chemours believes its valuation methods are appropriate and consistent with other market participants, the use of different methodologies or assumptions to determine the fair value of certain financial instruments could result in a different fair value measurement at the reporting date.

The following tables set forth the fair values of the Company’s pension assets by level within the fair value hierarchy at December 31, 2017 and 2016.

	Fair Value Measurements at December 31, 2017
	Total			Level 1		Level 2
Asset category:
Debt - government issued	$	505		$	1	$	504
Debt - corporate issued		144			24		120
Debt - asset backed		40			—		40
U.S. and non-U.S. equities		581			295		286
Derivatives - asset position		8			2		6
Derivatives - liability position		(1	)		—		(1	)
Cash and cash equivalents		65			65		—
Other		14			11		3
Total pension assets before pension receivables		1,356		$	398	$	958
Pension trust receivables, net (1)		7
Total pension assets	$	1,363

(1)

Receivables are primarily for investment income earned but not yet received.

	Fair Value Measurements at December 31, 2016
	Total			Level 1		Level 2
Asset category:
Debt - government issued	$	433		$	8	$	425
Debt - corporate issued		142			76		66
Debt - asset backed		42			25		17
U.S. and non-U.S. equities		502			28		474
Derivatives - asset position		3			—		3
Derivatives - liability position		(32	)		—		(32	)
Cash and cash equivalents		77			77		—
Other		7			—		7
Total pension assets before pension payables		1,174		$	214	$	960
Pension trust payables, net (1)		(5	)
Total pension assets	$	1,169

(1)

Payables are primarily for investment securities purchased.

For pension plan assets classified as Level 1 instruments within the fair value hierarchy, total fair value is either the price of the most recent trade at the time of the market close or the official close price, as defined by the exchange on which the asset is most actively traded on the last trading day of the period, multiplied by the number of units held without consideration of transaction costs.

For pension plan assets classified as Level 2 instruments within the fair value hierarchy, where the security is frequently traded in less active markets, fair value is based on the closing price at the end of the period; where the security is less frequently traded, fair value is based on the price a dealer would pay for the security or similar securities, adjusted for any terms specific to that asset or liability. Market inputs are obtained from well-established, recognized vendors of market data and subjected to tolerance and/or quality checks. For derivative assets and liabilities, standard industry models are used to calculate the fair value of the various financial instruments based on significant observable market inputs, such as foreign exchange rates, commodity prices, swap rates, interest rates, and implied volatilities obtained from various market sources.

Cash Flows

Defined Benefit Plan

For the years ended December 31, 2017 and 2016, Chemours contributed $38 and $16, respectively, to its defined benefit plans. DuPont contributed, on behalf of Chemours, $38 to its pension and other long-term benefit plans during the first half of 2015. Chemours contributed $8 to its pension plans during 2015.

Of the contributions made in 2017, $10 relates to the settlement of the U.S. Pension Restoration Plan (U.S. PRP), which was a supplemental pension plan for certain U.S. employees. The liability associated with the U.S. PRP was transferred to Chemours from DuPont at the Separation Date, at which point the plan ceased accepting new participants. In October 2017, the Company made a cash payment of $10 to settle the remaining liability attributable to the remaining participants in the U.S. PRP.

Chemours expects to contribute $15 to its pension plans in 2018.

The following table sets forth the benefit payments that are expected to be paid by the Company over the next five years and the five years thereafter as of December 31, 2017.

2018	$	45
2019		47
2020		48
2021		47
2022		48
2023 to 2027		262

Defined Contribution Plan

DuPont contributed, on behalf of Chemours, $26 to its defined contribution plans during the first half of 2015. From July 1 to December 31, 2015, Chemours contributed $28 to its defined contribution plan. For the years ended December 31, 2016 and 2017, Chemours contributed $44 and $45, respectively, to its defined contribution plan.

Stock-based Compensation

12 Months Ended

Dec. 31, 2017

Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]

Share-based Compensation

Note 24. Stock-based Compensation

Total stock-based compensation cost included in the consolidated statements of operations was $29, $20, and $17 for the years ended December 31, 2017, 2016, and 2015, respectively. The income tax provision for the year ended December 31, 2017 is inclusive of $22 in federal and state income tax benefits from windfalls on share-based payments due to the Company’s adoption of ASU No. 2016-09 during 2017.

Stock-based compensation expense prior to the Separation on July 1, 2015 was allocated to Chemours based on the portion of DuPont’s incentive stock program in which Chemours’ employees participated.

Adopted at the Separation, The Chemours Company Equity and Incentive Plan (Prior Plan) provided for grants to certain employees, independent contractors, or non-employee directors of the Company of different forms of awards, including stock options, RSUs, and PSUs. The Prior Plan had a maximum shares reserve of 13,500,000 for the grant of equity awards plus the number of shares of converted awards, as discussed below. As of December 31, 2016, 7,806,040 shares of the Prior Plan were still available for grants.

In accordance with the employee matters agreement between DuPont and Chemours, certain executives and employees were entitled to receive equity compensation awards of Chemours in replacement of previously outstanding awards granted under various DuPont stock incentive plans prior to the Separation. In connection with the Separation, these awards were converted into new Chemours equity awards using a formula designed to preserve the intrinsic value of the awards immediately prior to the Separation Date. At the date of conversion, the total intrinsic value of the converted options was $18. As a result of the conversion of these awards, the Company recorded a $3 incremental charge in the third quarter of 2015. The terms and conditions of the DuPont awards were replicated and, as necessary, adjusted to ensure that the vesting schedule and economic value of the awards were unchanged by the conversion.

On April 26, 2017, Chemours’ stockholders approved The Chemours Company 2017 Equity and Incentive Plan (2017 Plan), which replaces the Prior Plan in providing for grants to certain employees, independent contractors, or non-employee directors of the Company of different forms of awards, including stock options, RSUs, and PSUs. As a result, no further grants will be made under the Prior Plan.

A total of 19,000,000 shares of the Company’s common stock may be subject to awards granted under the 2017 Plan, less one share for every one share that was subject to an option or stock appreciation right granted after December 31, 2016 under the Prior Plan, and one-and-a-half shares for every one share that was subject to an award other than an option or stock appreciation right granted after December 31, 2016 under the Prior Plan. Any shares that are subject to options or stock appreciation rights will be counted against this limit as one share for every one share granted, and any shares that are subject to awards other than options or stock appreciation rights will be counted against this limit as one-and-a-half shares for every one share granted. Awards that were outstanding under the Prior Plan remain outstanding under the Prior Plan in accordance with their terms. Shares underlying awards granted under the Prior Plan after December 31, 2016 that are forfeited, cancelled, or that otherwise do not result in the issuance of shares, will be available for issuance under the 2017 Plan. At December 31, 2017, 17,677,641 shares of equity and incentive plan reserve are available for grants under the 2017 Plan.

The Chemours Compensation Committee determines the long-term incentive mix, including stock options, RSUs, and PSUs, and may authorize new grants annually.

Stock Options

In connection with the Separation from DuPont, Chemours granted non-qualified stock options to certain employees in July 2015, which represented replacement of previously granted performance stock unit awards at DuPont. The July 2015 grant will cliff vest March 1, 2018 and expire 10 years from the date of grant. Other than those options, Chemours’ expense for the year ended December 31, 2015 was entirely related to options granted to replace outstanding option awards from DuPont that were converted to Chemours’ options on July 1, 2015.

During 2016 and 2017, Chemours granted non-qualified stock options to certain of its employees, which will serially vest over a three-year period and expire 10 years from the date of grant.

The following table sets forth the weighted-average assumptions used to determine expense related to stock option awards granted during the years ended December 31, 2017, 2016, and 2015.

	Year Ended December 31,
	2017			2016			2015
Risk-free interest rate		2.14	%		1.46	%		1.50	%
Expected term (years)		6.00			6.00			5.40
Volatility		44.49	%		60.00	%		42.00	%
Dividend yield		0.35	%		2.14	%		6.90	%
Fair value per stock option	$	15.21		$	3.41		$	3.17

The Company determined the dividend yield by dividing the expected annual dividend on the Company's stock by the option exercise price. A historical daily measurement of volatility is determined based on the average volatility of peer companies adjusted for the Company’s debt leverage. The risk-free interest rate is determined by reference to the yield on an outstanding U.S. Treasury note with a term equal to the expected life of the option granted. The expected life is determined using a simplified approach, calculated as the mid-point between the graded vesting period and the contractual life of the award.

The following table sets forth Chemours’ stock option activity for the year ended December 31, 2017.

	Number of Shares (in thousands)			Weighted-average Exercise Price (per share)		Weighted-average Remaining Contractual Term (in years)		Aggregate Intrinsic Value (in thousands)
Outstanding, December 31, 2016		7,969		$	13.72		5.08	$	66,668
Granted		878			34.84
Exercised		(2,173	)		14.36
Forfeited		(47	)		20.55
Expired		(30	)		12.29
Outstanding, December 31, 2017		6,597		$	15.72		5.11	$	226,524
Exercisable, December 31, 2017		3,599		$	14.00		3.46	$	129,800

The aggregate intrinsic values in the table above represent the total pre-tax intrinsic value (the difference between the Company's closing stock price on the last trading day at the end of the quarter and the exercise price, multiplied by the number of in-the-money options) that would have been received by the option holders had all option holders exercised their in-the-money options at quarter-end. The amount changes based on the fair market value of the Company’s stock. The total intrinsic value of all options exercised for the years ended December 31, 2017 and 2016 amounted to $49 and $9, respectively. The total intrinsic value of all options exercised for the year ended December 31, 2015 was insignificant.

At December 31, 2017, $6 of total unrecognized compensation cost related to stock options is expected to be recognized over a weighted-average period of 2.00 years.

Restricted Stock Units

In the years following the Separation, as well as at the time of Separation in accordance with the employee matters agreement, Chemours granted RSUs to key management employees that generally vest over a three-year period and, upon vesting, convert one-for-one to Chemours’ common stock. The fair value of all stock-settled RSUs is based upon the market price of the underlying common stock as of the grant date.

Non-vested awards of RSUs primarily include awards without a performance condition, as well as a small subset of awards for which specific levels of cost savings and revenue enhancements must be achieved for vesting to occur. The following table sets forth non-vested RSUs, both with and without a performance condition, at December 31, 2017.

	Number of Shares (in thousands)			Weighted-average Grant Date Fair Value (per share)
Non-vested, December 31, 2016		2,316		$	11.23
Granted		214			36.68
Vested		(1,316	)		11.46
Forfeited		(49	)		14.27
Non-vested, December 31, 2017		1,165		$	15.34

At December 31, 2017, there was $5 of unrecognized stock-based compensation expense related to RSUs that is expected to be recognized over a weighted average period of 0.57 years.

Performance Share Units

Beginning in 2016, Chemours issued PSUs to key senior management employees which, upon vesting, convert one-for-one to Chemours’ common stock if specified performance goals, including certain market-based conditions, are met over the three-year performance period specified in the grant, subject to exceptions through the respective vesting period of three years. Each grantee is granted a target award of PSUs, and may earn between 0% and 200% of the target amount depending on the Company’s performance against stated performance goals.

The following table sets forth non-vested PSUs at 100% of target amounts at December 31, 2017.

	Number of Shares (in thousands)			Weighted-average Grant Date Fair Value (per share)
Non-vested, December 31, 2016		803		$	6.10
Granted		211			40.30
Vested		—			—
Forfeited		(27	)		16.62
Non-vested, December 31, 2017		987		$	12.94

A portion of the fair value of PSUs was estimated at the grant date based on the probability of satisfying the market-based conditions associated with the PSUs using the Monte Carlo valuation method, which assesses probabilities of various outcomes of market conditions. The other portion of the fair value of the PSUs is based on the fair market value of the Company’s stock at the grant date, regardless of whether the market-based condition is satisfied. The per unit weighted-average fair value at the date of grant for PSUs granted during the year ended December 31, 2017 was $40.30. The fair value of each PSU grant is amortized monthly into compensation expense based on its respective vesting conditions over four equally weighted measurement periods, three of which are annual and one of which is cumulative. Compensation cost is incurred based on the Company’s estimate of the final expected value of the award, which is adjusted as required for the portion based on the performance-based condition. The Company assumes that forfeitures will be minimal and recognizes forfeitures as they occur, which results in a reduction in compensation expense. As the payout of PSUs includes dividend equivalents, no separate dividend yield assumption is required in calculating the fair value of the PSUs.

At December 31, 2017, based on the Company’s assessment of its performance goals for 2016 and 2017, approximately 700,000 additional shares may be awarded under the 2016 and 2017 grant awards.

Employee Stock Purchase Plan

On January 26, 2017, the Company’s board of directors approved The Chemours Company Employee Stock Purchase Plan (ESPP), which was approved by Chemours’ stockholders on April 26, 2017. Under the ESPP, a total of 7,000,000 shares of Chemours’ common stock are reserved and authorized for issuance to participating employees, as defined by the ESPP, which excludes executive officers of the Company. The ESPP provides for consecutive 12-month offering periods, each with four purchase periods beginning and ending on the calendar quarters within those offering periods. The initial offering period under the ESPP began on October 2, 2017. Participating employees are eligible to purchase the Company’s common stock at a discounted rate equal to 95% of its fair value on the last trading day of each purchase period. In January 2018, the Company executed an open market transaction to purchase Company stock on behalf of ESPP participants. Total purchases amounted to less than $1, which was used to purchase 11,894 shares.

Geographic and Segment Information

12 Months Ended

Dec. 31, 2017

Segments Geographical Areas [Abstract]

Geographic and Segment Information

Note 25. Geographic and Segment Information

Geographic Information

	Year Ended December 31,
	2017				2016				2015
	Net Sales (1)		Property, Plant, and Equipment, Net		Net Sales (1)		Property, Plant, and Equipment, Net		Net Sales (1)		Property, Plant, and Equipment, Net
North America	$	2,255	$	2,018	$	2,288	$	1,861	$	2,570	$	2,184
Asia Pacific		1,593		131		1,315		129		1,393		136
Europe, the Middle East, and Africa		1,506		302		1,081		278		977		308
Latin America (2)		829		557		716		516		777		549
Total net sales and property, plant, and equipment, net	$	6,183	$	3,008	$	5,400	$	2,784	$	5,717	$	3,177

(1)

Net sales are attributed to countries based on customer location.

(2)

Latin America includes Mexico.

Segment Information

Chemours’ operations consist of three reportable segments based on similar economic characteristics, the nature of products and production processes, end-use markets, channels of distribution, and regulatory environments. Chemours’ reportable segments are: Titanium Technologies, Fluoroproducts and Chemical Solutions. The Titanium Technologies segment is a leading, global producer of TiO₂ pigment, a premium white pigment used to deliver whiteness, brightness, opacity, and protections in a variety of applications. The Fluoroproducts segment is a leading, global provider of fluoroproducts, including refrigerants and industrial fluoropolymer resins. The Chemical Solutions segment is a leading, North American provider of industrial chemicals used in gold production, industrials, and consumer applications. Corporate costs and certain legal and environmental expenses that are not allocated to the reportable segments and foreign exchange gains and losses are reflected in Corporate and Other.

Segment sales include transfers to another reportable segment. Certain products are transferred between segments on a basis intended to reflect, as nearly as practicable, the market value of the products. These product transfers were limited and were not significant for each of the periods presented. Depreciation and amortization includes depreciation on R&D facilities and amortization of other intangible assets, excluding write-down of assets. Segment net assets include net working capital, net property, plant, and equipment, and other non-current operating assets and liabilities of the segment. This is the measure of segment assets reviewed by the Company’s Chief Operating Decision Maker (CODM).

Adjusted earnings before interest, taxes, depreciation, and amortization (Adjusted EBITDA) is the primary measure of segment profitability used by the CODM and is defined as income (loss) before income taxes, excluding the following:

•

interest expense, depreciation, and amortization;

•

non-operating pension and other post-retirement employee benefit costs, which represent the components of net periodic pension (income) costs excluding the service cost component;

•

exchange (gains) losses included in other income (expense), net;

•

restructuring, asset-related charges, and other charges, net;

•

asset impairments;

•

(gains) losses on sale of business or assets; and,

•

other items not considered indicative of the Company’s ongoing operational performance and expected to occur infrequently.

The following table sets forth certain summary financial information for the Company’s reportable segments as of, and for the years ended December 31, 2017, 2016, and 2015.

Year Ended December 31,	Titanium Technologies		Fluoroproducts		Chemical Solutions		Corporate and Other			Total
2017
Net sales to external customers	$	2,958	$	2,654	$	571	$	—		$	6,183
Adjusted EBITDA		862		669		57		(166	)		1,422
Depreciation and amortization		118		109		18		28			273
Equity in earnings of affiliates		—		33		—		—			33
Net assets		1,785		1,842		460		(3,222	)		865
Investments in affiliates		—		173		—		—			173
Purchases of property, plant, and equipment		65		249		65		32			411

2016
Net sales to external customers	$	2,364	$	2,264	$	772	$	—		$	5,400
Adjusted EBITDA		466		445		39		(128	)		822
Depreciation and amortization		119		101		30		34			284
Equity in earnings of affiliates		—		26		—		3			29
Net assets		1,513		1,400		292		(3,101	)		104
Investments in affiliates		—		116		—		20			136
Purchases of property, plant, and equipment		105		120		104		9			338

2015
Net sales to external customers	$	2,392	$	2,230	$	1,095	$	—		$	5,717
Adjusted EBITDA		326		300		29		(82	)		573
Depreciation and amortization		125		88		52		2			267
Equity in earnings of affiliates		—		21		—		1			22
Net assets		1,659		1,567		839		(3,935	)		130
Investments in affiliates		—		127		—		9			136
Purchases of property, plant, and equipment		255		142		117		5			519

The following table sets forth a reconciliation of Adjusted EBITDA to the Company’s consolidated net income (loss) before income taxes for the years ended December 31, 2017, 2016, and 2015.

	Year Ended December 31,
	2017			2016			2015
Income (loss) before income taxes	$	912		$	(11	)	$	(188	)
Interest expense, net		215			213			132
Depreciation and amortization		273			284			267
Non-operating pension and other post-retirement employee benefit income		(34	)		(20	)		(3	)
Exchange (gains) losses		(3	)		57			(19	)
Restructuring charges		57			51			285
Asset-related charges (1)		3			124			73
(Gain) loss on sale of assets and businesses (2)		(22	)		(254	)		9
Transaction costs (3)		3			19			9
Legal and other charges (4)		18			359			8
Adjusted EBITDA	$	1,422		$	822		$	573

(1)

The year ended December 31, 2016 includes pre-tax impairment charges of $13 and $58 associated with the sales of the Company’s corporate headquarters building located in Wilmington, Delaware and Sulfur business, respectively, and $48 in pre-tax impairment charges associated with the Company’s aniline facility in Pascagoula, Mississippi, as well as certain other asset write-offs. The year ended December 31, 2015 includes pre-tax impairment charges of $45 associated with the Company’s RMS facility in Niagara Falls, New York, and $25 of goodwill impairment charges associated with its Sulfur business.

(2)

The year ended December 31, 2017 includes gains of $13 and $12 associated with the sale of the Company’s land in Repauno, New Jersey that was previously deferred and realized upon meeting certain milestones, and for the sale of its Edge Moor, Delaware plant site, respectively, net of certain losses on other disposals. The year ended December 31, 2016 includes gains of $169 and $89 associated with the sales of the Company’s C&D business and its aniline facility in Beaumont, Texas, respectively.

(3)

Includes accounting, legal, and bankers’ transaction fees incurred related to the Company’s strategic initiatives, which includes pre-sale transaction costs incurred in connection with the sales of the C&D and Sulfur businesses during 2016.

(4)

Includes litigation settlements, water treatment accruals, lease termination charges, and other expenses. The year ended December 31, 2016 includes $335 in litigation accruals associated with the PFOA MDL Settlement.

The Company’s net sales to external customers by product group for the years ended December 31, 2017, 2016, and 2015 are set forth in the following table.

	Year Ended December 31,
	2017		2016		2015
Titanium dioxide	$	2,958	$	2,364	$	2,392
Fluorochemicals		1,378		1,093		984
Fluoropolymers		1,276		1,171		1,246
Mining solutions		261		262		301
Performance chemicals and intermediates		306		298		363
Divested business (1)		4		212		431
Total net sales to external customers	$	6,183	$	5,400	$	5,717

(1)

Inclusive of the Company’s C&D and Sulfur businesses, as well as its aniline facility in Beaumont, Texas, which were all sold in 2016.

Accumulated Other Comprehensive Income (Loss)

12 Months Ended

Dec. 31, 2017

Equity [Abstract]

Accumulated Other Comprehensive Loss

Note 26. Accumulated Other Comprehensive Loss

The following table sets forth the components of accumulated other comprehensive loss, net of income taxes, for the years ended December 31, 2017, 2016, and 2015.

	Currency Translation Adjustment			Net Investment Hedge			Employee Benefits			Total
Balance at January 1, 2015	$	19		$	—		$	—		$	19
Assumption and establishment of pension plans, net		—			—			(311	)		(311	)
Other comprehensive (loss) income		(304	)		8			52			(244	)
Balance at December 31, 2015		(285	)		8			(259	)		(536	)
Other comprehensive (loss) income		(73	)		14			18			(41	)
Balance at December 31, 2016		(358	)		22			(241	)		(577	)
Other comprehensive income (loss)		200			(62	)		(3	)		135
Balance at December 31, 2017	$	(158	)	$	(40	)	$	(244	)	$	(442	)

Subsequent Event	12 Months Ended
Subsequent Event	Dec. 31, 2017
Subsequent Events [Abstract]
Subsequent Event	Note 27. Subsequent Event In connection with Chemours’ share repurchase program, the Company purchased an additional $34 of its issued and outstanding common stock in January 2018.

Quarterly Financial Data (Unaudited)

12 Months Ended

Dec. 31, 2017

Quarterly Financial Information Disclosure [Abstract]

Quarterly Financial Data (Unaudited)

Note 28. Quarterly Financial Data (Unaudited)

The following table sets forth a summary of the Company’s quarterly results of operations for the years ended December 31, 2017 and 2016.

	For the Three Months Ended
2017	March 31,		June 30,		September 30,		December 31,		Full Year (1),
Net sales	$	1,437	$	1,588	$	1,584	$	1,575	$	6,183
Cost of goods sold		1,079		1,147		1,117		1,087		4,429
Income before income taxes		173		225		250		264		912
Net income		151		161		207		228		747
Net income attributable to Chemours		150		161		207		228		746
Basic earnings per share of common stock		0.82		0.87		1.12		1.23		4.04
Diluted earnings per share of common stock		0.79		0.84		1.08		1.19		3.91

	For the Three Months Ended
2016	March 31,		June 30,			September 30,		December 31,			Full Year (1),
Net sales	$	1,297	$	1,383		$	1,398	$	1,322		$	5,400
Cost of goods sold		1,095		1,116			1,056		1,024			4,290
Income (loss) before income taxes		70		(41	)		234		(273	)		(11	)
Net income (loss)		51		(18	)		204		(230	)		7
Net income (loss) attributable to Chemours		51		(18	)		204		(230	)		7
Basic earnings (loss) per share of common stock		0.28		(0.10	)		1.12		(1.26	)		0.04
Diluted earnings (loss) per share of common stock		0.28		(0.10	)		1.11		(1.26	)		0.04

(1)

Individual quarters may not sum to full year amounts due to rounding.

Guarantor Condensed Consolidating Financial Information

12 Months Ended

Dec. 31, 2017

Organization Consolidation And Presentation Of Financial Statements [Abstract]

Guarantor Condensed Consolidating Financial Information

Note 29. Guarantor Condensed Consolidating Financial Information

The following guarantor financial information is included in accordance with Rule 3-10 of Regulation S-X (Rule 3-10) in connection with the issuance of the Notes by The Chemours Company (Parent Issuer). The Notes are fully and unconditionally guaranteed, jointly and severally, on a senior unsecured unsubordinated basis, in each case, subject to certain exceptions, by the Parent Issuer and by certain subsidiaries (together, the Guarantor Subsidiaries). Each of the Guarantor Subsidiaries is 100% owned by the Company. None of the other subsidiaries of the Company, either direct or indirect, guarantee the Notes (together, the Non-Guarantor Subsidiaries). The Guarantor Subsidiaries, excluding the Parent Issuer, will be automatically released from those guarantees upon the occurrence of certain customary release provisions.

The following condensed consolidating financial information is presented to comply with the Company’s requirements under Rule 3-10:

•

the consolidating statements of comprehensive income (loss) for the years ended December 31, 2017, 2016, and 2015;

•

the consolidating balance sheets at December 31, 2017 and 2016; and,

•

the consolidating statements of cash flows for the years ended December 31, 2017, 2016, and 2015.

Consistent with the discussion in Note 2, Chemours did not operate as a separate, stand-alone entity for all periods included within these condensed consolidating financial statements. Prior to the Separation on July 1, 2015, Chemours’ operations were included in DuPont’s financial results in different legal forms, including, but not limited to, wholly-owned subsidiaries for which Chemours was the sole business, components of legal entities in which Chemours operated in conjunction with other DuPont businesses, and a majority-owned joint venture. For periods prior to July 1, 2015, the condensed consolidating financial information has been prepared from DuPont’s historical accounting records and is presented on a stand-alone basis as if Chemours’ operations had been conducted independently from DuPont.

The condensed consolidating financial information is presented using the equity method of accounting for the Company’s investments in 100% owned subsidiaries. Under the equity method, the investments in subsidiaries are recorded at cost and adjusted for the Company’s share of its subsidiaries’ cumulative results of operations, capital contributions, distributions, and other equity changes. The elimination entries principally eliminate investments in subsidiaries and intercompany balances and transactions. The financial information included herein should be read in conjunction with the consolidated financial statements presented and the related notes.

As discussed in Note 7, the Company entered into a stock and asset purchase agreement with Lanxess, pursuant to which Lanxess acquired the Company’s C&D business which comprise certain assets and subsidiaries of the Company, including International Dioxide, Inc., which was a guarantor subsidiary.

Condensed Consolidating Statements of Comprehensive Income (Loss)

	Year Ended December 31, 2017
	Parent Issuer			Guarantor Subsidiaries		Non-Guarantor Subsidiaries			Eliminations and Adjustments			Consolidated
Net sales	$	—		$	3,887	$	4,030		$	(1,734	)	$	6,183
Cost of goods sold		—			3,084		3,036			(1,691	)		4,429
Gross profit		—			803		994			(43	)		1,754
Selling, general, and administrative expense		36			449		155			(38	)		602
Research and development expense		—			74		6			—			80
Restructuring and asset-related charges, net		—			56		1			—			57
Total expenses		36			579		162			(38	)		739
Equity in earnings of affiliates		—			—		33			—			33
Equity in earnings of subsidiaries		849			—		—			(849	)		—
Interest (expense) income, net		(221	)		3		3			—			(215	)
Intercompany interest income (expense), net		64			—		(64	)		—			—
Other income (expense), net		29			139		(55	)		(34	)		79
Income before income taxes		685			366		749			(888	)		912
(Benefit from) provision for income taxes		(62	)		117		114			(4	)		165
Net income		747			249		635			(884	)		747
Less: Net income attributable to non-controlling interests		—			—		1			—			1
Net income attributable to Chemours	$	747		$	249	$	634		$	(884	)	$	746
Comprehensive income attributable to Chemours	$	881		$	253	$	828		$	(1,081	)	$	881

Condensed Consolidating Statements of Comprehensive Income (Loss)

	Year Ended December 31, 2016
	Parent Issuer			Guarantor Subsidiaries			Non-Guarantor Subsidiaries			Eliminations and Adjustments			Consolidated
Net sales	$	—		$	3,749		$	3,222		$	(1,571	)	$	5,400
Cost of goods sold		—			3,218			2,615			(1,543	)		4,290
Gross profit		—			531			607			(28	)		1,110
Selling, general, and administrative expense		21			794			139			(20	)		934
Research and development expense		—			77			3			—			80
Restructuring and asset-related charges, net		—			168			2			—			170
Total expenses		21			1,039			144			(20	)		1,184
Equity in earnings of affiliates		—			4			25			—			29
Equity in earnings of subsidiaries		100			—			—			(100	)		—
Interest (expense) income, net		(211	)		(3	)		1			—			(213	)
Intercompany interest income (expense), net		60			4			(64	)		—			—
Other income, net		20			193			54			(20	)		247
(Loss) income before income taxes		(52	)		(310	)		479			(128	)		(11	)
(Benefit from) provision for income taxes		(59	)		(52	)		100			(7	)		(18	)
Net income (loss)		7			(258	)		379			(121	)		7
Less: Net income attributable to non-controlling interests		—			—			—			—			—
Net income (loss) attributable to Chemours	$	7		$	(258	)	$	379		$	(121	)	$	7
Comprehensive (loss) income attributable to Chemours	$	(34	)	$	(255	)	$	321		$	(66	)	$	(34	)

Condensed Consolidating Statements of Comprehensive Income (Loss)

	Year Ended December 31, 2015
	Parent Issuer			Guarantor Subsidiaries			Non-Guarantor Subsidiaries			Eliminations and Adjustments			Consolidated
Net sales	$	—		$	4,044		$	3,269		$	(1,596	)	$	5,717
Cost of goods sold		—			3,708			2,650			(1,596	)		4,762
Gross profit		—			336			619			—			955
Selling, general, and administrative expense		15			426			204			(13	)		632
Research and development expense		—			95			2			—			97
Restructuring and asset-related charges, net		—			295			38			—			333
Goodwill impairment		—			25			—			—			25
Total expenses		15			841			244			(13	)		1,087
Equity in earnings of affiliates		—			1			21			—			22
Equity in earnings of subsidiaries		(47	)		—			—			47			—
Interest expense, net		(131	)		(1	)		—			—			(132	)
Intercompany interest income (expense), net		44			—			(44	)		—			—
Other income (expense), net		13			92			(31	)		(20	)		54
(Loss) income before income taxes		(136	)		(413	)		321			40			(188	)
(Benefit from) provision for income taxes		(46	)		(89	)		40			(3	)		(98	)
Net (loss) income		(90	)		(324	)		281			43			(90	)
Less: Net income attributable to non-controlling interests		—			—			—			—			—
Net (loss) income attributable to Chemours	$	(90	)	$	(324	)	$	281		$	43		$	(90	)
Comprehensive (loss) income attributable to Chemours	$	(334	)	$	(324	)	$	29		$	295		$	(334	)

Condensed Consolidating Balance Sheets

	Year Ended December 31, 2017
	Parent Issuer		Guarantor Subsidiaries			Non-Guarantor Subsidiaries			Eliminations and Adjustments			Consolidated
Assets
Current assets:
Cash and cash equivalents	$	—	$	761		$	795		$	—		$	1,556
Accounts and notes receivable, net		—		308			611			—			919
Intercompany receivable		3		904			581			(1,488	)		—
Inventories		—		394			631			(90	)		935
Prepaid expenses and other		—		57			15			11			83
Total current assets		3		2,424			2,633			(1,567	)		3,493
Property, plant, and equipment		—		6,449			2,062			—			8,511
Less: Accumulated depreciation		—		(4,438	)		(1,065	)		—			(5,503	)
Property, plant, and equipment, net		—		2,011			997			—			3,008
Goodwill and other intangible assets, net		—		152			14			—			166
Investments in affiliates		—		—			173			—			173
Investment in subsidiaries		4,393		—			—			(4,393	)		—
Intercompany notes receivable		1,150		—			—			(1,150	)		—
Other assets		23		115			328			(13	)		453
Total assets	$	5,569	$	4,702		$	4,145		$	(7,123	)	$	7,293
Liabilities
Current liabilities:
Accounts payable	$	31	$	606		$	438		$	—		$	1,075
Current maturities of long-term debt		15		—			—			—			15
Intercompany payable		542		581			365			(1,488	)		—
Other accrued liabilities		34		343			181			—			558
Total current liabilities		622		1,530			984			(1,488	)		1,648
Long-term debt, net		4,087		10			—			—			4,097
Intercompany notes payable		—		—			1,150			(1,150	)		—
Deferred income taxes		—		127			105			(24	)		208
Other liabilities		—		388			87			—			475
Total liabilities		4,709		2,055			2,326			(2,662	)		6,428
Commitments and contingent liabilities
Equity
Total Chemours stockholders’ equity		860		2,647			1,814			(4,461	)		860
Non-controlling interests		—		—			5			—			5
Total equity		860		2,647			1,819			(4,461	)		865
Total liabilities and equity	$	5,569	$	4,702		$	4,145		$	(7,123	)	$	7,293

Condensed Consolidating Balance Sheets

	Year Ended December 31, 2016
	Parent Issuer		Guarantor Subsidiaries			Non-Guarantor Subsidiaries			Eliminations and Adjustments			Consolidated
Assets
Current assets:
Cash and cash equivalents	$	—	$	224		$	678		$	—		$	902
Accounts and notes receivable, net		—		299			508			—			807
Intercompany receivable		3		1,050			46			(1,099	)		—
Inventories		—		341			476			(50	)		767
Prepaid expenses and other		—		38			32			7			77
Total current assets		3		1,952			1,740			(1,142	)		2,553
Property, plant, and equipment		—		6,136			1,861			—			7,997
Less: Accumulated depreciation		—		(4,285	)		(928	)		—			(5,213	)
Property, plant, and equipment, net		—		1,851			933			—			2,784
Goodwill and other intangible assets, net		—		156			14			—			170
Investments in affiliates		—		—			136			—			136
Investment in subsidiaries		3,258		—			—			(3,258	)		—
Intercompany notes receivable		1,150		—			—			(1,150	)		—
Other assets		13		178			226			—			417
Total assets	$	4,424	$	4,137		$	3,049		$	(5,550	)	$	6,060
Liabilities
Current liabilities:
Accounts payable	$	—	$	573		$	311		$	—		$	884
Current maturities of long-term debt		15		—			—			—			15
Intercompany payable		762		46			291			(1,099	)		—
Other accrued liabilities		21		718			133			—			872
Total current liabilities		798		1,337			735			(1,099	)		1,771
Long-term debt, net		3,526		3			—			—			3,529
Intercompany notes payable		—		—			1,150			(1,150	)		—
Deferred income taxes		—		59			73			—			132
Other liabilities		—		428			96			—			524
Total liabilities		4,324		1,827			2,054			(2,249	)		5,956
Commitments and contingent liabilities
Equity
Total Chemours stockholders’ equity		100		2,310			991			(3,301	)		100
Non-controlling interests		—		—			4			—			4
Total equity		100		2,310			995			(3,301	)		104
Total liabilities and equity	$	4,424	$	4,137		$	3,049		$	(5,550	)	$	6,060

Condensed Consolidating Statements of Cash Flows

	Year Ended December 31, 2017
	Parent Issuer			Guarantor Subsidiaries			Non-Guarantor Subsidiaries			Eliminations and Adjustments			Consolidated
Cash flows from operating activities
Cash (used for) provided by operating activities	$	(133	)	$	603		$	169		$	—		$	639
Cash flows from investing activities
Purchases of property, plant, and equipment		—			(327	)		(84	)		—			(411	)
Proceeds from sales of assets and businesses, net		—			39			—			—			39
Intercompany investing activities		—			220			—			(220	)		—
Foreign exchange contract settlements, net		—			2			—			—			2
Cash used for investing activities		—			(66	)		(84	)		(220	)		(370	)
Cash flows from financing activities
Intercompany short-term repayments, net		(220	)		—			—			220			—
Proceeds from issuance of debt, net		495			—			—			—			495
Debt repayments		(27	)		—			—			—			(27	)
Payment of deferred financing fees		(6	)		—			—			—			(6	)
Purchases of treasury stock at cost		(106	)		—			—			—			(106	)
Proceeds from exercised stock options, net		31			—			—			—			31
Tax payments related to withholdings on vested restricted stock units		(12	)		—			—			—			(12	)
Payment of dividends		(22	)		—			—			—			(22	)
Cash provided by financing activities		133			—			—			220			353
Effect of exchange rate changes on cash and cash equivalents		—			—			32			—			32
Increase in cash and cash equivalents		—			537			117			—			654
Cash and cash equivalents at January 1,		—			224			678			—			902
Cash and cash equivalents at December 31,	$	—		$	761		$	795		$	—		$	1,556

Condensed Consolidating Statements of Cash Flows

	Year Ended December 31, 2016
	Parent Issuer			Guarantor Subsidiaries			Non-Guarantor Subsidiaries			Eliminations and Adjustments			Consolidated
Cash flows from operating activities
Cash (used for) provided by operating activities	$	(176	)	$	355		$	415		$	—		$	594
Cash flows from investing activities
Purchases of property, plant, and equipment		—			(233	)		(105	)		—			(338	)
Proceeds from sales of assets and businesses, net		—			591			117			—			708
Intercompany investing activities		—			(560	)		—			560			—
Investments in affiliates		—			—			(1	)		—			(1	)
Foreign exchange contract settlements, net		—			(12	)		—			—			(12	)
Cash (used for) provided by investing activities		—			(214	)		11			560			357
Cash flows from financing activities
Intercompany short-term borrowings, net		560			—			—			(560	)		—
Debt repayments		(369	)		(12	)		—			—			(381	)
Payment of deferred financing fees		(4	)		—			—			—			(4	)
Proceeds from exercised stock options, net		11			—			—			—			11
Payment of dividends		(22	)		—			—			—			(22	)
Cash provided by (used for) financing activities		176			(12	)		—			(560	)		(396	)
Effect of exchange rate changes on cash and cash equivalents		—			—			(19	)		—			(19	)
Increase in cash and cash equivalents		—			129			407			—			536
Cash and cash equivalents at January 1,		—			95			271			—			366
Cash and cash equivalents at December 31,	$	—		$	224		$	678		$	—		$	902

Condensed Consolidating Statements of Cash Flows

	Year Ended December 31, 2015
	Parent Issuer			Guarantor Subsidiaries			Non-Guarantor Subsidiaries			Eliminations and Adjustments			Consolidated
Cash flows from operating activities
Cash (used for) provided by operating activities	$	(119	)	$	171		$	121		$	9		$	182
Cash flows from investing activities
Purchases of property, plant, and equipment		—			(292	)		(227	)		—			(519	)
Proceeds from sales of assets and businesses, net		—			6			6			—			12
Intercompany investing activities		—			(202	)		—			202			—
Investments in affiliates		—			—			(32	)		—			(32	)
Foreign exchange contract settlements, net		—			42			—			—			42
Cash used for investing activities		—			(446	)		(253	)		202			(497	)
Cash flows from financing activities
Intercompany short-term borrowings, net		202			—			—			(202	)		—
Proceeds from issuance of debt, net		3,489			2			—			—			3,491
Debt repayments		(8	)		(2	)		—			—			(10	)
Payment of deferred financing fees		(79	)		—			—			—			(79	)
Cash provided at Separation by DuPont		—			87			160			—			247
Net transfers (to) from DuPont		(3,380	)		283			249			(9	)		(2,857	)
Payment of dividends		(105	)		—			—			—			(105	)
Cash provided by financing activities		119			370			409			(211	)		687
Effect of exchange rate changes on cash and cash equivalents		—			—			(6	)		—			(6	)
Increase in cash and cash equivalents		—			95			271			—			366
Cash and cash equivalents at January 1,		—			—			—			—			—
Cash and cash equivalents at December 31,	$	—		$	95		$	271		$	—		$	366

Summary of Significant Accounting Policies (Policies)	12 Months Ended
Summary of Significant Accounting Policies (Policies)	Dec. 31, 2017
Accounting Policies [Abstract]
Preparation of Financial Statements	Preparation of Financial Statements The consolidated financial statements have been prepared in conformity with GAAP, which requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the consolidated financial statements, and the reported amounts of revenues and expenses, including the allocations of costs as discussed above, during the reporting period. Management’s estimates are based on historical experiences, facts, and circumstances available at the time and various other assumptions that management believes are reasonable. Actual results could differ from those estimates.
Principles of Consolidation and Combination	Principles of Consolidation and Combination The consolidated financial statements include the accounts of Chemours and its subsidiaries, as well as entities in which a controlling interest is maintained. For those consolidated subsidiaries in which the Company’s ownership is less than 100%, the outside shareholders’ interests are shown as non-controlling interests. Investments in companies in which Chemours, directly or indirectly, owns 20% to 50% of the voting stock, or has the ability to exercise significant influence over the operating and financial policies of the investee, are accounted for using the equity method of accounting. As a result, Chemours’ share of the earnings or losses of such equity affiliates is included in the consolidated statements of operations, and Chemours’ share of such equity affiliates’ equity is included in the consolidated balance sheets. The financial statements for the periods prior to the Separation Date include the combined assets, liabilities, revenues, and expenses of Chemours. All intercompany accounts and transactions were eliminated in the preparation of the accompanying consolidated financial statements.
Revenue Recognition	Revenue Recognition Revenue is recognized when the earnings process is complete. Revenue for product sales is recognized when products are shipped to the customer in accordance with the terms of the agreement, title and risk of loss have been transferred, collectability is reasonably assured, and pricing is fixed or determinable. Revenue associated with advance payments are recorded as deferred revenue and are recognized as shipments are made and title, ownership, and risk of loss pass to the customer. Accruals are made for sales returns and other allowances based on historical experience. Cash sales incentives are accounted for as a reduction in sales, and non-cash sales incentives are recorded as a charge to cost of goods sold at the time that the revenue or selling expense, depending on the nature of the incentive, is recorded. Amounts billed to customers for shipping and handling fees are included in net sales, and costs incurred by Chemours for the delivery of goods are classified as cost of goods sold in the consolidated statements of operations. Taxes on revenue-producing transactions are excluded from net sales. Licensing and royalty income is recognized in accordance with agreed upon terms, when performance obligations are satisfied, the amount is fixed or determinable, and collectability is reasonably assured.
Research and Development Expense	Research and Development Expense Research and development (R&D) costs are expensed as incurred. R&D expenses include costs (primarily consisting of employee costs, materials, contract services, research agreements, and other external spend) relating to the discovery and development of new products, enhancement of existing products, and regulatory approval of new and existing products.
Provision for (Benefit from) Income Taxes	Provision for (Benefit from) Income Taxes The provision for (benefit from) income taxes is determined using the asset and liability approach of accounting for income taxes. Under this approach, deferred taxes represent the future tax consequences expected to occur when the reported amounts of assets and liabilities are recovered or paid. The provision for (benefit from) income taxes represents income taxes paid or payable for the current year, plus the change in deferred taxes during the year. Deferred taxes result from differences between the financial and tax bases of Chemours’ assets and liabilities and are adjusted for changes in tax rates and tax laws when changes are enacted. Valuation allowances are recorded to reduce deferred tax assets when it is more-likely-than-not that a tax benefit will not be realized. Chemours recognizes income tax positions that meet the more-likely-than-not threshold and accrues any interest related to unrecognized income tax positions as a component of other income, net in the consolidated statements of operations. Income tax-related penalties are included in the provision for (benefit from) income taxes. Chemours does not provide for income taxes on the undistributed earnings of all of its foreign subsidiaries that are intended to be indefinitely reinvested. Prior to the Separation, the amounts recorded for income taxes attributed certain current and deferred income taxes of DuPont to Chemours’ stand-alone financial statements in a manner that is systematic, rational, and consistent with the asset and liability method prescribed by Accounting Standards Codification Topic 740, Income Taxes (Topic 740). Accordingly, Chemours’ income tax provision was prepared following the separate return method. The separate return method applies Topic 740 to the stand-alone financial statements of each member of the consolidated group as if the group member were a separate taxpayer and a stand-alone enterprise.
Earnings Per Share	Earnings Per Share Chemours presents both basic earnings per share and diluted earnings per share. Basic earnings per share excludes dilution and is computed by dividing the total net income (loss) attributable to Chemours by the weighted-average number of shares outstanding for the period. Diluted earnings per share reflects the dilution that could occur if the Company’s outstanding stock-based compensation awards, including any unvested restricted shares, were vested and exercised, thereby resulting in the issuance of common stock as determined under the treasury stock method. In periods where the Company incurs a net loss, stock-based compensation awards are excluded from the calculation of earnings per share as their inclusion would have an anti-dilutive effect.
Cash and Cash Equivalents	Cash and Cash Equivalents Cash and cash equivalents generally include cash, time deposits, or highly liquid investments with original maturities of three months or less.
Receivables and Allowance for Doubtful Accounts	Receivables and Allowance for Doubtful Accounts Receivables are recognized net of an allowance for doubtful accounts. The allowance for doubtful accounts reflects the best estimate of losses inherent in Chemours’ receivables portfolio, which is determined on the basis of historical experience, specific allowances for known troubled accounts, and other available evidence. Receivables are written-off when management determines that they are uncollectible.
Inventories	Inventories Chemours’ U.S. inventories are valued at the lower of cost or market, as inventories held at substantially all U.S. locations are valued using the last-in, first-out (LIFO) method. Chemours’ non-U.S. inventories are valued at the lower of cost or net realizable value, as inventories held outside the U.S. are valued using the average cost method. The elements of cost in inventories include raw materials, direct labor, and manufacturing overhead. Stores and supplies are valued at the lower of cost or net realizable value. Cost is generally determined by the average cost method.
Property, Plant and Equipment	Property, Plant, and Equipment Property, plant, and equipment is carried at cost and is depreciated using the straight-line method. Property, plant, and equipment placed in service prior to 1995 is depreciated under the sum-of-the-years’ digits method, or other substantially-similar methods. Substantially all equipment and buildings are depreciated over useful lives ranging from 15 to 25 years. Capitalizable costs associated with computer software for internal use are amortized on a straight-line basis over five to seven years. When assets are surrendered, retired, sold, or otherwise disposed of, their gross carrying values and related accumulated depreciation are removed from the consolidated balance sheets and are included in the determination of any gain or loss on such disposals. Repair and maintenance costs that materially add to the value of the asset or prolong its useful life are capitalized and depreciated based on their extension to the asset’s useful life. Capitalized repair and maintenance costs are recorded on the consolidated balance sheets as a component of other assets.
Impairment of Long-Lived Assets	Impairment of Long-lived Assets Chemours evaluates the carrying value of its long-lived assets to be held and used when events or changes in circumstances indicate the carrying value may not be recoverable. For the purposes of recognition or measurement of an impairment charge, the assessment is performed on the asset or asset group at the lowest level for which identifiable cash flows are largely independent of the cash flows of other groups of assets and liabilities. To determine the level at which the assessment is performed, Chemours considers factors such as revenue dependency, shared costs, and the extent of vertical integration. The carrying value of a long-lived asset is considered impaired when the total projected undiscounted cash flows from the use and eventual disposition of the asset or asset group are separately identifiable and are less than its carrying value. In that event, a loss is recognized based on the amount by which the carrying value exceeds the fair value of the long-lived asset. The fair value methodology used is an estimate of fair market value, which is made based on prices of similar assets or other valuation methodologies, including present value techniques. Long-lived assets to be disposed of by means other than sale are classified as held for use until their disposal. Long-lived assets to be disposed of by sale are classified as held for sale and are reported at the lower of carrying amount or fair market value, less the estimated cost to sell. Depreciation is discontinued for any long-lived assets classified as held for sale.
Goodwill and Other Intangible Assets	Goodwill and Other Intangible Assets The excess of the purchase price over the estimated fair value of the net assets acquired in a business combination, including any identified intangible assets, is recorded as goodwill. Chemours tests its goodwill for impairment at least annually on October 1; however, these tests are performed more frequently when events or changes in circumstances indicate that the asset may be impaired. Goodwill is evaluated for impairment at the reporting unit level, which is defined as an operating segment, or one level below an operating segment. A reporting unit is the level at which discrete financial information is available and reviewed by business management on a regular basis. An impairment exists when the carrying value of a reporting unit exceeds its fair value. Chemours has the option to first qualitatively assess whether it is more-likely-than-not that an impairment exists for a reporting unit. Such qualitative factors include, among other things, prevailing macroeconomic conditions, industry and market conditions, changes in costs associated with raw materials, labor, or other inputs, the Company’s overall financial performance, and certain other entity-specific events that impact Chemours’ reporting units. When performing a quantitative assessment, the Company weights the results of an income-based valuation technique, the discounted cash flows method, and a market-based valuation technique, the guideline public companies method, to determine its reporting units’ fair value. Definite-lived intangible assets, such as purchased and licensed technology, patents, trademarks, and customer lists, are amortized over their estimated useful lives, generally for periods ranging from five to 20 years. The reasonableness of the useful lives of these assets is continually evaluated.
Defined Benefit Plans	Defined Benefit Plans Due to local regulations outside the U.S., Chemours has defined benefit plans covering certain of its employees. The benefits of these plans, which primarily relate to pension, are accrued over the employees’ service periods. The Company uses actuarial methods and assumptions in the valuation of its defined benefit obligations and the determination of any net periodic pension income or expense. Any differences between actual and expected results, or changes in the value of defined benefit obligations and plan assets, if any, are not recognized in earnings as they occur. Rather, they are systematically recognized over subsequent periods.
Derivatives	Derivatives Chemours enters into forward currency exchange contracts to minimize its volatility in earnings related to foreign exchange gains and losses, which result from remeasuring any net monetary assets denominated in non-functional currencies held by Chemours. Chemours does not hold or issue financial instruments for speculative or trading purposes. Derivative assets and liabilities are reported on a gross basis on the consolidated balance sheets. All gains and losses resulting from the revaluation of the Company’s derivative assets and liabilities are recognized in other income, net in the consolidated statements of operations during the period in which they occur.
Asset Retirement Obligations	Asset Retirement Obligations Chemours records its asset retirement obligations at their fair value at the time the liability is incurred. Fair value is measured using the expected future cash outflows discounted at Chemours’ credit-adjusted, risk-free interest rate, which is considered to be a Level 3 input within the fair value hierarchy. Accretion expense is recognized as an operating expense classified within cost of goods sold in the consolidated statements of operations using the credit-adjusted, risk-free interest rate in effect when the liability was recognized. The associated asset retirement obligations are capitalized as part of the carrying amount of the long-lived asset and depreciated over the estimated remaining useful life of the asset, generally for periods ranging from two to 30 years.
Insurance	Insurance Chemours insures for certain risks where permitted by law or regulation, including workers’ compensation, vehicle liability, and employee-related benefits. Liabilities associated with these risks are estimated in part by considering any historical claims experience, demographic factors, and other actuarial assumptions. For certain other risks, the Company uses a combination of third-party insurance and self-insurance, reflecting its comprehensive reviews of relevant risks. A receivable for an insurance recovery is generally recognized when the loss has occurred and collection is considered probable. Prior to the Separation, Chemours was a participant in DuPont’s self-insurance program where permitted by law or regulation, including workers’ compensation, vehicle liability, and employee-related benefits. Liabilities associated with these risks were estimated in part by considering any historical claims experience, demographic factors, and other actuarial assumptions. For other risks, a combination of third-party insurance and self-insurance was used, reflecting DuPont’s comprehensive reviews of relevant risks. The annual cost was allocated to all of the participating businesses using methodologies deemed reasonable by management. All obligations pursuant to these plans had historically been obligations of DuPont. As such, these obligations were not included in the consolidated balance sheets, with the exception of self-insurance liabilities related to workers’ compensation, vehicle liability, and employee-related benefits.
Litigation	Litigation Chemours accrues for legal matters when it is probable that a liability has been incurred and the amount of the liability can be reasonably estimated. Litigation-related liabilities and expenditures included in the consolidated financial statements represent legal matters that are liabilities of DuPont and its subsidiaries, which Chemours may be required to indemnify pursuant to the Separation-related agreements executed prior to the Separation. Legal costs, such as outside counsel fees and expenses, are charged to expense in the period that services are rendered.
Environmental Liabilities and Expenditures	Environmental Liabilities and Expenditures Chemours accrues for remediation activities when it is probable that a liability has been incurred and a reasonable estimate of the liability can be made. Where the available information is sufficient to estimate the amount of liability, that estimate has been used. Where the available information is only sufficient to establish a range of probable liability, and no point within the range is more likely than any other, the lower end of the range has been used. Estimated liabilities are determined based on existing remediation laws and technologies. Inherent uncertainties exist in such evaluations, primarily due to unknown environmental conditions, changing governmental regulations and legal standards regarding liability, and emerging remediation technologies. These accruals are adjusted periodically as remediation efforts progress and as additional technological, regulatory, and legal information become available. Environmental liabilities and expenditures include claims for matters that are liabilities of DuPont and its subsidiaries, which Chemours may be required to indemnify pursuant to the Separation-related agreements executed prior to the Separation. Accrued liabilities are undiscounted and do not include claims against third-parties, and are included in other accrued liabilities and other liabilities on the consolidated balance sheets. Costs related to environmental remediation are charged to expense in the period incurred, within cost of goods sold in the consolidated statements of operations. Other environmental costs are also charged to expense in the period incurred, unless they increase the value of the property or reduce or prevent contamination from future operations, in which case they are capitalized and amortized.
Treasury Stock	Treasury Stock Chemours accounts for repurchases of the Company’s common stock as treasury stock using the cost method, whereby the entire cost of the acquired common stock is recorded as treasury stock.
Stock-based Compensation	Stock-based Compensation Chemours’ stock-based compensation consists of stock options, restricted stock units (RSUs), and performance share units (PSUs) awarded to employees and non-employee directors. Stock options and PSUs are measured at their fair value on the grant date or date of modification, as applicable. RSUs are measured at the stock price on the grant date or date of modification, as applicable. The Company recognizes compensation expense on a straight-line basis over the requisite service and/or performance period, as applicable. Forfeitures of awards are accounted as a reduction in stock-based compensation expense in the period such awards are forfeited.
Foreign Currency Translation	Foreign Currency Translation Chemours identifies its separate and distinct foreign entities and groups them into two categories: (i) extensions of the parent (U.S. dollar functional currency); and, (ii) self-contained (local functional currency). If a foreign entity does not align with either category, factors are evaluated, and a judgment is made to determine the functional currency. Chemours changes the functional currency of its separate and distinct foreign entities only when significant changes in economic facts and circumstances clearly indicate that the functional currency has changed. During the periods covered by the consolidated financial statements, part of Chemours’ business operated within foreign entities. For foreign entities where the U.S. dollar is the functional currency, all foreign currency-denominated asset and liability amounts are remeasured into U.S. dollars at end-of-period exchange rates, with the exception of inventories, prepaid expenses, property, plant, and equipment, goodwill, and other intangible assets. These aforementioned assets are remeasured at historical rates. Foreign currency-denominated revenue and expense amounts are remeasured at average exchange rates in effect during the period, with the exception of expenses related to any balance sheet amounts remeasured at historical exchange rates. Exchange gains and losses arising from remeasurement of foreign currency-denominated monetary assets and liabilities are included in other income, net in the period in which they occur. For foreign entities where the local currency is the functional currency, assets and liabilities denominated in local currencies are translated into U.S. dollars at end-of-period exchange rates, and the resulting translation adjustments are reported as a component of accumulated other comprehensive loss within equity. Assets and liabilities denominated in currencies other than the functional currency are remeasured into the functional currency prior to translation into U.S. dollars, and the resulting exchange gains or losses are included in income in the period in which they occur. Revenues and expenses are translated into U.S. dollars at average exchange rates in effect during the period. During 2015, when Chemours’ operations were legally and operationally separated within DuPont in anticipation of the Separation, certain of Chemours’ foreign entities set their respective local currencies as the functional currency.
Fair Value Measurement	Fair Value Measurement Fair value is defined as the exit price, the price that would be received to sell an asset or transfer a liability in an orderly transaction between market participants at the measurement date. Under the accounting for fair value measurements and disclosures, a fair value hierarchy was established to prioritize the valuation inputs used to measure fair value. The hierarchy gives highest priority to unadjusted, quoted prices in active markets for identical assets and liabilities (Level 1 measurements) and lowest priority to unobservable inputs (Level 3 measurements). A financial instrument’s level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement. Chemours applies the following valuation hierarchy in measuring the fair values of its assets and liabilities: Level 1 – Quoted prices in active markets for identical assets and liabilities; Level 2 – Significant other observable inputs (e.g., quoted prices for similar items in active markets, quoted prices for identical or similar items in markets that are not active, inputs other than quoted prices that are observable, such as interest rate and yield curves, and market-corroborated inputs); and, Level 3 – Unobservable inputs for the asset or liability, which are valued based on management’s estimates of assumptions that market participants would use in pricing the asset or liability.
Recent Accounting Pronouncements	Recent Accounting Pronouncements Accounting Guidance Issued and Not Yet Adopted In May 2014, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) No. 2014-09, Revenue from Contracts with Customers (Topic 606) (ASU No. 2014-09). The objective of this standard is to remove inconsistent practices regarding revenue recognition between GAAP and International Financial Reporting Standards. The standard intends to improve the comparability of revenue recognition practices across entities, industries, jurisdictions, and capital markets. Subsequent to the issuance of ASU No. 2014-09, the FASB issued multiple clarifying updates in connection with the standard. The provisions of ASU No. 2014-09 and its related updates will be adopted by the Company in the first quarter of 2018 under the modified retrospective transition method. The Company believes that the adoption of the standard will not have a material impact on its consolidated financial statements. Substantially all of the Company’s revenue consists of sales of products that represent a single performance obligation where control transfers at the point in time title and risk of loss pass to the customer. The Company continues to evaluate the impact of the standard update on its consolidated financial statements and related disclosures, and additional differences may be identified as new or amended contracts with customers that will impact future periods are executed. The Company expects that its disclosure in the notes to the consolidated financial statements related to revenue recognition will be expanded in the first quarter of 2018 in line with the requirements of the standard to further describe the nature, timing, and uncertainty of revenue and cash flows arising from contracts with customers. In February 2016, the FASB issued ASU No. 2016-02, Leases (Topic 842) (ASU No. 2016-02), which supersedes the leases requirements in Topic 840. The core principle of ASU No. 2016-02 is that a lessee should recognize on the balance sheet the lease assets and lease liabilities that arise from all lease arrangements with terms greater than 12 months. Recognition of these lease assets and lease liabilities represents a change from previous GAAP, which did not require lease assets and lease liabilities to be recognized for operating leases. Qualitative disclosures along with specific quantitative disclosures will be required to provide enough information to supplement the amounts recorded in the financial statements so that users can understand more about the nature of an entity’s leasing activities. The Company will be required to recognize and measure leases at the beginning of the earliest period presented using a modified retrospective approach, which includes a number of optional practical expedients that the Company may elect to apply. The provisions of ASU No. 2016-02 are effective for the Company’s fiscal year beginning January 1, 2019, including interim periods within that fiscal year. At adoption, the Company will recognize a right-of-use asset and a lease liability initially measured at the present value of its operating lease payments. The Company is currently evaluating the impacts of adopting this guidance on its financial position, results of operations, and cash flows. In August 2016, the FASB issued various updates to ASU No. 2016-15, Statement of Cash Flows (Topic 230): Classification of Certain Cash Receipts and Cash Payments (ASU No. 2016-15), which clarifies and amends the presentation and classification of certain cash receipts and cash payments in the statement of cash flows. The provisions of ASU No. 2016-15 are effective for the Company’s fiscal year beginning January 1, 2018, including interim periods within that fiscal year, and will be applied using a retrospective transition method. The Company is currently evaluating the impacts of adopting this guidance on its cash flows. In March 2017, the FASB issued ASU No. 2017-07, Compensation - Retirement Benefits (Topic 715) (ASU No. 2017-07), which requires that employers offering their employees defined benefit pension plans disaggregate the service cost component from the other components of net benefit cost. The amendments also provide explicit guidance on how to present the service cost component and the other components of net benefit cost in the income statement and allow only the service cost component of net benefit cost to be eligible for capitalization. The provisions of ASU No. 2017-07 are effective for the Company’s fiscal year beginning January 1, 2018, including interim periods within that fiscal year, and should be applied retrospectively for the presentation of the service cost component and the other components of net periodic pension cost and net periodic post-retirement benefit cost in the income statement, and prospectively for the capitalization of the service cost component of net periodic pension cost and net periodic post-retirement benefit in assets. Upon adoption in 2018, Chemours will reclassify $34 and $20 of non-operating pension income from the operating expense captions of the consolidated statements of operations to other income, net for the years ended December 31, 2017 and 2016, respectively. In August 2017, the FASB issued ASU No. 2017-12, Derivatives and Hedging (Topic 815) (ASU No. 2017-12), which simplifies financial statement reporting for qualifying hedging relationships by eliminating the requirement to separately measure and report hedge ineffectiveness. For net investment hedges, the entire change in fair value of the hedging instruments is recorded in the currency translation adjustment section of other comprehensive income or loss. Pursuant to the amendments, these amounts are required to be subsequently reclassified to earnings in the same income statement line item in which the earnings effect of the hedged item is presented when the hedged item affects earnings. The provisions of ASU No. 2017-12 are effective for the Company’s fiscal year beginning January 1, 2019, including interim periods within that fiscal year. Early adoption is permitted in any interim period. The amendments in this update will be applied to hedging relationships existing on the date of adoption, which includes a cumulative-effect adjustment to eliminate any ineffectiveness recorded to accumulated other comprehensive income or loss with a corresponding adjustment to the opening balance of retained earnings as of the beginning of the fiscal year in which adoption occurred. Presentation and disclosure amendments are required to be applied prospectively. Chemours is currently evaluating the timing of adoption and does not expect the adoption of this guidance to have a significant impact on its financial position, results of operations, and cash flows. Recently Adopted Accounting Guidance In March 2016, the FASB issued ASU No. 2016-09, Compensation - Stock Compensation (Topic 718) (ASU No. 2016-09). ASU No. 2016-09 sets forth areas for simplification within several aspects of the accounting for shared-based payment transactions, including the income tax consequences, classification of awards as either equity or liabilities, and classification on the statement of cash flows. The amendments in ASU No. 2016-09 are effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2016. Chemours adopted this guidance effective January 1, 2017, and the adoption did not have a significant impact on the Company’s financial position, results of operations, or cash flows, except for the impact of windfall income tax benefits on share-based payments and the classification of employee withholding tax payments on vested RSUs as a financing activity on the statements of cash flows. Specific to the impact of windfall tax benefits, the Company expects the guidance will cause volatility in its income tax rates going forward. As of the adoption date, there were no windfall tax benefits from prior periods recognized; therefore, prior period adjustments were not required under a modified retrospective basis. For the year ended December 31, 2017, Chemours recognized $22 of federal and state windfall income tax benefits, primarily from options exercised and RSUs vested, which were included in the provision for income taxes in the consolidated statements of operations. In January 2017, the FASB issued ASU No. 2017-04, Intangibles - Goodwill and Other (Topic 350): Simplifying the Test for Goodwill Impairment (ASU No. 2017-04), which eliminates the requirement to determine the fair value of the individual assets and liabilities of a reporting unit to measure goodwill impairment. Under the amendments, goodwill impairment testing will be performed by comparing the fair value of the reporting unit with its carrying amount and recognizing an impairment charge for the amount by which the carrying amount exceeds the reporting unit’s fair value. Any impairment charges recognized would not exceed the total amount of goodwill allocated to the reporting unit. The provisions of ASU No. 2017-04 are effective for annual and interim goodwill impairment tests performed in fiscal years beginning after December 15, 2019. Early adoption is permitted for annual or interim goodwill impairment testing performed after January 1, 2017. The Company adopted this guidance and implemented its provisions for the annual goodwill impairment testing performed on October 1, 2017. Pursuant to the amendment, the Company will implement the provisions of ASU No. 2017-04 for interim and annual goodwill impairment tests performed prospectively. The adoption of this guidance did not have a significant impact on the Company’s financial position, results of operations, or cash flows. In May 2017, the FASB issued ASU No. 2017-09, Compensation - Stock Compensation (Topic 718): Scope of Modification Accounting (ASU No. 2017-09), which provides clarity and reduces both diversity in practice and the cost and complexity of applying the guidance in Topic 718 to a change in the terms or conditions of a share-based payment award. Pursuant to this update, modification accounting is required to be applied to changes in the terms and conditions of a share-based payment award unless all of the following criteria remain unchanged before and after the award is modified: (i) the fair value of the award; (ii) the vesting conditions of the award; and, (iii) the classification of the award as an equity instrument or a liability instrument. The provisions of ASU No. 2017-09 are effective for annual periods, and interim periods within those annual periods, beginning after December 15, 2017, and are to be applied prospectively to an award modified on or after the adoption date. Early adoption, including adoption in any interim period, is permitted for public business entities in reporting periods for which financial statements have not yet been issued. The Company has adopted this guidance and will implement its provisions prospectively for changes in the terms and conditions of share-based payment awards. The Company does not expect that the adoption of this guidance will have a significant impact on its financial position, results of operations, or cash flows.

Restructuring and Asset-Related Charges, Net (Tables)

12 Months Ended

Dec. 31, 2017

Restructuring And Related Activities [Abstract]

Schedule of Restructuring Program

The following table sets forth the components of the Company’s restructuring and asset-related charges, net for the years ended December 31, 2017, 2016, and 2015.

	Year Ended December 31,
	2017		2016		2015
Restructuring-related charges:
Employee separation charges	$	23	$	4	$	137
Decommissioning and other charges, net		33		47		18
Asset-related charges - restructuring		—		—		133
Total restructuring-related charges, net		56		51		288
Asset-related charges - impairment (1)		1		119		45
Total restructuring and asset-related charges, net	$	57	$	170	$	333

(1)

Schedule of Restructuring Charges

The impacts of the Company’s restructuring programs to segment earnings for the years ended December 31, 2017, 2016, and 2015 are set forth in the following table.

	Year Ended December 31,
	2017		2016		2015
Plant and product line closures (1) :
Titanium Technologies	$	4	$	30	$	140
Fluoroproducts		3		7		24
Chemical Solutions		17		8		12
Total plant and product line closures		24		45		176
2015 Global Restructuring Program (2) :
Titanium Technologies		—		2		33
Fluoroproducts		—		4		54
Chemical Solutions		—		—		25
Total 2015 Global Restructuring Program		—		6		112
2017 Restructuring Program		32		—		—
Total restructuring-related charges, net	$	56	$	51	$	288

(1)

Includes charges related to employee separation, decommissioning and dismantling costs, and asset-related charges in connection with the restructuring activities.

(2)

Includes $24 related to corporate support functions that were allocated to the segments for the year ended December 31, 2015.

The following table sets forth the change in the Company’s employee separation-related liabilities associated with its restructuring programs for the years ended December 31, 2017, 2016, and 2015.

	Titanium Technologies Site Closures			Fluoroproducts Lines Shutdown			Chemical Solutions Site Closures			2015 Global Restructuring Program			2017 Restructuring Program		Total
Balance at December 31, 2015	$	11		$	2		$	12		$	73		$	—	$	98
Charges (credits) to income (1)		—			—			(2	)		6			—		4
Payments		(7	)		(1	)		(1	)		(59	)		—		(68	)
Currency translation and other adjustments (2)		—			—			(1	)		1			—		—
Balance at December 31, 2016		4			1			8			21			—		34
Charges to income		—			—			—			1			23		24
Payments		(3	)		(1	)		(6	)		(21	)		—		(31	)
Currency translation and other adjustments (2)		—			—			—			—			—		—
Balance at December 31, 2017	$	1		$	—		$	2		$	1		$	23	$	27

(1)

(2)

Amounts include net currency translation adjustments of $1 or less for the periods presented and/or immaterial rounding differences.

Sales of Assets and Businesses (Tables)

12 Months Ended

Dec. 31, 2017

Discontinued Operations And Disposal Groups [Abstract]

Major Components of Assets and Liabilities Disposed

	Chemical Solutions Portfolio Optimization
Current assets:
Accounts receivable - trade	$	22
Inventories		17
Total current assets		39
Non-current assets:
Property, plant, and equipment, net		298
Goodwill		17
Other assets		136
Less: Impairment loss		(58	)
Total non-current assets, net		393
Total assets		432
Accounts payable and accrued liabilities		17
Total liabilities		17
Total net assets disposed	$	415

- Definition

Tabular disclosure of information related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 45
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=65878427&loc=SL51721533-107759

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 4B
-URI http://asc.fasb.org/extlink&oid=64827811&loc=SL51721665-107760

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=64827811&loc=d3e1474-107760

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=64827811&loc=d3e1361-107760

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=64827811&loc=SL51721683-107760

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 50
-Paragraph 3A
-URI http://asc.fasb.org/extlink&oid=84176398&loc=SL51724579-110230

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 5C
-URI http://asc.fasb.org/extlink&oid=64827811&loc=SL51721675-107760

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 4A
-URI http://asc.fasb.org/extlink&oid=64827811&loc=SL51721663-107760

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=84176398&loc=d3e2941-110230

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 5B
-URI http://asc.fasb.org/extlink&oid=64827811&loc=SL51721673-107760

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 3A
-URI http://asc.fasb.org/extlink&oid=64827811&loc=SL51721659-107760

Reference 12: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 5A
-URI http://asc.fasb.org/extlink&oid=64827811&loc=SL51721671-107760

Reference 13: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 5D
-URI http://asc.fasb.org/extlink&oid=64827811&loc=SL51721677-107760

+ Details

Other Income, Net (Tables)

12 Months Ended

Dec. 31, 2017

Other Income And Expenses [Abstract]

Components of Other Income

The following table sets forth the components of the Company’s other income, net for the years ended December 31, 2017, 2016, and 2015.

	Year Ended December 31,
	2017		2016			2015
Leasing, contract services, and miscellaneous income	$	30	$	35		$	25
Royalty income (1)		24		15			19
Gain (loss) on sale of assets and businesses (2)		22		254			(9	)
Exchange gains (losses), net (3)		3		(57	)		19
Total other income, net	$	79	$	247		$	54

(1)

Royalty income is primarily from technology and trademark licensing.

(2)

(3)

Exchange gains (losses), net includes gains and losses on foreign currency forward contracts.

Income Taxes (Tables)

12 Months Ended

Dec. 31, 2017

Income Tax Disclosure [Abstract]

Schedule of Components of Provision for (Benefit from) Income Taxes

The following table sets forth the components of the Company’s provision for (benefit from) income taxes for the years ended December 31, 2017, 2016, and 2015.

	Year Ended December 31,
	2017			2016			2015
Current tax expense:
U.S. federal (1)	$	(8	)	$	—		$	37
U.S. state and local (1)		1			—			1
International		89			93			62
Total current tax expense		82			93			100
Deferred tax expense (benefit):
U.S. federal		60			(101	)		(187	)
U.S. state and local		6			(17	)		(14	)
International		17			7			3
Total deferred tax expense (benefit)		83			(111	)		(198	)
Total provision for (benefit from) income taxes	$	165		$	(18	)	$	(98	)

(1)

Amounts for the year ended December 31, 2015 were recorded pursuant to the Separation-related tax matters agreement.

Schedule of Deferred Tax Assets and Liabilities Components

The following table sets forth the components of the Company’s deferred tax assets and liabilities at December 31, 2017 and 2016.

	December 31,
	2017			2016
Deferred tax assets:
Environmental and other reserves	$	89		$	150
Litigation reserves		14			149
Stock-based compensation and accrued employee benefits		26			35
Other assets and other accrued liabilities		8			27
Tax loss carryforwards		27			45
Foreign tax credit carryforwards		17			50
Total deferred tax assets		181			456
Less: Valuation allowance		(17	)		(50	)
Total deferred tax assets, net		164			406
Deferred tax liabilities:
Pension and other liabilities		(55	)		(16	)
Property, plant, and equipment		(274	)		(441	)
Inventories and other assets		(4	)		(40	)
Total deferred tax liabilities		(333	)		(497	)
Deferred tax liability, net	$	(169	)	$	(91	)

Schedule of Effective Income Tax Rate

The following table sets forth an analysis of the Company’s effective tax rate for the years ended December 31, 2017, 2016, and 2015.

	Year Ended December 31,
	2017						2016						2015
	$			%			$			%			$			%
Statutory U.S. federal income tax rate	$	319			35.0	%	$	(4	)		35.0	%	$	(66	)		35.0	%
State income taxes, net of federal benefit (1)		7			0.7	%		(16	)		150.4	%		(10	)		5.1	%
Lower effective tax rate on international operations, net		(149	)		(16.3	)%		(61	)		552.5	%		(23	)		12.0	%
Depletion		(8	)		(0.9	)%		(6	)		51.2	%		(6	)		3.4	%
Goodwill		—			—	%		5			(47.9	)%		6			(3.2	)%
Exchange losses (gains)		5			0.6	%		4			(39.1	)%		(1	)		0.5	%
Provision to return and other adjustments		6			0.6	%		6			(57.9	)%		—			—	%
Permanent items		9			1.0	%		3			(27.3	)%		1			(0.5	)%
Valuation allowance (2)		(33	)		(3.6	)%		50			(451.6	)%		—			—	%
Net impact of U.S. tax reform		39			4.3	%		—			(—	)%		—			—	%
Stock-based compensation (1)		(20	)		(2.2	)%		—			(—	)%		—			—	%
Other, net		(10	)		(1.2	)%		1			(1.7	)%		1			(0.2	)%
Total effective tax rate	$	165			18.1	%	$	(18	)		163.6	%	$	(98	)		52.1	%

(1)

Total windfall benefits on stock-based compensation amounted to $22 for the year ended December 31, 2017, which is inclusive of $20 in federal income tax benefit and $2 in state income tax benefit.

(2)

Schedule of Income (Loss) before Income Taxes

The following table sets forth the Company’s income (loss) before income taxes for its U.S. and international operations for the years ended December 31, 2017, 2016, and 2015.

	Year Ended December 31,
	2017			2016			2015
U.S. operations (including exports)	$	(306	)	$	(481	)	$	(492	)
International operations		1,218			470			304
Total income (loss) before income taxes	$	912		$	(11	)	$	(188	)

Schedule of open tax years by significant jurisdiction

Each year, Chemours and/or its subsidiaries file income tax returns in the U.S. federal jurisdiction and various states and non-U.S. jurisdictions.

The following table sets forth the Company’s significant jurisdictions’ tax returns that are subject to examination by their respective taxing authorities for the open years listed.


Jurisdiction	Open Years
China		2011 through 2017
Mexico		2012 through 2017
Netherlands		2014 through 2017
Taiwan		2014 through 2017
U.S.		2015 through 2017

Schedule of Unrecognized Tax Benefits

The following table sets forth the change in the Company’s unrecognized tax benefit for the years ended December 31, 2017, 2016, and 2015.

	Year Ended December 31,
	2017			2016			2015
Balance at January 1,	$	6		$	7		$	39
Gross amounts of decreases in unrecognized tax benefits as a result of adjustments to tax provisions taken during the prior period		(6	)		(1	)		—
Gross amounts of increases in unrecognized tax benefits as a result of tax positions taken during the current period		—			—			—
Reduction to unrecognized tax benefits as a result of a lapse of the applicable statute of limitations (1)		—			—			(32	)
Balance at December 31,	$	—		$	6		$	7

Total unrecognized tax benefits, if recognized, that would impact the effective tax rate	$	—		$	—		$	—
Total amount of interest and penalties recognized in the consolidated statements of operations (1)		—			—			1
Total amount of interest and penalties recognized in the consolidated balance sheets		—			—			—

(1)

Summary of Deferred Tax Asset Valuation Allowance

The following table sets forth a rollforward of the Company’s deferred tax asset valuation allowance for the years ended December 31, 2017, 2016, and 2015.

	Year Ended December 31,
	2017			2016		2015
Balance at January 1,	$	50		$	—	$	36
Net charges to income tax expense		—			50		—
Release of valuation allowance (1)		(33	)		—		(36	)
Balance at December 31,	$	17		$	50	$	—

(1)

Earnings Per Share of Common Stock (Tables)

12 Months Ended

Dec. 31, 2017

Earnings Per Share [Abstract]

Schedule of Earnings Per Share, Basic and Diluted

	Year Ended December 31,
	2017		2016		2015
Numerator:
Net income (loss) attributable to Chemours	$	746	$	7	$	(90	)
Denominator:
Weighted-average number of common shares outstanding - basic		184,844,106		181,621,422		180,993,623
Dilutive effect of the Company’s employee compensation plans		6,139,885		1,795,078		—
Weighted-average number of common shares outstanding - diluted		190,983,991		183,416,500		180,993,623

Schedule of Anti-dilutive Securities Excluded from Computation of Earnings Per Share

	Year Ended December 31,
	2017		2016		2015
Average number of stock options		43,072		5,820,499		8,358,894

Accounts and Notes Receivable, Net (Tables)

12 Months Ended

Dec. 31, 2017

Receivables [Abstract]

Schedule of Accounts, Notes, Loans and Financing Receivable

The following table sets forth the components of the Company’s accounts and notes receivable, net at December 31, 2017 and 2016.

	December 31,
	2017		2016
Accounts receivable - trade, net (1)	$	847	$	742
VAT, GST, and other taxes (2)		54		46
Other receivables (3)		18		19
Total accounts and notes receivable, net	$	919	$	807

(1)

(2)

Value added tax (VAT) and goods and services tax (GST) for various jurisdictions.

(3)

Other receivables consist of notes receivable, advances, and other deposits.

Inventories (Tables)

12 Months Ended

Dec. 31, 2017

Inventory Net [Abstract]

Schedule of Inventories

	December 31,
	2017			2016
Finished products	$	648		$	532
Semi-finished products		164			150
Raw materials, stores, and supplies		313			285
Inventories before LIFO adjustment		1,125			967
Adjustment of inventories to LIFO basis		(190	)		(200	)
Total inventories	$	935		$	767

Property, Plant, and Equipment, Net (Tables)

12 Months Ended

Dec. 31, 2017

Property Plant And Equipment [Abstract]

Summary of Property, Plant, and Equipment, Net

The following table sets forth the components of the Company’s property, plant, and equipment, net at December 31, 2017 and 2016.

	December 31,
	2017			2016
Equipment	$	6,961		$	6,748
Buildings		875			814
Construction-in-progress		520			293
Land		119			106
Mineral rights		36			36
Property, plant, and equipment		8,511			7,997
Less: Accumulated depreciation		(5,503	)		(5,213	)
Total property, plant, and equipment, net	$	3,008		$	2,784

Goodwill and Other Intangible Assets, Net (Tables)

12 Months Ended

Dec. 31, 2017

Goodwill And Intangible Assets Disclosure [Abstract]

Schedule of Goodwill

The following table sets forth the changes in the carrying amount of the Company’s goodwill by reportable segment for the years ended December 31, 2017 and 2016.

	Titanium Technologies		Fluoroproducts		Chemical Solutions			Total
Balance at January 1, 2016	$	13	$	85	$	68		$	166
Sale of business (1)		—		—		(13	)		(13	)
Balance at December 31, 2016		13		85		55			153
Balance at December 31, 2017	$	13	$	85	$	55		$	153

(1)

Represents goodwill disposed of in connection with the sale of the Company’s C&D business.

Schedule of Other Intangible Assets

The following table sets forth the gross carrying amounts and accumulated amortization of the Company’s other intangible assets by major class at December 31, 2017 and 2016.

	December 31, 2017							December 31, 2016
	Cost		Accumulated Amortization			Net		Cost		Accumulated Amortization			Net
Customer lists	$	9	$	(8	)	$	1	$	9	$	(7	)	$	2
Patents		19		(18	)		1		19		(18	)		1
Purchased trademarks		5		(2	)		3		5		(2	)		3
Purchased and licensed technology		3		(2	)		1		3		(2	)		1
Other (1)		10		(3	)		7		10		—			10
Total other intangible assets, net	$	46	$	(33	)	$	13	$	46	$	(29	)	$	17

(1)

Other Assets (Tables)

12 Months Ended

Dec. 31, 2017

Deferred Costs Capitalized Prepaid And Other Assets Disclosure [Abstract]

Schedule of Other Assets

The following table sets forth the components of the Company’s other assets at December 31, 2017 and 2016.

	December 31,
	2017		2016
Capitalized repair and maintenance costs	$	117	$	145
Pension assets (1)		260		159
Deferred income taxes		40		41
Asset held for sale (2)		—		29
Miscellaneous (3)		36		43
Total other assets	$	453	$	417

(1)

Pension assets represent the funded status of certain of the Company’s long-term employee benefit plans.

(2)

Asset held for sale at December 31, 2016 represents the Company’s corporate headquarters building located in Wilmington, Delaware, which was sold in 2017.

(3)

Miscellaneous includes deferred financing fees related to the Company’s senior secured revolving credit facility of $9 and $13 at December 31, 2017 and 2016, respectively.

Accounts Payable (Tables)

12 Months Ended

Dec. 31, 2017

Payables And Accruals [Abstract]

Schedule of Accounts Payable

The following table sets forth the components of the Company’s accounts payable at December 31, 2017 and 2016.

	December 31,
	2017		2016
Trade payables	$	1,008	$	858
Dividends payable (1)		31		—
VAT and other payables		36		26
Total accounts payable	$	1,075	$	884

(1)

Represents a $0.17 per share dividend declared in December 2017, which will be paid on March 15, 2018 to the Company’s shareholders of record as of the close of business on February 15, 2018.

Other Accrued Liabilities (Tables)

12 Months Ended

Dec. 31, 2017

Payables And Accruals [Abstract]

Schedule of Other Accrued Liabilities

The following table sets forth the components of the Company’s other accrued liabilities at December 31, 2017 and 2016.

	December 31,
	2017		2016
Compensation and other employee-related costs	$	174	$	154
Employee separation costs (1)		27		31
Accrued litigation (2)		13		344
Environmental remediation (3)		66		71
Income taxes		58		39
Customer rebates		83		53
Deferred revenue (4)		8		76
Accrued interest		24		21
Miscellaneous (5)		105		83
Total other accrued liabilities	$	558	$	872

(1)

Represents the current portion of accrued employee separation costs related to the Company’s restructuring activities.

(2)

(3)

Represents the current portion of accrued environmental remediation, which is discussed further in Note 20.

(4)

Deferred revenue includes a $58 prepayment from DuPont for specified goods and services at December 31, 2016, which were fulfilled and/or delivered during 2017.

(5)

Debt (Tables)

12 Months Ended

Dec. 31, 2017

Debt Disclosure [Abstract]

Components of Total Debt

The following table sets forth the components of the Company’s total debt at December 31, 2017 and 2016.

	December 31,
	2017			2016
Senior secured term loans:
Tranche B term loan due May 2022	$	—		$	1,372
Tranche B-1 Dollar Term Loan due May 2022		923			—
Tranche B-1 Euro Term Loan due May 2022 (€394 at December 31, 2017)		469			—
Senior unsecured notes:
6.625% due May 2023		1,158			1,158
7.000% due May 2025		750			750
6.125% due May 2023 (€295 at December 31, 2017 and 2016)		350			308
5.375% due May 2027		500			—
Capital lease obligations		3			3
Build-to-suit lease obligation		8			—
Total debt		4,161			3,591
Less: Unamortized issue discounts		(8	)		(5	)
Less: Unamortized debt issuance costs		(41	)		(42	)
Less: Current maturities of long-term debt		(15	)		(15	)
Total long-term debt, net	$	4,097		$	3,529

Schedule of Repurchases of Debt

	Year Ended December 31, 2016
	Aggregate Principal		Cash Payments
Prior Term Loan (1)	$	105	$	104
2023 Notes		192		182
Euro Notes		73		68
	$	370	$	354

(1)

The Prior Term Loan’s aggregate principal amounts exclude the required quarterly installment repayments, which are equivalent to $15 per year.

- Definition

Tabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.22)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=84159872&loc=d3e21475-112644

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 470
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=75038535&loc=d3e64711-112823

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08.(e),(f))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 835
-SubTopic 30
-Section 55
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=64930739&loc=d3e28878-108400

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=84159872&loc=d3e21538-112644

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=84159872&loc=d3e21506-112644

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 835
-SubTopic 30
-Section 45
-Paragraph 1A
-URI http://asc.fasb.org/extlink&oid=64930785&loc=d3e28541-108399

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 835
-SubTopic 30
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=64930785&loc=d3e28551-108399

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=84159872&loc=d3e21521-112644

+ Details

Other Liabilities (Tables)

12 Months Ended

Dec. 31, 2017

Other Liabilities Disclosure [Abstract]

Schedule of Other Liabilities

The following table sets forth the components of the Company’s other liabilities at December 31, 2017 and 2016.

	December 31,
	2017		2016
Environmental remediation (1)	$	187	$	208
Employee-related costs (2)		123		113
Employee separation costs		—		3
Accrued litigation (1)		48		53
Asset retirement obligations (1)		43		41
Deferred revenue		6		5
Miscellaneous (3)		68		101
Total other liabilities	$	475	$	524

(1)

The Company’s accrued environmental remediation, accrued litigation, and asset retirement obligations liabilities are discussed further in Note 20.

(2)

Employee-related costs primarily represent liabilities associated with the Company’s long-term employee benefits plans.

(3)

Miscellaneous primarily includes an accrued indemnification liability of $52 and $78 at December 31, 2017 and 2016, respectively.

Commitments and Contingent Liabilities (Tables)

12 Months Ended

Dec. 31, 2017

Commitments And Contingencies Disclosure [Abstract]

Summary of Asset Retirement Obligations

The following table sets forth the activity in the Company’s asset retirement obligations for the years ended December 31, 2017 and 2016.

	Year Ended December 31,
	2017			2016
Balance at January 1,	$	43		$	42
Accretion expense		6			2
Settlements and payments		(1	)		(1	)
Balance at December 31,	$	48		$	43

Current portion	$	5		$	2
Non-current portion		43			41

Financial Instruments (Tables)

12 Months Ended

Dec. 31, 2017

Derivative Instruments And Hedging Activities Disclosure [Abstract]

Schedule of Derivative Assets at Fair Value

The following table sets forth the fair value of Chemours’ derivative assets and liabilities, and their level within the fair value hierarchy, at December 31, 2017 and 2016.

		Fair Value Using Level 2 Inputs
		December 31,
	Balance Sheet Location	2017		2016
Asset derivatives:
Foreign currency forward contracts	Accounts and notes receivable - trade, net	$	—	$	2
Total asset derivatives		$	—	$	2

Liability derivatives:
Foreign currency forward contracts	Other accrued liabilities	$	—	$	4
Total liability derivatives		$	—	$	4

Schedule of Derivative Liabilities at Fair Value

The following table sets forth the fair value of Chemours’ derivative assets and liabilities, and their level within the fair value hierarchy, at December 31, 2017 and 2016.

		Fair Value Using Level 2 Inputs
		December 31,
	Balance Sheet Location	2017		2016
Asset derivatives:
Foreign currency forward contracts	Accounts and notes receivable - trade, net	$	—	$	2
Total asset derivatives		$	—	$	2

Liability derivatives:
Foreign currency forward contracts	Other accrued liabilities	$	—	$	4
Total liability derivatives		$	—	$	4

Long-term Employee Benefits (Tables)

12 Months Ended

Dec. 31, 2017

General Discussion Of Pension And Other Postretirement Benefits [Abstract]

Schedule of Multiemployer Plans

	EIN / Pension	Year Ended December 31,
Plan Name	Number	2017		2016		2015
DuPont Pension and Retirement Plan (U.S.)	51-0014090/001	$	—	$	—	$	48
All other U.S. and non-U.S. Plans			—		—		5

Schedules of Net Periodic Pension Income

The following table sets forth the Company’s net periodic pension income and amounts recognized in other comprehensive income (loss) for the years ended December 31, 2017, 2016, and 2015.

	Year Ended December 31,
	2017			2016			2015
Net periodic pension cost (income):
Service cost	$	16		$	14		$	16
Interest cost		16			19			19
Expected return on plan assets		(75	)		(63	)		(83	)
Amortization of actuarial loss		22			23			16
Amortization of prior service (credit) cost		(2	)		(1	)		4
Curtailment gain		—			(2	)		—
Settlement loss		1			5			—
Net periodic pension income		(22	)		(5	)		(28	)
Changes in plan assets and benefit obligations recognized in other comprehensive income (loss):
Net (gain) loss		(24	)		17			11
Amortization of actuarial loss		(24	)		(28	)		(16	)
Prior service credit		—			—			(24	)
Amortization of prior service credit (cost)		2			3			(4	)
Effect of foreign exchange rates		38			(15	)		(33	)
Benefit recognized in other comprehensive income (loss)		(8	)		(23	)		(66	)
Total net periodic pension income and benefit recognized in other comprehensive income (loss)	$	(30	)	$	(28	)	$	(94	)

Schedule of Amounts Recognized in Other Comprehensive Income (Loss)

The following table sets forth the pre-tax amounts recognized in accumulated other comprehensive loss for the years ended December 31, 2017, 2016, and 2015.

	Year Ended December 31,
	2017			2016			2015
Net loss	$	329		$	336		$	363
Prior service credit		(11	)		(11	)		(16	)
Total amount recognized in accumulated other comprehensive loss	$	318		$	325		$	347

Summary of Benefit Obligations and Fair Value of Plan Assets and Funded Status of Plan

The following table sets forth summarized information on the Company’s pension plans at December 31, 2017 and 2016.

	December 31,
	2017			2016
Change in benefit obligation:
Benefit obligation at beginning of year	$	1,105		$	1,103
Service cost		16			14
Interest cost		16			19
Plan participants’ contributions		2			2
Actuarial (gain) loss		(39	)		69
Benefits paid		(53	)		(36	)
Plan Amendments		(1	)		—
Curtailments		—			(3	)
Settlements and transfers		(3	)		(12	)
Other events		(4	)		(2	)
Currency translation		138			(49	)
Benefit obligation at end of year		1,177			1,105
Change in plan assets:
Fair value of plan assets at beginning of year		1,169			1,137
Actual return on plan assets		60			113
Employer contributions		38			16
Plan participants’ contributions		2			2
Benefits paid		(53	)		(36	)
Settlements and transfers		(3	)		(12	)
Other events		(3	)		—
Currency translation		153			(51	)
Fair value of plan assets at end of year		1,363			1,169
Total funded status at end of year	$	186		$	64

Schedule of Amounts Recognized in the Consolidated Balance Sheet

The following table sets forth the net amounts recognized in the Company’s consolidated balance sheets at December 31, 2017 and 2016.

	December 31,
	2017			2016
Non-current assets	$	258		$	159
Current liabilities		(1	)		(1	)
Non-current liabilities		(71	)		(94	)
Total net amount recognized	$	186		$	64

Schedule of Projected Benefit Obligations in Excess of Fair Value of Plan Assets

	December 31,
Pension plans with projected benefit obligation in excess of plan assets	2017		2016
Projected benefit obligation	$	178	$	183
Accumulated benefit obligation		149		152
Fair value of plan assets		106		87

Schedule of Accumulated Benefit Obligations in Excess of Fair Value of Plan Assets

	December 31,
Pension plans with accumulated benefit obligation in excess of plan assets	2017		2016
Projected benefit obligation	$	178	$	179
Accumulated benefit obligation		149		151
Fair value of plan assets		106		84

Schedule of Assumptions Used

The following tables set forth the assumptions that have been used to determine the Company’s benefit obligations and net benefit cost at December 31, 2017 and 2016.

	December 31,
Weighted average assumptions used to determine benefit obligations	2017			2016
Discount rate		1.9	%		1.8	%
Rate of compensation increase (1)		2.5	%		2.5	%

(1)

The rate of compensation increase represents the single annual effective salary increase that an average plan participant would receive during the participant’s entire career at Chemours.

	December 31,
Weighted average assumptions used to determine net benefit cost	2017			2016
Discount rate		1.8	%		2.4	%
Rate of compensation increase (1)		2.5	%		2.5	%
Expected return on plan assets		5.7	%		5.7	%

(1)

The rate of compensation increase represents the single annual effective salary increase that an average plan participant would receive during the participant’s entire career at Chemours.

Schedule of Allocation of Plan Assets

The following table sets forth the weighted-average allocation for the Company’s pension plan assets at December 31, 2017 and 2016.

	December 31,
	2017			2016
Cash and cash equivalents		4.8	%		2.5	%
U.S. and non-U.S. equity securities		42.6	%		41.6	%
Fixed income securities		52.6	%		55.9	%
Total weighted-average target allocation		100.0	%		100.0	%

The following tables set forth the fair values of the Company’s pension assets by level within the fair value hierarchy at December 31, 2017 and 2016.

	Fair Value Measurements at December 31, 2017
	Total			Level 1		Level 2
Asset category:
Debt - government issued	$	505		$	1	$	504
Debt - corporate issued		144			24		120
Debt - asset backed		40			—		40
U.S. and non-U.S. equities		581			295		286
Derivatives - asset position		8			2		6
Derivatives - liability position		(1	)		—		(1	)
Cash and cash equivalents		65			65		—
Other		14			11		3
Total pension assets before pension receivables		1,356		$	398	$	958
Pension trust receivables, net (1)		7
Total pension assets	$	1,363

(1)

Receivables are primarily for investment income earned but not yet received.

	Fair Value Measurements at December 31, 2016
	Total			Level 1		Level 2
Asset category:
Debt - government issued	$	433		$	8	$	425
Debt - corporate issued		142			76		66
Debt - asset backed		42			25		17
U.S. and non-U.S. equities		502			28		474
Derivatives - asset position		3			—		3
Derivatives - liability position		(32	)		—		(32	)
Cash and cash equivalents		77			77		—
Other		7			—		7
Total pension assets before pension payables		1,174		$	214	$	960
Pension trust payables, net (1)		(5	)
Total pension assets	$	1,169

(1)

Payables are primarily for investment securities purchased.

Schedule of Expected Benefit Payments

The following table sets forth the benefit payments that are expected to be paid by the Company over the next five years and the five years thereafter as of December 31, 2017.

2018	$	45
2019		47
2020		48
2021		47
2022		48
2023 to 2027		262

Stock-based Compensation (Tables)

12 Months Ended

Dec. 31, 2017

Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]

Schedule of Weighted Average Assumptions of Stock Options

The following table sets forth the weighted-average assumptions used to determine expense related to stock option awards granted during the years ended December 31, 2017, 2016, and 2015.

	Year Ended December 31,
	2017			2016			2015
Risk-free interest rate		2.14	%		1.46	%		1.50	%
Expected term (years)		6.00			6.00			5.40
Volatility		44.49	%		60.00	%		42.00	%
Dividend yield		0.35	%		2.14	%		6.90	%
Fair value per stock option	$	15.21		$	3.41		$	3.17

Schedule of Stock Options Activity

The following table sets forth Chemours’ stock option activity for the year ended December 31, 2017.

	Number of Shares (in thousands)			Weighted-average Exercise Price (per share)		Weighted-average Remaining Contractual Term (in years)		Aggregate Intrinsic Value (in thousands)
Outstanding, December 31, 2016		7,969		$	13.72		5.08	$	66,668
Granted		878			34.84
Exercised		(2,173	)		14.36
Forfeited		(47	)		20.55
Expired		(30	)		12.29
Outstanding, December 31, 2017		6,597		$	15.72		5.11	$	226,524
Exercisable, December 31, 2017		3,599		$	14.00		3.46	$	129,800

Schedule of Restricted Stock Units Activity

	Number of Shares (in thousands)			Weighted-average Grant Date Fair Value (per share)
Non-vested, December 31, 2016		2,316		$	11.23
Granted		214			36.68
Vested		(1,316	)		11.46
Forfeited		(49	)		14.27
Non-vested, December 31, 2017		1,165		$	15.34

Schedule of Performance Share Units Activity

The following table sets forth non-vested PSUs at 100% of target amounts at December 31, 2017.

	Number of Shares (in thousands)			Weighted-average Grant Date Fair Value (per share)
Non-vested, December 31, 2016		803		$	6.10
Granted		211			40.30
Vested		—			—
Forfeited		(27	)		16.62
Non-vested, December 31, 2017		987		$	12.94

Geographic and Segment Information (Tables)

12 Months Ended

Dec. 31, 2017

Segments Geographical Areas [Abstract]

Schedule of Net Sales and Net Property, Plant and Equipment by Geographical Area

	Year Ended December 31,
	2017				2016				2015
	Net Sales (1)		Property, Plant, and Equipment, Net		Net Sales (1)		Property, Plant, and Equipment, Net		Net Sales (1)		Property, Plant, and Equipment, Net
North America	$	2,255	$	2,018	$	2,288	$	1,861	$	2,570	$	2,184
Asia Pacific		1,593		131		1,315		129		1,393		136
Europe, the Middle East, and Africa		1,506		302		1,081		278		977		308
Latin America (2)		829		557		716		516		777		549
Total net sales and property, plant, and equipment, net	$	6,183	$	3,008	$	5,400	$	2,784	$	5,717	$	3,177

(1)

Net sales are attributed to countries based on customer location.

(2)

Latin America includes Mexico.

Schedule of Segment Information

The following table sets forth certain summary financial information for the Company’s reportable segments as of, and for the years ended December 31, 2017, 2016, and 2015.

Year Ended December 31,	Titanium Technologies		Fluoroproducts		Chemical Solutions		Corporate and Other			Total
2017
Net sales to external customers	$	2,958	$	2,654	$	571	$	—		$	6,183
Adjusted EBITDA		862		669		57		(166	)		1,422
Depreciation and amortization		118		109		18		28			273
Equity in earnings of affiliates		—		33		—		—			33
Net assets		1,785		1,842		460		(3,222	)		865
Investments in affiliates		—		173		—		—			173
Purchases of property, plant, and equipment		65		249		65		32			411

2016
Net sales to external customers	$	2,364	$	2,264	$	772	$	—		$	5,400
Adjusted EBITDA		466		445		39		(128	)		822
Depreciation and amortization		119		101		30		34			284
Equity in earnings of affiliates		—		26		—		3			29
Net assets		1,513		1,400		292		(3,101	)		104
Investments in affiliates		—		116		—		20			136
Purchases of property, plant, and equipment		105		120		104		9			338

2015
Net sales to external customers	$	2,392	$	2,230	$	1,095	$	—		$	5,717
Adjusted EBITDA		326		300		29		(82	)		573
Depreciation and amortization		125		88		52		2			267
Equity in earnings of affiliates		—		21		—		1			22
Net assets		1,659		1,567		839		(3,935	)		130
Investments in affiliates		—		127		—		9			136
Purchases of property, plant, and equipment		255		142		117		5			519

Reconciliation of EBITDA from Segments to Consolidated Net Income (Loss) Before Income Taxes

The following table sets forth a reconciliation of Adjusted EBITDA to the Company’s consolidated net income (loss) before income taxes for the years ended December 31, 2017, 2016, and 2015.

	Year Ended December 31,
	2017			2016			2015
Income (loss) before income taxes	$	912		$	(11	)	$	(188	)
Interest expense, net		215			213			132
Depreciation and amortization		273			284			267
Non-operating pension and other post-retirement employee benefit income		(34	)		(20	)		(3	)
Exchange (gains) losses		(3	)		57			(19	)
Restructuring charges		57			51			285
Asset-related charges (1)		3			124			73
(Gain) loss on sale of assets and businesses (2)		(22	)		(254	)		9
Transaction costs (3)		3			19			9
Legal and other charges (4)		18			359			8
Adjusted EBITDA	$	1,422		$	822		$	573

(1)

(2)

(3)

(4)

Schedule of Net Sales to External Customers by Product Group

The Company’s net sales to external customers by product group for the years ended December 31, 2017, 2016, and 2015 are set forth in the following table.

	Year Ended December 31,
	2017		2016		2015
Titanium dioxide	$	2,958	$	2,364	$	2,392
Fluorochemicals		1,378		1,093		984
Fluoropolymers		1,276		1,171		1,246
Mining solutions		261		262		301
Performance chemicals and intermediates		306		298		363
Divested business (1)		4		212		431
Total net sales to external customers	$	6,183	$	5,400	$	5,717

(1)

Inclusive of the Company’s C&D and Sulfur businesses, as well as its aniline facility in Beaumont, Texas, which were all sold in 2016.

Accumulated Other Comprehensive Income (Loss) (Tables)

12 Months Ended

Dec. 31, 2017

Equity [Abstract]

Schedule of Components of Accumulated Other Comprehensive Loss

The following table sets forth the components of accumulated other comprehensive loss, net of income taxes, for the years ended December 31, 2017, 2016, and 2015.

	Currency Translation Adjustment			Net Investment Hedge			Employee Benefits			Total
Balance at January 1, 2015	$	19		$	—		$	—		$	19
Assumption and establishment of pension plans, net		—			—			(311	)		(311	)
Other comprehensive (loss) income		(304	)		8			52			(244	)
Balance at December 31, 2015		(285	)		8			(259	)		(536	)
Other comprehensive (loss) income		(73	)		14			18			(41	)
Balance at December 31, 2016		(358	)		22			(241	)		(577	)
Other comprehensive income (loss)		200			(62	)		(3	)		135
Balance at December 31, 2017	$	(158	)	$	(40	)	$	(244	)	$	(442	)

Quarterly Financial Data (Unaudited) (Tables)

12 Months Ended

Dec. 31, 2017

Quarterly Financial Information Disclosure [Abstract]

Schedule of Quarterly Financial Data

The following table sets forth a summary of the Company’s quarterly results of operations for the years ended December 31, 2017 and 2016.

	For the Three Months Ended
2017	March 31,		June 30,		September 30,		December 31,		Full Year (1),
Net sales	$	1,437	$	1,588	$	1,584	$	1,575	$	6,183
Cost of goods sold		1,079		1,147		1,117		1,087		4,429
Income before income taxes		173		225		250		264		912
Net income		151		161		207		228		747
Net income attributable to Chemours		150		161		207		228		746
Basic earnings per share of common stock		0.82		0.87		1.12		1.23		4.04
Diluted earnings per share of common stock		0.79		0.84		1.08		1.19		3.91

	For the Three Months Ended
2016	March 31,		June 30,			September 30,		December 31,			Full Year (1),
Net sales	$	1,297	$	1,383		$	1,398	$	1,322		$	5,400
Cost of goods sold		1,095		1,116			1,056		1,024			4,290
Income (loss) before income taxes		70		(41	)		234		(273	)		(11	)
Net income (loss)		51		(18	)		204		(230	)		7
Net income (loss) attributable to Chemours		51		(18	)		204		(230	)		7
Basic earnings (loss) per share of common stock		0.28		(0.10	)		1.12		(1.26	)		0.04
Diluted earnings (loss) per share of common stock		0.28		(0.10	)		1.11		(1.26	)		0.04

(1)

Individual quarters may not sum to full year amounts due to rounding.

Guarantor Condensed Consolidating Financial Information (Tables)

12 Months Ended

Dec. 31, 2017

Organization Consolidation And Presentation Of Financial Statements [Abstract]

Condensed Consolidating Statements of Comprehensive Income (Loss)

	Year Ended December 31, 2017
	Parent Issuer			Guarantor Subsidiaries		Non-Guarantor Subsidiaries			Eliminations and Adjustments			Consolidated
Net sales	$	—		$	3,887	$	4,030		$	(1,734	)	$	6,183
Cost of goods sold		—			3,084		3,036			(1,691	)		4,429
Gross profit		—			803		994			(43	)		1,754
Selling, general, and administrative expense		36			449		155			(38	)		602
Research and development expense		—			74		6			—			80
Restructuring and asset-related charges, net		—			56		1			—			57
Total expenses		36			579		162			(38	)		739
Equity in earnings of affiliates		—			—		33			—			33
Equity in earnings of subsidiaries		849			—		—			(849	)		—
Interest (expense) income, net		(221	)		3		3			—			(215	)
Intercompany interest income (expense), net		64			—		(64	)		—			—
Other income (expense), net		29			139		(55	)		(34	)		79
Income before income taxes		685			366		749			(888	)		912
(Benefit from) provision for income taxes		(62	)		117		114			(4	)		165
Net income		747			249		635			(884	)		747
Less: Net income attributable to non-controlling interests		—			—		1			—			1
Net income attributable to Chemours	$	747		$	249	$	634		$	(884	)	$	746
Comprehensive income attributable to Chemours	$	881		$	253	$	828		$	(1,081	)	$	881

Condensed Consolidating Statements of Comprehensive Income (Loss)

	Year Ended December 31, 2016
	Parent Issuer			Guarantor Subsidiaries			Non-Guarantor Subsidiaries			Eliminations and Adjustments			Consolidated
Net sales	$	—		$	3,749		$	3,222		$	(1,571	)	$	5,400
Cost of goods sold		—			3,218			2,615			(1,543	)		4,290
Gross profit		—			531			607			(28	)		1,110
Selling, general, and administrative expense		21			794			139			(20	)		934
Research and development expense		—			77			3			—			80
Restructuring and asset-related charges, net		—			168			2			—			170
Total expenses		21			1,039			144			(20	)		1,184
Equity in earnings of affiliates		—			4			25			—			29
Equity in earnings of subsidiaries		100			—			—			(100	)		—
Interest (expense) income, net		(211	)		(3	)		1			—			(213	)
Intercompany interest income (expense), net		60			4			(64	)		—			—
Other income, net		20			193			54			(20	)		247
(Loss) income before income taxes		(52	)		(310	)		479			(128	)		(11	)
(Benefit from) provision for income taxes		(59	)		(52	)		100			(7	)		(18	)
Net income (loss)		7			(258	)		379			(121	)		7
Less: Net income attributable to non-controlling interests		—			—			—			—			—
Net income (loss) attributable to Chemours	$	7		$	(258	)	$	379		$	(121	)	$	7
Comprehensive (loss) income attributable to Chemours	$	(34	)	$	(255	)	$	321		$	(66	)	$	(34	)

Condensed Consolidating Statements of Comprehensive Income (Loss)

	Year Ended December 31, 2015
	Parent Issuer			Guarantor Subsidiaries			Non-Guarantor Subsidiaries			Eliminations and Adjustments			Consolidated
Net sales	$	—		$	4,044		$	3,269		$	(1,596	)	$	5,717
Cost of goods sold		—			3,708			2,650			(1,596	)		4,762
Gross profit		—			336			619			—			955
Selling, general, and administrative expense		15			426			204			(13	)		632
Research and development expense		—			95			2			—			97
Restructuring and asset-related charges, net		—			295			38			—			333
Goodwill impairment		—			25			—			—			25
Total expenses		15			841			244			(13	)		1,087
Equity in earnings of affiliates		—			1			21			—			22
Equity in earnings of subsidiaries		(47	)		—			—			47			—
Interest expense, net		(131	)		(1	)		—			—			(132	)
Intercompany interest income (expense), net		44			—			(44	)		—			—
Other income (expense), net		13			92			(31	)		(20	)		54
(Loss) income before income taxes		(136	)		(413	)		321			40			(188	)
(Benefit from) provision for income taxes		(46	)		(89	)		40			(3	)		(98	)
Net (loss) income		(90	)		(324	)		281			43			(90	)
Less: Net income attributable to non-controlling interests		—			—			—			—			—
Net (loss) income attributable to Chemours	$	(90	)	$	(324	)	$	281		$	43		$	(90	)
Comprehensive (loss) income attributable to Chemours	$	(334	)	$	(324	)	$	29		$	295		$	(334	)

Condensed Consolidating Balance Sheets

	Year Ended December 31, 2017
	Parent Issuer		Guarantor Subsidiaries			Non-Guarantor Subsidiaries			Eliminations and Adjustments			Consolidated
Assets
Current assets:
Cash and cash equivalents	$	—	$	761		$	795		$	—		$	1,556
Accounts and notes receivable, net		—		308			611			—			919
Intercompany receivable		3		904			581			(1,488	)		—
Inventories		—		394			631			(90	)		935
Prepaid expenses and other		—		57			15			11			83
Total current assets		3		2,424			2,633			(1,567	)		3,493
Property, plant, and equipment		—		6,449			2,062			—			8,511
Less: Accumulated depreciation		—		(4,438	)		(1,065	)		—			(5,503	)
Property, plant, and equipment, net		—		2,011			997			—			3,008
Goodwill and other intangible assets, net		—		152			14			—			166
Investments in affiliates		—		—			173			—			173
Investment in subsidiaries		4,393		—			—			(4,393	)		—
Intercompany notes receivable		1,150		—			—			(1,150	)		—
Other assets		23		115			328			(13	)		453
Total assets	$	5,569	$	4,702		$	4,145		$	(7,123	)	$	7,293
Liabilities
Current liabilities:
Accounts payable	$	31	$	606		$	438		$	—		$	1,075
Current maturities of long-term debt		15		—			—			—			15
Intercompany payable		542		581			365			(1,488	)		—
Other accrued liabilities		34		343			181			—			558
Total current liabilities		622		1,530			984			(1,488	)		1,648
Long-term debt, net		4,087		10			—			—			4,097
Intercompany notes payable		—		—			1,150			(1,150	)		—
Deferred income taxes		—		127			105			(24	)		208
Other liabilities		—		388			87			—			475
Total liabilities		4,709		2,055			2,326			(2,662	)		6,428
Commitments and contingent liabilities
Equity
Total Chemours stockholders’ equity		860		2,647			1,814			(4,461	)		860
Non-controlling interests		—		—			5			—			5
Total equity		860		2,647			1,819			(4,461	)		865
Total liabilities and equity	$	5,569	$	4,702		$	4,145		$	(7,123	)	$	7,293

Condensed Consolidating Balance Sheets

	Year Ended December 31, 2016
	Parent Issuer		Guarantor Subsidiaries			Non-Guarantor Subsidiaries			Eliminations and Adjustments			Consolidated
Assets
Current assets:
Cash and cash equivalents	$	—	$	224		$	678		$	—		$	902
Accounts and notes receivable, net		—		299			508			—			807
Intercompany receivable		3		1,050			46			(1,099	)		—
Inventories		—		341			476			(50	)		767
Prepaid expenses and other		—		38			32			7			77
Total current assets		3		1,952			1,740			(1,142	)		2,553
Property, plant, and equipment		—		6,136			1,861			—			7,997
Less: Accumulated depreciation		—		(4,285	)		(928	)		—			(5,213	)
Property, plant, and equipment, net		—		1,851			933			—			2,784
Goodwill and other intangible assets, net		—		156			14			—			170
Investments in affiliates		—		—			136			—			136
Investment in subsidiaries		3,258		—			—			(3,258	)		—
Intercompany notes receivable		1,150		—			—			(1,150	)		—
Other assets		13		178			226			—			417
Total assets	$	4,424	$	4,137		$	3,049		$	(5,550	)	$	6,060
Liabilities
Current liabilities:
Accounts payable	$	—	$	573		$	311		$	—		$	884
Current maturities of long-term debt		15		—			—			—			15
Intercompany payable		762		46			291			(1,099	)		—
Other accrued liabilities		21		718			133			—			872
Total current liabilities		798		1,337			735			(1,099	)		1,771
Long-term debt, net		3,526		3			—			—			3,529
Intercompany notes payable		—		—			1,150			(1,150	)		—
Deferred income taxes		—		59			73			—			132
Other liabilities		—		428			96			—			524
Total liabilities		4,324		1,827			2,054			(2,249	)		5,956
Commitments and contingent liabilities
Equity
Total Chemours stockholders’ equity		100		2,310			991			(3,301	)		100
Non-controlling interests		—		—			4			—			4
Total equity		100		2,310			995			(3,301	)		104
Total liabilities and equity	$	4,424	$	4,137		$	3,049		$	(5,550	)	$	6,060

Condensed Consolidating Statements of Cash Flows

	Year Ended December 31, 2017
	Parent Issuer			Guarantor Subsidiaries			Non-Guarantor Subsidiaries			Eliminations and Adjustments			Consolidated
Cash flows from operating activities
Cash (used for) provided by operating activities	$	(133	)	$	603		$	169		$	—		$	639
Cash flows from investing activities
Purchases of property, plant, and equipment		—			(327	)		(84	)		—			(411	)
Proceeds from sales of assets and businesses, net		—			39			—			—			39
Intercompany investing activities		—			220			—			(220	)		—
Foreign exchange contract settlements, net		—			2			—			—			2
Cash used for investing activities		—			(66	)		(84	)		(220	)		(370	)
Cash flows from financing activities
Intercompany short-term repayments, net		(220	)		—			—			220			—
Proceeds from issuance of debt, net		495			—			—			—			495
Debt repayments		(27	)		—			—			—			(27	)
Payment of deferred financing fees		(6	)		—			—			—			(6	)
Purchases of treasury stock at cost		(106	)		—			—			—			(106	)
Proceeds from exercised stock options, net		31			—			—			—			31
Tax payments related to withholdings on vested restricted stock units		(12	)		—			—			—			(12	)
Payment of dividends		(22	)		—			—			—			(22	)
Cash provided by financing activities		133			—			—			220			353
Effect of exchange rate changes on cash and cash equivalents		—			—			32			—			32
Increase in cash and cash equivalents		—			537			117			—			654
Cash and cash equivalents at January 1,		—			224			678			—			902
Cash and cash equivalents at December 31,	$	—		$	761		$	795		$	—		$	1,556

Condensed Consolidating Statements of Cash Flows

	Year Ended December 31, 2016
	Parent Issuer			Guarantor Subsidiaries			Non-Guarantor Subsidiaries			Eliminations and Adjustments			Consolidated
Cash flows from operating activities
Cash (used for) provided by operating activities	$	(176	)	$	355		$	415		$	—		$	594
Cash flows from investing activities
Purchases of property, plant, and equipment		—			(233	)		(105	)		—			(338	)
Proceeds from sales of assets and businesses, net		—			591			117			—			708
Intercompany investing activities		—			(560	)		—			560			—
Investments in affiliates		—			—			(1	)		—			(1	)
Foreign exchange contract settlements, net		—			(12	)		—			—			(12	)
Cash (used for) provided by investing activities		—			(214	)		11			560			357
Cash flows from financing activities
Intercompany short-term borrowings, net		560			—			—			(560	)		—
Debt repayments		(369	)		(12	)		—			—			(381	)
Payment of deferred financing fees		(4	)		—			—			—			(4	)
Proceeds from exercised stock options, net		11			—			—			—			11
Payment of dividends		(22	)		—			—			—			(22	)
Cash provided by (used for) financing activities		176			(12	)		—			(560	)		(396	)
Effect of exchange rate changes on cash and cash equivalents		—			—			(19	)		—			(19	)
Increase in cash and cash equivalents		—			129			407			—			536
Cash and cash equivalents at January 1,		—			95			271			—			366
Cash and cash equivalents at December 31,	$	—		$	224		$	678		$	—		$	902

Condensed Consolidating Statements of Cash Flows

	Year Ended December 31, 2015
	Parent Issuer			Guarantor Subsidiaries			Non-Guarantor Subsidiaries			Eliminations and Adjustments			Consolidated
Cash flows from operating activities
Cash (used for) provided by operating activities	$	(119	)	$	171		$	121		$	9		$	182
Cash flows from investing activities
Purchases of property, plant, and equipment		—			(292	)		(227	)		—			(519	)
Proceeds from sales of assets and businesses, net		—			6			6			—			12
Intercompany investing activities		—			(202	)		—			202			—
Investments in affiliates		—			—			(32	)		—			(32	)
Foreign exchange contract settlements, net		—			42			—			—			42
Cash used for investing activities		—			(446	)		(253	)		202			(497	)
Cash flows from financing activities
Intercompany short-term borrowings, net		202			—			—			(202	)		—
Proceeds from issuance of debt, net		3,489			2			—			—			3,491
Debt repayments		(8	)		(2	)		—			—			(10	)
Payment of deferred financing fees		(79	)		—			—			—			(79	)
Cash provided at Separation by DuPont		—			87			160			—			247
Net transfers (to) from DuPont		(3,380	)		283			249			(9	)		(2,857	)
Payment of dividends		(105	)		—			—			—			(105	)
Cash provided by financing activities		119			370			409			(211	)		687
Effect of exchange rate changes on cash and cash equivalents		—			—			(6	)		—			(6	)
Increase in cash and cash equivalents		—			95			271			—			366
Cash and cash equivalents at January 1,		—			—			—			—			—
Cash and cash equivalents at December 31,	$	—		$	95		$	271		$	—		$	366

Background and Description of the Business (Narrative) (Details)		12 Months Ended
	Jul. 02, 2015	Dec. 31, 2017 segment facility $ / shares	Dec. 31, 2016 $ / shares	Jun. 23, 2015 $ / shares
Segment Reporting Information [Line Items]
Number of reportable segments \| segment		3
Number of facilities		26
Common stock , par value (USD per share) \| $ / shares		$ 0.01	$ 0.01	$ 0.01
Spin off transaction distribution ratio	20.00%
Parent Issuer [Member]
Segment Reporting Information [Line Items]
Common stock , par value (USD per share) \| $ / shares				$ 0.30
Operating Segments [Member]
Segment Reporting Information [Line Items]
Number of facilities		1
Titanium Technologies [Member]
Segment Reporting Information [Line Items]
Number of facilities		5
Fluoroproducts [Member]
Segment Reporting Information [Line Items]
Number of facilities		18
Chemical Solutions [Member]
Segment Reporting Information [Line Items]
Number of facilities		2

Basis of Presentation (Details) - USD ($) $ in Millions	12 Months Ended
Basis of Presentation (Details) - USD ($) $ in Millions	Dec. 31, 2016	Dec. 31, 2015
Organization Consolidation And Presentation Of Financial Statements [Abstract]
Noncash contribution		$ 109
Cumulative translation adjustment	$ 31

Summary of Significant Accounting Policies (Narrative) (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
ASU 2017-07 [Member]
Summary Of Significant Accounting Policies [Line Items]
Reclassification of non-operating pension income from the operating expense captions to other income, net	$ 34	$ 20
ASU 2016-09 [Member]
Summary Of Significant Accounting Policies [Line Items]
Tax benefits from significant options exercised and RSUs vested	22
ASU 2016-09 [Member] \| Stock Options Exercised and RSUs Vested [Member]
Summary Of Significant Accounting Policies [Line Items]
Tax benefits from significant options exercised and RSUs vested	$ 22
Consolidated Subsidiaries [Member] \| Maximum [Member]
Summary Of Significant Accounting Policies [Line Items]
Non controlling interests, ownership percentage by parent	100.00%
Voting stock ownership percentage	50.00%
Consolidated Subsidiaries [Member] \| Minimum [Member]
Summary Of Significant Accounting Policies [Line Items]
Voting stock ownership percentage	20.00%

Summary of Significant Accounting Policies - Property, Plant and Equipment (Details)	12 Months Ended
	Dec. 31, 2017
Equipment and Buildings [Member] \| Minimum [Member]
Property Plant And Equipment [Line Items]
Useful Life	15 years
Equipment and Buildings [Member] \| Maximum [Member]
Property Plant And Equipment [Line Items]
Useful Life	25 years
Software Development [Member] \| Minimum [Member]
Property Plant And Equipment [Line Items]
Useful Life	5 years
Software Development [Member] \| Maximum [Member]
Property Plant And Equipment [Line Items]
Useful Life	7 years

Summary of Significant Accounting Policies - Goodwill and Other Intangible Assets and Asset Retirement Obligations (Details)	12 Months Ended
	Dec. 31, 2017
Minimum [Member]
Finite-Lived Intangible Assets [Line Items]
Intangible assets, useful life	5 years
Useful life of asset retirement obligation	2 years
Maximum [Member]
Finite-Lived Intangible Assets [Line Items]
Intangible assets, useful life	20 years
Useful life of asset retirement obligation	30 years

Relationship with DuPont and Related Entities (Narrative) (Details) - USD ($)	1 Months Ended	12 Months Ended		30 Months Ended
	Feb. 29, 2016	Dec. 31, 2017	Dec. 31, 2015	Dec. 31, 2017
Affiliated Entity [Member]
Related Party Transaction [Line Items]
Expenses from transactions with related party			$ 238,000,000	$ 0
Affiliated Entity [Member] \| Arrangement to Purchase Services and Materials [Member]
Related Party Transaction [Line Items]
Amount of agreement with related party	$ 190,000,000
Recognition of deferred revenue		$ 190,000,000
Affiliated Entity [Member] \| Cost of Goods Sold [Member]
Related Party Transaction [Line Items]
Expenses from transactions with related party			23,000,000
Affiliated Entity [Member] \| Selling, General and Administrative Expenses [Member]
Related Party Transaction [Line Items]
Expenses from transactions with related party			205,000,000
Affiliated Entity [Member] \| R&D Expense [Member]
Related Party Transaction [Line Items]
Expenses from transactions with related party			10,000,000
Operating Segments [Member] \| Titanium Technologies [Member] \| Subsidiary of Common Parent [Member]
Related Party Transaction [Line Items]
Revenue from related parties			2,000,000
Operating Segments [Member] \| Fluoroproducts [Member] \| Subsidiary of Common Parent [Member]
Related Party Transaction [Line Items]
Revenue from related parties			34,000,000
Operating Segments [Member] \| Chemical Solutions [Member] \| Subsidiary of Common Parent [Member]
Related Party Transaction [Line Items]
Revenue from related parties			$ 21,000,000

Research and Development Expense (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Research and Development [Line Items]
Research and development expense	$ 80	$ 80	$ 97
Projects Incurred by Chemours [Member]
Research and Development [Line Items]
Research and development expense	$ 80	$ 80	97
Corporate Central Research and Development [Member]
Research and Development [Line Items]
Research and development expense			$ 10

Restructuring and Asset-Related Charges, Net (Charges) (Details) - USD ($) $ in Millions	3 Months Ended	12 Months Ended
	Jun. 30, 2016	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Restructuring Cost and Reserve [Line Items]
Employee separation charges		$ 23	$ 4	$ 137
Decommissioning and other charges, net		33	47	18
Asset-related charges - restructuring		0	0	133
Total restructuring-related charges, net		56	51	288
Asset-related charges - impairment		1	119	45
Total restructuring and asset-related charges, net		$ 57	170	333
Disposed by Sale [Member] \| Sulfur Business [Member]
Restructuring Cost and Reserve [Line Items]
Asset-related charges - impairment	$ 58		58
Chemical Solutions [Member] \| Corporate Headquarter Building [Member]
Restructuring Cost and Reserve [Line Items]
Asset-related charges - impairment			13
Pascagoula, Mississippi [Member] \| Aniline Facility [Member]
Restructuring Cost and Reserve [Line Items]
Asset-related charges - impairment			$ 48
Niagara Falls, NY [Member] \| Reactive Metals Solutions Plant (RMS) Closure [Member] \| Operating Segments [Member] \| Chemical Solutions [Member]
Restructuring Cost and Reserve [Line Items]
Asset-related charges - impairment				$ 45

Restructuring and Asset-Related Charges, Net (Narrative) (Details) $ in Millions	1 Months Ended				3 Months Ended			12 Months Ended
	Oct. 31, 2017 Employee	Nov. 30, 2015 position	Aug. 31, 2015 production_line	Jun. 30, 2015 position	Dec. 31, 2017 USD ($)	Mar. 31, 2017 USD ($)	Dec. 31, 2015 USD ($) position	Dec. 31, 2018 USD ($)	Dec. 31, 2017 USD ($)	Dec. 31, 2016 USD ($)	Dec. 31, 2015 USD ($)
Restructuring Cost and Reserve [Line Items]
Employee separation and asset related charges									$ 56	$ 51	$ 288
2015 Global Restructuring Program [Member]
Restructuring Cost and Reserve [Line Items]
Employee separation and asset related charges									0	6	112
Expected number of positions to be eliminated \| position		430
Number of positions eliminated (more than) \| position				430
2017 Restructuring Program [Member]
Restructuring Cost and Reserve [Line Items]
Employee separation and asset related charges									32	0	0
2017 Restructuring Program [Member] \| Minimum [Member] \| Restructuring-Related Charges Expected to be Incurred Though December 31, 2018 [Member]
Restructuring Cost and Reserve [Line Items]
Employee separation and asset related charges								$ 20
2017 Restructuring Program [Member] \| Maximum [Member] \| Restructuring-Related Charges Expected to be Incurred Though December 31, 2018 [Member]
Restructuring Cost and Reserve [Line Items]
Employee separation and asset related charges								$ 25
Operating Segments [Member] \| Titanium Technologies [Member]
Restructuring Cost and Reserve [Line Items]
Employee separation and asset related charges											140
Land sold						$ 10
Operating Segments [Member] \| Titanium Technologies [Member] \| 2015 Global Restructuring Program [Member]
Restructuring Cost and Reserve [Line Items]
Employee separation and asset related charges									0	2	33
Operating Segments [Member] \| Fluoroproducts [Member]
Restructuring Cost and Reserve [Line Items]
Employee separation and asset related charges									3	7	21
Operating Segments [Member] \| Fluoroproducts [Member] \| 2015 Global Restructuring Program [Member]
Restructuring Cost and Reserve [Line Items]
Employee separation and asset related charges									0	4	54
Operating Segments [Member] \| Chemical Solutions [Member]
Restructuring Cost and Reserve [Line Items]
Employee separation and asset related charges										8
Operating Segments [Member] \| Chemical Solutions [Member] \| 2015 Global Restructuring Program [Member]
Restructuring Cost and Reserve [Line Items]
Employee separation and asset related charges									0	0	25
Employee separation [Member] \| 2015 Global Restructuring Program [Member]
Restructuring Cost and Reserve [Line Items]
Employee separation and asset related charges							$ 48				64
Employee separation [Member] \| Operating Segments [Member] \| Titanium Technologies [Member]
Restructuring Cost and Reserve [Line Items]
Employee separation and asset related charges											11
Employee separation [Member] \| Operating Segments [Member] \| Fluoroproducts [Member]
Restructuring Cost and Reserve [Line Items]
Employee separation and asset related charges											2
Employee separation [Member] \| Operating Segments [Member] \| Chemical Solutions [Member]
Restructuring Cost and Reserve [Line Items]
Employee separation and asset related charges											12
Property, Plant and Equipment Related Charges [Member] \| Operating Segments [Member] \| Titanium Technologies [Member]
Restructuring Cost and Reserve [Line Items]
Employee separation and asset related charges											115
Property, Plant and Equipment Related Charges [Member] \| Operating Segments [Member] \| Fluoroproducts [Member]
Restructuring Cost and Reserve [Line Items]
Employee separation and asset related charges											18
Decommissioning Costs [Member] \| Operating Segments [Member] \| Titanium Technologies [Member]
Restructuring Cost and Reserve [Line Items]
Employee separation and asset related charges											14
Decommissioning Costs [Member] \| Operating Segments [Member] \| Fluoroproducts [Member]
Restructuring Cost and Reserve [Line Items]
Employee separation and asset related charges											$ 1
Additional Restructuring Charges [Member] \| Operating Segments [Member] \| Titanium Technologies [Member]
Restructuring Cost and Reserve [Line Items]
Employee separation and asset related charges									4	30
Additional Restructuring Charges [Member] \| Operating Segments [Member] \| Chemical Solutions [Member]
Restructuring Cost and Reserve [Line Items]
Employee separation and asset related charges									17
Contract Termination [Member] \| Operating Segments [Member] \| Chemical Solutions [Member]
Restructuring Cost and Reserve [Line Items]
Employee separation and asset related charges										2
Decommissioning and Other Related Charges [Member] \| Operating Segments [Member] \| Chemical Solutions [Member]
Restructuring Cost and Reserve [Line Items]
Employee separation and asset related charges										$ 6
Corporate Function Efforts [Member] \| 2017 Restructuring Program [Member]
Restructuring Cost and Reserve [Line Items]
Employee separation and asset related charges									14
Voluntary Separation Program [Member] \| 2017 Restructuring Program [Member]
Restructuring Cost and Reserve [Line Items]
Expected number of positions to be eliminated \| Employee	300
Accrual of termination benefits recognized					$ 18
New Johnsonville, Tennessee [Member]
Restructuring Cost and Reserve [Line Items]
Number of production lines shut down during period \| production_line			1
Niagara Falls, NY [Member] \| Operating Segments [Member] \| Chemical Solutions [Member]
Restructuring Cost and Reserve [Line Items]
Expected number of positions to be eliminated \| position							200
Niagara Falls, NY [Member] \| Additional Restructuring Charges [Member] \| Operating Segments [Member] \| Chemical Solutions [Member]
Restructuring Cost and Reserve [Line Items]
Additional restructuring charges expected to be incurred in 2018					$ 4				$ 4

Restructuring and Asset-Related Charges, Net (Restructuring Program Schedule) (Details) - USD ($)	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Restructuring Reserve [Roll Forward]
Restructuring reserve, beginning	$ 34,000,000	$ 98,000,000
Charges (credits) to income	24,000,000	4,000,000
Payments	(31,000,000)	(68,000,000)
Currency translation and other adjustments	0	0
Restructuring reserve, ending	27,000,000	34,000,000	$ 98,000,000
Employee separation charges	23,000,000	4,000,000	137,000,000
Maximum [Member]
Restructuring Reserve [Roll Forward]
Currency translation and other adjustments	1,000,000
Employee separation [Member]
Restructuring Reserve [Roll Forward]
Employee separation charges		2,000,000
Titanium Technologies Site Closure [Member]
Restructuring Reserve [Roll Forward]
Restructuring reserve, beginning	4,000,000	11,000,000
Charges (credits) to income	0	0
Payments	(3,000,000)	(7,000,000)
Currency translation and other adjustments	0	0
Restructuring reserve, ending	1,000,000	4,000,000	11,000,000
Fluoroproducts Lines Shutdown [Member]
Restructuring Reserve [Roll Forward]
Restructuring reserve, beginning	1,000,000	2,000,000
Charges (credits) to income	0	0
Payments	(1,000,000)	(1,000,000)
Currency translation and other adjustments	0	0
Restructuring reserve, ending	0	1,000,000	2,000,000
Chemical Solutions Site Closures [Member]
Restructuring Reserve [Roll Forward]
Restructuring reserve, beginning	8,000,000	12,000,000
Charges (credits) to income	0	(2,000,000)
Payments	(6,000,000)	(1,000,000)
Currency translation and other adjustments	0	(1,000,000)
Restructuring reserve, ending	2,000,000	8,000,000	12,000,000
2015 Global Restructuring Program [Member]
Restructuring Reserve [Roll Forward]
Restructuring reserve, beginning	21,000,000	73,000,000
Charges (credits) to income	1,000,000	6,000,000
Payments	(21,000,000)	(59,000,000)
Currency translation and other adjustments	0	1,000,000
Restructuring reserve, ending	1,000,000	21,000,000	73,000,000
2017 Restructuring Program [Member]
Restructuring Reserve [Roll Forward]
Restructuring reserve, beginning	0	0
Charges (credits) to income	23,000,000	0
Payments	0	0
Currency translation and other adjustments	0	0
Restructuring reserve, ending	$ 23,000,000	$ 0	$ 0

Sales of Assets and Businesses (Narrative) (Details) - USD ($) $ in Millions	1 Months Ended						3 Months Ended	12 Months Ended
	Apr. 30, 2017	Dec. 31, 2016	Aug. 31, 2016	Jul. 31, 2016	May 31, 2016	Mar. 31, 2016	Jun. 30, 2016	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015	Apr. 30, 2016
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Other assets, impairment charges		$ 13
Net proceeds from sale and leaseback transaction	$ 29
Sale and leaseback transaction, deferred gain	2
Repayment of senior secured term loans									$ 354
Asset related charges								$ 1	119	$ 45
Other Income, Net [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Gain on sale of assets									89
Sulfur Business [Member] \| Assets Held-for-sale [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Cash proceeds from sale of facility					$ 10
Loss on sale				$ 4
Sulfur Business [Member] \| Disposal Group, Held-for-sale or Disposed of by Sale, Not Discontinued Operations [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Purchase price							$ 325
Proceeds from sale				311
Net assets disposed				342
Liabilities of assets held-for-sale				$ 11
Sulfur Business [Member] \| Disposed by Sale [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Asset related charges							$ 58		58
Clean and Disinfect Product Line [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Gain on sale of assets									169
Clean and Disinfect Product Line [Member] \| Disposal Group, Held-for-sale or Disposed of by Sale, Not Discontinued Operations [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Purchase price											$ 230
Net assets disposed		48							48
Liabilities of assets held-for-sale		6							6
Proceeds from sale			$ 223
Cash transferred in sale			$ 2
Goodwill		$ 13							13
Transaction and other charges									$ 9
Aniline Facility, Beaumont, Texas [Member] \| Disposed by Sale [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Cash proceeds from sale of facility						$ 140
Net assets disposed						41
Goodwill						4
Transaction costs						$ 11
Senior secured term loan [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Repayment of senior secured term loans	$ 13

Sales of Assets and Businesses (Major Components of Assets and Liabilities Disposed) (Details) - Disposed by Sale [Member] - Chemical Solutions Portfolio Optimization [Member] $ in Millions	Dec. 31, 2016 USD ($)
Current assets:
Accounts receivable - trade	$ 22
Inventories	17
Total current assets	39
Non-current assets:
Property, plant, and equipment, net	298
Goodwill	17
Other assets	136
Less: Impairment loss	(58)
Total non-current assets, net	393
Total assets	432
Accounts payable and accrued liabilities	17
Total liabilities	17
Total net assets disposed	$ 415

Other Income, Net (Components of Other Income) (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Other Income And Expenses [Abstract]
Leasing, contract services and miscellaneous income	$ 30	$ 35	$ 25
Royalty income	24	15	19
Gain (loss) on sale of assets and businesses	22	254	(9)
Exchange gains (losses), net	3	(57)	19
Total other income, net	$ 79	$ 247	$ 54

Other Income, Net (Components of Other Income) (Parenthetical) (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
Land [Member] \| Repauno New Jersey [Member]
Component of Other Income [Line Items]
Gain on sale of asset	$ 13
Edge Moor Site [Member]
Component of Other Income [Line Items]
Gain on sale of asset	$ 12
Clean and Disinfect Product Line [Member]
Component of Other Income [Line Items]
Gain on sale of asset		$ 169
Beaumont Site [Member]
Component of Other Income [Line Items]
Gain on sale of asset		$ 89

Income Taxes (Narrative) (Details) - USD ($) $ in Millions		3 Months Ended	12 Months Ended
Income Taxes (Narrative) (Details) - USD ($) $ in Millions	Jan. 01, 2018	Dec. 31, 2017	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Tax Credit Carryforward [Line Items]
U.S. federal corporate tax rate			35.00%	35.00%	35.00%
Provision (benefit) for income taxes			$ 165	$ (18)	$ (98)
Provisional repatriation transition tax obligation			322
Foreign tax credits			202
Unremitted earnings of foreign subsidiaries		$ 2,400	2,400
Change in valuation allowance on foreign tax credits		(33)	$ (33)	50
Percentage of pro rata portion shareholder equity			10.00%
Valuation allowance		17	$ 17	50
Unrecognized income tax benefits released			6	$ 1	$ 0
U.S Federal and State [Member] \| Expiration Between Years 2035 to 2037 [Member]
Tax Credit Carryforward [Line Items]
Tax loss carryforwards		24	24
U.S Federal [Member]
Tax Credit Carryforward [Line Items]
Valuation allowance		17	17
U.S Federal [Member] \| Expiration Year 2026 [Member]
Tax Credit Carryforward [Line Items]
Tax credit carryforwards		17	17
Foreign [Member] \| Expiration Between Years 2025 to 2026 [Member]
Tax Credit Carryforward [Line Items]
Tax loss carryforwards		$ 1	$ 1
Subsequent Event [Member]
Tax Credit Carryforward [Line Items]
U.S. federal corporate tax rate	21.00%
Provision (benefit) for income taxes	$ 68

Income Taxes - Components of Provision for (Benefit from) Income Taxes (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Current tax expense:
U.S. federal	$ (8)	$ 0	$ 37
U.S. state and local	1	0	1
International	89	93	62
Total current tax expense	82	93	100
Deferred tax expense (benefit):
U.S. federal	60	(101)	(187)
U.S. state and local	6	(17)	(14)
International	17	7	3
Total deferred tax expense (benefit)	83	(111)	(198)
Total provision for (benefit from) income taxes	$ 165	$ (18)	$ (98)

Income Taxes - Components of Deferred Tax Assets and Liabilities (Details) - USD ($) $ in Millions	Dec. 31, 2017	Dec. 31, 2016
Deferred tax assets:
Environmental and other reserves	$ 89	$ 150
Litigation reserves	14	149
Stock-based compensation and accrued employee benefits	26	35
Other assets and other accrued liabilities	8	27
Tax loss carryforwards	27	45
Foreign tax credit carryforwards	17	50
Total deferred tax assets	181	456
Less: Valuation allowance	(17)	(50)
Total deferred tax assets, net	164	406
Deferred tax liabilities:
Pension and other liabilities	(55)	(16)
Property, plant, and equipment	(274)	(441)
Inventories and other assets	(4)	(40)
Total deferred tax liabilities	(333)	(497)
Deferred tax liability, net	$ (169)	$ (91)

Income Taxes - Effective Income Tax Rate Reconciliation (Details)	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Effective Income Tax Rate Reconciliation, Percent [Abstract]
Statutory U.S. federal income tax rate	35.00%	35.00%	35.00%
State income taxes, net of federal benefit	0.70%	150.40%	5.10%
Lower effective tax rate on international operations, net	(16.30%)	552.50%	12.00%
Depletion	(0.90%)	51.20%	3.40%
Goodwill	(0.00%)	(47.90%)	(3.20%)
Exchange losses (gains)	0.60%	(39.10%)	0.50%
Provision to return and other adjustments	0.60%	(57.90%)	0.00%
Permanent items	1.00%	(27.30%)	(0.50%)
Valuation allowance	(3.60%)	(451.60%)	0.00%
Net impact of U.S. tax reform	4.30%	0.00%	0.00%
Stock-based compensation	(2.20%)	0.00%	0.00%
Other, net	(1.20%)	(1.70%)	(0.20%)
Total effective tax rate	18.10%	163.60%	52.10%

Income Taxes - Effective Income Tax Reconciliation (Details) - USD ($) $ in Millions	3 Months Ended	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Effective Income Tax Rate Reconciliation, Amount [Abstract]
Statutory U.S. federal income tax rate		$ 319	$ (4)	$ (66)
State income taxes, net of federal benefit		7	(16)	(10)
Lower effective tax rate on international operations, net		(149)	(61)	(23)
Depletion		(8)	(6)	(6)
Goodwill			5	6
Exchange losses (gains)		5	4	(1)
Provision to return and other adjustments		6	6
Permanent items		9	3	1
Valuation allowance	$ (33)	(33)	50
Net impact of U.S. tax reform		39
Stock-based compensation		(20)
Other, net		(10)	1	1
Total provision for (benefit from) income taxes		$ 165	$ (18)	$ (98)

Income Taxes - Effective Income Tax Reconciliation (Parenthetical) (Details) $ in Millions	12 Months Ended
	Dec. 31, 2017 USD ($)
Income Tax Examination [Line Items]
Total windfall benefits on stock-based compensation	$ (22)
U.S Federal [Member]
Income Tax Examination [Line Items]
Total windfall benefits on stock-based compensation	(20)
State [Member]
Income Tax Examination [Line Items]
Total windfall benefits on stock-based compensation	$ (2)

Income Taxes - Summary of Income (Loss) Before Income Taxes (Details) - USD ($) $ in Millions	3 Months Ended								12 Months Ended
	Dec. 31, 2017	Sep. 30, 2017	Jun. 30, 2017	Mar. 31, 2017	Dec. 31, 2016	Sep. 30, 2016	Jun. 30, 2016	Mar. 31, 2016	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Income Tax Disclosure [Abstract]
U.S. operations (including exports)									$ (306)	$ (481)	$ (492)
International operations									1,218	470	304
Income (loss) before income taxes	$ 264	$ 250	$ 225	$ 173	$ (273)	$ 234	$ (41)	$ 70	$ 912	$ (11)	$ (188)

Income Taxes - Summary of open tax years by significant jurisdiction (Details)	12 Months Ended
	Dec. 31, 2017
Non-U.S Jurisdiction [Member] \| Earliest Tax Year [Member] \| China [Member]
Income Tax Contingency [Line Items]
Tax years open to examination	2011
Non-U.S Jurisdiction [Member] \| Earliest Tax Year [Member] \| Mexico [Member]
Income Tax Contingency [Line Items]
Tax years open to examination	2012
Non-U.S Jurisdiction [Member] \| Earliest Tax Year [Member] \| Netherlands [Member]
Income Tax Contingency [Line Items]
Tax years open to examination	2014
Non-U.S Jurisdiction [Member] \| Earliest Tax Year [Member] \| Taiwan [Member]
Income Tax Contingency [Line Items]
Tax years open to examination	2014
Non-U.S Jurisdiction [Member] \| Latest Tax Year [Member] \| China [Member]
Income Tax Contingency [Line Items]
Tax years open to examination	2017
Non-U.S Jurisdiction [Member] \| Latest Tax Year [Member] \| Mexico [Member]
Income Tax Contingency [Line Items]
Tax years open to examination	2017
Non-U.S Jurisdiction [Member] \| Latest Tax Year [Member] \| Netherlands [Member]
Income Tax Contingency [Line Items]
Tax years open to examination	2017
Non-U.S Jurisdiction [Member] \| Latest Tax Year [Member] \| Taiwan [Member]
Income Tax Contingency [Line Items]
Tax years open to examination	2017
U.S Federal [Member] \| Earliest Tax Year [Member]
Income Tax Contingency [Line Items]
Tax years open to examination	2015
U.S Federal [Member] \| Latest Tax Year [Member]
Income Tax Contingency [Line Items]
Tax years open to examination	2017

Income Taxes - Unrecognized Tax Benefits (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]
Balance at January 1,	$ 6	$ 7	$ 39
Gross amounts of decreases in unrecognized tax benefits as a result of adjustments to tax provisions taken during the prior period	(6)	(1)	0
Gross amounts of increases in unrecognized tax benefits as a result of tax positions taken during the current period	0	0	0
Reduction to unrecognized tax benefits as a result of a lapse of the applicable statute of limitations	0	0	(32)
Balance at December 31,	0	6	7
Total unrecognized tax benefits, if recognized, that would impact the effective tax rate	0	0	0
Total amount of interest and penalties recognized in the consolidated statements of operations	0	0	1
Total amount of interest and penalties recognized in the consolidated balance sheets	$ 0	$ 0	$ 0

Income Taxes - Summary of Valuation Allowance (Details) - Valuation Allowance of Deferred Tax Assets [Member] - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Movement in Valuation Allowances and Reserves [Roll Forward]
Balance at January 1,	$ 50	$ 0	$ 36
Net charges to income tax expense	0	50	0
Release of valuation allowance	(33)	0	(36)
Balance at December 31,	$ 17	$ 50	$ 0

Earnings Per Share of Common Stock (Earnings per Share Calculation) (Details) - USD ($) $ in Millions	3 Months Ended								12 Months Ended
	Dec. 31, 2017	Sep. 30, 2017	Jun. 30, 2017	Mar. 31, 2017	Dec. 31, 2016	Sep. 30, 2016	Jun. 30, 2016	Mar. 31, 2016	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Numerator:
Net income (loss) attributable to Chemours	$ 228	$ 207	$ 161	$ 150	$ (230)	$ 204	$ (18)	$ 51	$ 746	$ 7	$ (90)
Denominator:
Weighted-average number of common shares outstanding - basic									184,844,106	181,621,422	180,993,623
Dilutive effect of the Company’s employee compensation plans									6,139,885	1,795,078
Weighted-average number of common shares outstanding - diluted									190,983,991	183,416,500	180,993,623

Earnings Per Share of Common Stock (Anti-dilutive Shares Excluded from Computation of Earnings per Share) (Details) - shares	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Earnings Per Share [Abstract]
Average number of stock options	43,072	5,820,499	8,358,894

Accounts and Notes Receivable, Net (Schedule of Accounts and Notes Receivable) (Details) - USD ($) $ in Millions	Dec. 31, 2017	Dec. 31, 2016
Receivables [Abstract]
Accounts receivable—trade, net	$ 847	$ 742
VAT, GST and other taxes	54	46
Other receivables	18	19
Total accounts and notes receivable, net	$ 919	$ 807

Accounts and Notes Receivable, Net (Schedule of Accounts and Notes Receivable) (Parenthetical) (Details) - USD ($) $ in Millions	Dec. 31, 2017	Dec. 31, 2016
Receivables [Abstract]
Allowance for doubtful accounts receivable	$ 5	$ 5

Accounts and Notes Receivable, Net (Narrative) (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2004
Receivables [Abstract]
Bad debt expense	$ 1	$ 7	$ 1

Inventories (Details) - USD ($) $ in Millions	Dec. 31, 2017	Dec. 31, 2016
Inventory Net [Abstract]
Finished products	$ 648	$ 532
Semi-finished products	164	150
Raw materials, stores, and supplies	313	285
Inventories before LIFO adjustment	1,125	967
Adjustment of inventories to LIFO basis	(190)	(200)
Total inventories	935	767
LIFO inventory amount	$ 509	$ 465
Percentage of LIFO inventory	45.00%	48.00%

Property, Plant, and Equipment, Net (Details) - USD ($) $ in Millions	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Property Plant And Equipment [Line Items]
Property, plant and equipment, gross	$ 8,511	$ 7,997
Less: Accumulated depreciation	(5,503)	(5,213)
Property, plant, and equipment, net	3,008	2,784	$ 3,177
Equipment [Member]
Property Plant And Equipment [Line Items]
Property, plant and equipment, gross	6,961	6,748
Building [Member]
Property Plant And Equipment [Line Items]
Property, plant and equipment, gross	875	814
Construction-in-progress [Member]
Property Plant And Equipment [Line Items]
Property, plant and equipment, gross	520	293
Land [Member]
Property Plant And Equipment [Line Items]
Property, plant and equipment, gross	119	106
Mineral rights [Member]
Property Plant And Equipment [Line Items]
Property, plant and equipment, gross	$ 36	$ 36

Property, Plant, and Equipment, Net (Narrative) (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Property Plant And Equipment [Abstract]
Depreciation expense	$ 269	$ 281	$ 264
Capital leased assets	7	5
Build to suit lease assets	8
Interest capitalized	$ 9	$ 18	$ 21

Goodwill and Other Intangible Assets, Net (Schedule of Goodwill) (Details)
$ in Millions

12 Months Ended

Dec. 31, 2016

USD ($)

Goodwill [Roll Forward]

Goodwill, beginning balance

$ 166

Sale of business

(13)

^[1]

Goodwill, ending balance

153

Operating Segments [Member] | Titanium Technologies [Member]

Goodwill [Roll Forward]

Goodwill, beginning balance

Sale of business

^[1]

Goodwill, ending balance

Operating Segments [Member] | Fluoroproducts [Member]

Goodwill [Roll Forward]

Goodwill, beginning balance

Sale of business

^[1]

Goodwill, ending balance

Operating Segments [Member] | Chemical Solutions [Member]

Goodwill [Roll Forward]

Goodwill, beginning balance

Sale of business

(13)

^[1]

Goodwill, ending balance

$ 55

[1]	Represents goodwill disposed of in connection with the sale of the Company’s C&D business.

Goodwill and Other Intangible Assets, Net (Narrative) (Details)	3 Months Ended	12 Months Ended
	Sep. 30, 2015 USD ($)	Dec. 31, 2017 USD ($) segment	Dec. 31, 2016 USD ($)	Dec. 31, 2015 USD ($)
Goodwill and Other Intangible Assets
Number of operating segments \| segment		3
Goodwill impairment		$ 0	$ 0	$ 25,000,000
Accumulated impairment losses included in goodwill		0	0
Amortization expense, 2018		3,000,000
Amortization expense, 2019		3,000,000
Amortization expense, 2020		3,000,000
Amortization expense, 2021		2,000,000
Amortization expense, 2022		$ 1,000,000
Minimum [Member]
Goodwill and Other Intangible Assets
Useful life		5 years
Maximum [Member]
Goodwill and Other Intangible Assets
Useful life		20 years
Continuing Operations [Member]
Goodwill and Other Intangible Assets
Aggregate pre-tax amortization expense		$ 4,000,000	$ 3,000,000	$ 3,000,000
Sulfur [Member]
Goodwill and Other Intangible Assets
Goodwill impairment	$ 25,000,000

Goodwill and Other Intangible Assets, Net (Schedule of Other Intangible Assets) (Details) - USD ($)
$ in Millions

Dec. 31, 2017

Dec. 31, 2016

Finite-Lived and Indefinite-Lived Intangible Assets [Line Items]

Cost

$ 46

Accumulated Amortization

(33)

(29)

Net

Customer Lists [Member]

Finite-Lived and Indefinite-Lived Intangible Assets [Line Items]

Cost

Accumulated Amortization

(8)

(7)

Net

Patents [Member]

Finite-Lived and Indefinite-Lived Intangible Assets [Line Items]

Cost

Accumulated Amortization

(18)

Net

Purchased Trademarks [Member]

Finite-Lived and Indefinite-Lived Intangible Assets [Line Items]

Cost

Accumulated Amortization

(2)

Net

Purchased and Licensed Technology [Member]

Finite-Lived and Indefinite-Lived Intangible Assets [Line Items]

Cost

Accumulated Amortization

(2)

Net

Other [Member]

Finite-Lived and Indefinite-Lived Intangible Assets [Line Items]

Cost

^[1]

Accumulated Amortization

^[1]

(3)

Net

^[1]

$ 7

$ 10

[1]

Other Assets (Details) - USD ($) $ in Millions	Dec. 31, 2017	Dec. 31, 2016
Other Assets [Line Items]
Capitalized repair and maintenance costs	$ 117	$ 145
Pension assets	260	159
Deferred income taxes	40	41
Asset held for sale		29
Miscellaneous	36	43
Total other assets	453	417
Senior Secured Revolving Credit Facility [Member]
Other Assets [Line Items]
Deferred financing fee	$ 9	$ 13

Accounts Payable (Details) - USD ($) $ in Millions	Dec. 31, 2017	Dec. 31, 2016
Payables And Accruals [Abstract]
Trade payables	$ 1,008	$ 858
Dividends payable	31
VAT and other payables	36	26
Total accounts payable	$ 1,075	$ 884

Accounts Payable (Parenthetical) (Details)	12 Months Ended
Accounts Payable (Parenthetical) (Details)	Dec. 31, 2017 $ / shares
Payables And Accruals [Abstract]
Dividend per share	$ 0.17
Dividends payable declared date	2017-12
Dividends payable payment date	Mar. 15, 2018
Dividends payable record date	Feb. 15, 2018

Other Accrued Liabilities (Details) - USD ($)
$ in Millions

3 Months Ended

May 23, 2017

Sep. 30, 2017

Jun. 30, 2017

Dec. 31, 2017

Dec. 31, 2016

Accrued Liabilities, Current [Abstract]

Compensation and other employee-related costs

$ 174

$ 154

Employee separation costs

^[1]

Accrued litigation

^[2]

344

Environmental remediation

^[3]

^[4]

^[5]

105

Total other accrued liabilities

$ 558

872

Prepayment from DuPont for specified goods and services

PFOA MDL Settlement [Member]

Accrued Liabilities, Current [Abstract]

Settlement payments

$ 335

PFOA Matters [Member] | PFOA MDL Settlement [Member]

Accrued Liabilities, Current [Abstract]

Accrued litigation

$ 335

Settlement payments

$ 320

$ 15

[1]	Represents the current portion of accrued employee separation costs related to the Company’s restructuring activities.
[2]	Accrued litigation includes a $335 litigation accrual related to Company’s PFOA MDL Settlement at December 31, 2016, which is discussed further in Note 20. The Company made payments of $15 and $320 during the second and third quarters of 2017 for a full release of all claims by the settling plaintiffs.
[3]	Represents the current portion of accrued environmental remediation, which is discussed further in Note 20.
[4]	Deferred revenue includes a $58 prepayment from DuPont for specified goods and services at December 31, 2016, which were fulfilled and/or delivered during 2017.
[5]	Miscellaneous primarily includes accrued utility expenses, property taxes, an accrued indemnification liability, the current portion of the Company’s asset retirement obligations, and other miscellaneous expenses.

Debt (Components of Total Debt) (Details) € in Millions, $ in Millions	Dec. 31, 2017 USD ($)	Dec. 31, 2017 EUR (€)	Dec. 31, 2016 USD ($)	Dec. 31, 2016 EUR (€)	May 12, 2015 USD ($)
Debt Instrument [Line Items]
Capital lease obligations	$ 3		$ 3
Build-to-suit lease obligation	8
Total debt	4,161		3,591
Less: Unamortized issue discounts	(8)		(5)
Less: Unamortized debt issuance costs	(41)		(42)
Less: Current maturities of long-term debt	(15)		(15)
Total long-term debt, net	4,097		3,529
Senior unsecured notes [Member]
Debt Instrument [Line Items]
Long-term debt, gross					$ 2,503
Senior unsecured notes [Member] \| 6.625% Senior Notes Due May 2023 [Member]
Debt Instrument [Line Items]
Long-term debt	$ 1,158		$ 1,158
Debt instrument interest rate	6.625%	6.625%	6.625%	6.625%
Senior unsecured notes [Member] \| 7.000% Senior Notes Due May 2025 [Member]
Debt Instrument [Line Items]
Long-term debt	$ 750		$ 750
Debt instrument interest rate	7.00%	7.00%	7.00%	7.00%
Senior unsecured notes [Member] \| Senior Notes 6.125% Due May 2023 [Member]
Debt Instrument [Line Items]
Long-term debt	$ 350		$ 308
Long-term debt, gross \| €		€ 295		€ 295
Debt instrument interest rate	6.125%	6.125%	6.125%	6.125%
Senior unsecured notes [Member] \| 5.375% Senior Notes Due May 2027 [Member]
Debt Instrument [Line Items]
Long-term debt	$ 500
Debt instrument interest rate	5.375%	5.375%	5.375%	5.375%
Senior Secured Tranche B Term Loan Due May 2022 [Member]
Debt Instrument [Line Items]
Long-term debt			$ 1,372
Senior Secured Tranche B-1 Dollar Term Loan Due May 2022 [Member]
Debt Instrument [Line Items]
Long-term debt	$ 923
Senior Secured Tranche B-1 Euro Term Loan Due May 2022 [Member] \| Senior unsecured notes [Member]
Debt Instrument [Line Items]
Long-term debt, gross	$ 469	€ 394

Debt (Senior Secured Credit Facilities) (Details)			3 Months Ended	6 Months Ended	12 Months Ended		17 Months Ended
Debt (Senior Secured Credit Facilities) (Details)	Apr. 03, 2017 USD ($)	May 12, 2015 USD ($)	Jun. 30, 2017 USD ($)	Jun. 30, 2017	Dec. 31, 2017 USD ($)	Dec. 31, 2016 USD ($)	Jan. 01, 2019	Apr. 03, 2017 EUR (€)
Line of Credit Facility [Line Items]
Debt instrument net issue discount					$ 8,000,000	$ 5,000,000
Loss on debt extinguishment and related fees			$ 3,000,000
Domestic Subsidiary [Member]
Line of Credit Facility [Line Items]
Collateral as percentage of common stock		100.00%
Foreign Subsidiary [Member]
Line of Credit Facility [Line Items]
Collateral as percentage of common stock		65.00%
Prior Term Loan [Member]
Line of Credit Facility [Line Items]
Debt instrument term		7 years
Line of credit facility, maximum borrowing capacity		$ 1,500,000,000
Periodic payment, percentage of face amount		1.00%
Debt instrument net issue discount		$ 7,000,000
Prior Term Loan [Member] \| Maximum [Member] \| London Interbank Offered Rate (LIBOR) [Member]
Line of Credit Facility [Line Items]
Variable rate		3.00%
Prior Term Loan [Member] \| Minimum [Member] \| London Interbank Offered Rate (LIBOR) [Member]
Line of Credit Facility [Line Items]
Variable rate		0.75%
Revolving Credit Facility [Member]
Line of Credit Facility [Line Items]
Debt instrument term					5 years
Line of credit facility, maximum borrowing capacity					$ 750,000,000
Long-term debt					0	0
Letters of credit outstanding					$ 101,000,000	$ 132,000,000
Commitment fee percentage					0.20%
Maximum net leverage ratio				3.00%		3.50%
Minimum interest coverage ratio				1.75%
Revolving Credit Facility [Member] \| Scenario Forecast [Member]
Line of Credit Facility [Line Items]
Maximum net leverage ratio							2.00%
Maximum net leverage ratio decrease, semi-annually							0.25%
Minimum interest coverage ratio							3.00%
Minimum coverage ratio increase, semi-annually							0.25%
Revolving Credit Facility [Member] \| London Interbank Offered Rate (LIBOR) [Member]
Line of Credit Facility [Line Items]
Variable rate					1.50%
Revolving Credit Facility [Member] \| Base Rate [Member]
Line of Credit Facility [Line Items]
Variable rate					0.50%
Revolving Credit Facility [Member] \| Maximum [Member]
Line of Credit Facility [Line Items]
Unused capacity commitment fee percentage					0.35%
Revolving Credit Facility [Member] \| Maximum [Member] \| London Interbank Offered Rate (LIBOR) [Member]
Line of Credit Facility [Line Items]
Variable rate					2.25%
Revolving Credit Facility [Member] \| Maximum [Member] \| Base Rate [Member]
Line of Credit Facility [Line Items]
Variable rate					1.25%
Revolving Credit Facility [Member] \| Minimum [Member]
Line of Credit Facility [Line Items]
Unused capacity commitment fee percentage					0.20%
Revolving Credit Facility [Member] \| Minimum [Member] \| London Interbank Offered Rate (LIBOR) [Member]
Line of Credit Facility [Line Items]
Variable rate					1.50%
Revolving Credit Facility [Member] \| Minimum [Member] \| Base Rate [Member]
Line of Credit Facility [Line Items]
Variable rate					0.50%
Euro Term Loan [Member]
Line of Credit Facility [Line Items]
Line of credit facility, maximum borrowing capacity \| €								€ 400,000,000
Line of credit facility, maturity date	May 12, 2022
Effective interest rates on senior secured term loan					3.00%
Euro Term Loan [Member] \| Maximum [Member] \| Euro Interbank Offered Rate (EURIBOR) [Member]
Line of Credit Facility [Line Items]
Variable rate	2.25%
Euro Term Loan [Member] \| Minimum [Member] \| Euro Interbank Offered Rate (EURIBOR) [Member]
Line of Credit Facility [Line Items]
Variable rate	0.75%
Dollar Term Loan [Member]
Line of Credit Facility [Line Items]
Line of credit facility, maximum borrowing capacity	$ 940,000,000
Line of credit facility, maturity date	May 12, 2022
Effective interest rates on senior secured term loan					3.85%
Dollar Term Loan [Member] \| Maximum [Member] \| London Interbank Offered Rate (LIBOR) [Member]
Line of Credit Facility [Line Items]
Variable rate	2.50%
Dollar Term Loan [Member] \| Minimum [Member] \| London Interbank Offered Rate (LIBOR) [Member]
Line of Credit Facility [Line Items]
Variable rate	0.00%

Debt (Senior Unsecured Notes) (Details)			12 Months Ended
Debt (Senior Unsecured Notes) (Details)	May 23, 2017 USD ($)	May 12, 2015 USD ($)	Dec. 31, 2017 USD ($)	Dec. 31, 2015 USD ($)	Dec. 31, 2016 USD ($)	May 12, 2015 EUR (€)
Debt Instrument [Table]
Proceeds from issuance of debt, net			$ 495,000,000	$ 3,491,000,000
Debt instrument net issue discount			$ 8,000,000		$ 5,000,000
PFOA MDL Settlement [Member]
Debt Instrument [Table]
Settlement payments	$ 335,000,000
Senior unsecured notes [Member]
Debt Instrument [Table]
Long-term debt, gross		$ 2,503,000,000
Senior unsecured notes, payment terms			Interest on the Notes is payable semi-annually in cash in arrears on May 15 and November 15 of each year
Obligation threshold for debt to become guaranteed		$ 75,000,000
Repurchase price obligation, percentage of principal amount redeemed in event of change of control		101.00%				101.00%
Repurchase price obligation, percentage of principal amount redeemed in event of change of asset dispositions		100.00%				100.00%
Proceeds from issuance of debt, net	489,000,000
Senior unsecured notes [Member] \| 7.000% Senior Notes Due May 2025 [Member]
Debt Instrument [Table]
Debt Instrument, face amount		$ 507,000,000
Debt instrument interest rate			7.00%		7.00%
Senior unsecured notes [Member] \| 2023 Notes [Member]
Debt Instrument [Table]
Debt Instrument, face amount		$ 1,350,000,000
Debt instrument interest rate		6.625%				6.625%
Debt instrument maturity date		May 15, 2023
Senior unsecured notes [Member] \| 2025 Notes [Member]
Debt Instrument [Table]
Debt Instrument, face amount		$ 750,000,000
Debt instrument interest rate		7.00%				7.00%
Debt instrument maturity date		May 15, 2025
Senior unsecured notes [Member] \| Euro Notes [Member]
Debt Instrument [Table]
Debt Instrument, face amount \| €						€ 360,000,000
Debt instrument interest rate		6.125%				6.125%
Debt instrument maturity date		May 15, 2023
Senior unsecured notes [Member] \| 2027 Notes [Member]
Debt Instrument [Table]
Long-term debt, gross	$ 500,000,000
Debt instrument interest rate	5.375%
Obligation threshold for debt to become guaranteed	$ 100,000,000
Debt instrument net issue discount	5,000,000
Underwriting fees and other related expenses	$ 6,000,000
Repurchase price obligation, percentage of principal amount redeemed in event of change of contract	101.00%
Repurchase price obligation, percentage of principal amount redeemed	100.00%

Debt (Build-to-suit Lease Obligation) (Details) - Discovery Hub [Member] $ in Millions	3 Months Ended
	Dec. 31, 2017 USD ($)	Oct. 31, 2017 ft²
Debt Instrument [Line Items]
Build to suit lease area of land \| ft²		312,000
Build to suit lease project costs paid by third party owner lessor \| $	$ 8

Debt Debt (Repayment Amounts) (Details) $ in Millions	12 Months Ended
Debt Debt (Repayment Amounts) (Details) $ in Millions	Dec. 31, 2016 USD ($)
Debt Instrument [Line Items]
Aggregate Principal	$ 370
Cash Payments	354
Prior Term Loan [Member]
Debt Instrument [Line Items]
Aggregate Principal	105
Cash Payments	104
2023 Notes [Member]
Debt Instrument [Line Items]
Aggregate Principal	192
Cash Payments	182
Euro Notes [Member]
Debt Instrument [Line Items]
Aggregate Principal	73
Cash Payments	$ 68

Debt Debt (Repayment Amounts) (Parenthetical) (Details) $ in Millions	12 Months Ended
	Dec. 31, 2016 USD ($)
Debt Disclosure [Abstract]
Prior term loan repayments equivalent	$ 15

Debt Debt (Term Loans and Note Repayments) (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Debt Instrument [Line Items]
Interest expense, net	$ 215	$ 213	$ 132
Interest Expense [Member]
Debt Instrument [Line Items]
Gain on extinguishment of debt		10
Write off of financing costs		$ 5

Debt (Maturities and Fair Value) (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
Debt Instrument [Line Items]
2023 and beyond	$ 2,758
Senior unsecured notes [Member] \| 6.625% Senior Notes Due May 2023 [Member]
Debt Instrument [Line Items]
Debt instrument interest rate	6.625%	6.625%
Senior unsecured notes [Member] \| 7.000% Senior Notes Due May 2025 [Member]
Debt Instrument [Line Items]
Debt instrument interest rate	7.00%	7.00%
Senior unsecured notes [Member] \| Senior Notes 6.125% Due May 2023 [Member]
Debt Instrument [Line Items]
Debt instrument interest rate	6.125%	6.125%
Senior unsecured notes [Member] \| 5.375% Senior Notes Due May 2027 [Member]
Debt Instrument [Line Items]
Debt instrument interest rate	5.375%	5.375%
Fair Value, Inputs, Level 2 [Member] \| Senior unsecured notes [Member] \| 6.625% Senior Notes Due May 2023 [Member]
Debt Instrument [Line Items]
Notes, fair value	$ 1,228
Fair Value, Inputs, Level 2 [Member] \| Senior unsecured notes [Member] \| 7.000% Senior Notes Due May 2025 [Member]
Debt Instrument [Line Items]
Notes, fair value	816
Fair Value, Inputs, Level 2 [Member] \| Senior unsecured notes [Member] \| Senior Notes 6.125% Due May 2023 [Member]
Debt Instrument [Line Items]
Notes, fair value	373
Fair Value, Inputs, Level 2 [Member] \| Senior unsecured notes [Member] \| 5.375% Senior Notes Due May 2027 [Member]
Debt Instrument [Line Items]
Notes, fair value	$ 521
New Term Loans [Member]
Debt Instrument [Line Items]
Debt instrument interest rate	1.00%
2018	$ 14
2019	14
2020	14
2021	14
2022	$ 1,336
Additional principal repayment, percentage of excess cash flows		50.00%
Additional principal repayment, percentage of excess cash flows, step-downs level one		25.00%
Additional principal repayment, percentage of excess cash flows, step-downs level two		0.00%
Target leverage ratio		3.00%
Principal repayment, percentage of excess cash flows	0.00%
Euro Term Loan [Member] \| Fair Value, Inputs, Level 2 [Member]
Debt Instrument [Line Items]
Line of credit facility, fair value	$ 471
The Dollar Term Loans [Member] \| Fair Value, Inputs, Level 2 [Member]
Debt Instrument [Line Items]
Line of credit facility, fair value	$ 928

Other Liabilities (Details) - USD ($) $ in Millions	Dec. 31, 2017	Dec. 31, 2016
Other Liabilities Noncurrent [Abstract]
Environmental remediation	$ 187	$ 208
Employee-related costs	123	113
Employee separation costs		3
Accrued litigation	48	53
Asset retirement obligations	43	41
Deferred revenue	6	5
Miscellaneous	68	101
Total other liabilities	$ 475	$ 524

- Definition

The noncurrent portion of deferred revenue amount as of balance sheet date. Deferred revenue is a liability related to a revenue producing activity for which revenue has not yet been recognized, and is not expected to be recognized in the next twelve months. Generally, an entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP.

+ References + Details

Other Liabilities (Parenthetical) (Details) - USD ($) $ in Millions	Dec. 31, 2017	Dec. 31, 2016
Other Liabilities Noncurrent [Abstract]
Accrued indemnification liability	$ 52	$ 78

Commitments and Contingent Liabilities (Guarantees) (Details) - USD ($)	Dec. 31, 2017	Dec. 31, 2016
Loss Contingencies [Line Items]
Accrual amount	$ 0	$ 0
Maximum [Member]
Loss Contingencies [Line Items]
Guarantee obligations	$ 2,000,000	$ 1,000,000

Commitments and Contingent Liabilities (Operating Leases) (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Operating Leases, Future Minimum Payments Due, Fiscal Year Maturity [Abstract]
Future minimum lease payments, 2018	$ 59
Future minimum lease payments, 2019	52
Future minimum lease payments, 2020	38
Future minimum lease payments, 2021	33
Future minimum lease payments, 2022	37
Future minimum lease payments, thereafter	268
Net expense under operating leases	$ 76	$ 68	$ 83

Commitments and Contingent Liabilities (Summary of Asset Retirement Obligations) (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
Asset Retirement Obligation, Roll Forward Analysis [Roll Forward]
Balance at January 1,	$ 43	$ 42
Accretion expense	6	2
Settlements and payments	(1)	(1)
Balance at December 31,	48	43
Current portion	5	2
Non-current portion	$ 43	$ 41

Commitments and Contingent Liabilities (Litigation) (Narrative) (Details)			1 Months Ended		3 Months Ended				9 Months Ended	12 Months Ended
	May 23, 2017 USD ($)	Oct. 20, 2015 USD ($)	Sep. 30, 2014	May 31, 2013 doctor water_district	Sep. 30, 2017 USD ($)	Jun. 30, 2017 USD ($)	Mar. 31, 2017 USD ($)	Jun. 30, 2016 USD ($)	Sep. 30, 2017 USD ($)	Dec. 31, 2017 USD ($) lawsuit plaintiff subpoena	Dec. 31, 2016 USD ($) lawsuit	Dec. 31, 2005 USD ($)	Dec. 31, 2004 resident	Jan. 31, 2012 USD ($)
Maximum [Member]
Loss Contingencies [Line Items]
Loss contingency, potential additional loss										$ 510,000,000
PFOA MDL Settlement [Member]
Loss Contingencies [Line Items]
Additional estimated charges											$ 335,000,000
Settlement payments	$ 335,000,000
Funding for medical monitoring program [Member]
Loss Contingencies [Line Items]
Escrow deposit disbursements										1,000,000
MDL Settlement [Member]
Loss Contingencies [Line Items]
Accrual balance											$ 335,000,000
Settlement payments									$ 335,000,000	$ 335,000,000
Date of Agreement										Mar. 31, 2017
Total settlement amount							$ 670,700,000
Post-MDL Settlement Injury Matters [Member]
Loss Contingencies [Line Items]
Number of plaintiffs alleging negligence and other claims \| plaintiff										3
Benzene Related Illness [Member]
Loss Contingencies [Line Items]
Lawsuits alleging illness \| lawsuit										17	27
Years of exposure to benzene		24 years
Compensatory damages awarded		$ 6,900,000
Punitive damages awarded		$ 1,500,000
PFOA Matters [Member]
Loss Contingencies [Line Items]
Accrual balance										$ 14,000,000	$ 349,000,000
Additional estimated charges								$ 4,000,000
PFOA Matters [Member] \| Maximum [Member]
Loss Contingencies [Line Items]
Settlement payments										$ 25,000,000
Period of payments										5 years
PFOA Matters [Member] \| PFOA MDL Settlement [Member]
Loss Contingencies [Line Items]
Additional estimated charges											$ 335,000,000
Settlement payments					$ 320,000,000	$ 15,000,000
PFOA Matters: Drinking Water Actions [Member]
Loss Contingencies [Line Items]
Binding settlement agreement, class size \| resident													80,000
Number of doctors to release initial screening recommendations \| doctor				3
Follow-up screening and diagnostic testing recommended period after initial testing			3 years
Number of water districts Company must provide treatment \| water_district				6
PFOA Matters: Drinking Water Actions [Member] \| Payment for Plaintiffs Attorney Fees [Member]
Loss Contingencies [Line Items]
Settlement payments												$ 23,000,000
PFOA Matters: Drinking Water Actions [Member] \| Payment to fund community health project [Member]
Loss Contingencies [Line Items]
Settlement payments												$ 70,000,000
PFOA Matters: Drinking Water Actions [Member] \| Funding for medical monitoring program [Member]
Loss Contingencies [Line Items]
Loss contingency, potential additional loss										$ 235,000,000
Escrow deposit														$ 1,000,000
PFOA Matters: Additional Actions [Member]
Loss Contingencies [Line Items]
Lawsuits alleging personal injury - Filed \| lawsuit										3,500
DuPont [Member] \| Maximum [Member]
Loss Contingencies [Line Items]
Settlement payments										$ 25,000,000
GenX and Other Perfluorinated and Polyfluorinated Compounds [Member]
Loss Contingencies [Line Items]
Number of federal grand jury subpoenas \| subpoena										3
Asbestos Issue [Member]
Loss Contingencies [Line Items]
Lawsuits alleging personal injury - Filed \| lawsuit										1,600	1,900
Accrual balance										$ 38,000,000	$ 41,000,000

Commitments and Contingent Liabilities (Environmental) (Narrative) (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Environmental Remediation [Line Items]
Accrual for environmental remediation activities	$ 253	$ 278
Environmental remediation expense	$ 48	$ 44	$ 38
Minimum [Member]
Environmental Remediation [Line Items]
Average time frame of disbursements of environmental site remediation	15 years
Maximum [Member]
Environmental Remediation [Line Items]
Average time frame of disbursements of environmental site remediation	20 years
Loss contingency, potential additional loss	$ 510

Equity (Narrative) (Details) - USD ($)	12 Months Ended
Equity (Narrative) (Details) - USD ($)	Dec. 31, 2017	Nov. 30, 2017
Equity Class Of Treasury Stock [Line Items]
Purchase of common stock value under the share repurchase program	$ 116,000,000
Cash dividend declared, per share	$ 0.17
Accrued dividend payable	$ 31,000,000
Common Stock [Member]
Equity Class Of Treasury Stock [Line Items]
Stock repurchase program effective date	Nov. 30, 2017
Stock repurchase program expiration date	Dec. 31, 2020
Purchase of common stock under the share repurchase program	2,386,406
Purchase of common stock value under the share repurchase program	$ 116,000,000
Average share price	$ 48.81
Purchase of common stock under the share repurchase program, share Settled	206,106
Purchase of common stock value under the share repurchase program, for share Settled	$ 10,000,000
Remaining available amount of common stock under the share repurchase program	384,000,000
Cash dividend declared, per share		$ 0.17
Accrued dividend payable	$ 31,000,000
Common Stock [Member] \| Maximum [Member]
Equity Class Of Treasury Stock [Line Items]
Stock repurchase program, authorized amount		$ 500,000,000

Financial Instruments (Narrative) (Details) $ in Millions	12 Months Ended
Financial Instruments (Narrative) (Details) $ in Millions	Dec. 31, 2017 USD ($) contract	Dec. 31, 2016 USD ($) contract	Dec. 31, 2015 USD ($)
Designated as Hedging Instrument [Member]
Derivative [Line Items]
Recognized gain (loss) on derivative net investment hedge, pre-tax	$ (86)	$ 14	$ 8
Foreign currency forward contracts [Member]
Derivative [Line Items]
Number of forward exchange currency contracts \| contract	0	45
Derivative notional value		$ 518
Foreign currency forward contracts [Member] \| Not Designated as Hedging Instrument [Member] \| Other Income (Expense), Net [Member]
Derivative [Line Items]
Derivative gain (loss)	$ 4	$ (15)	$ 42

Financial Instruments (Schedule of the Fair Value of Derivative Instruments) (Details) - Fair Value, Measurements, Recurring [Member] - Fair Value, Inputs, Level 2 [Member] - Not Designated as Hedging Instrument [Member] $ in Millions	Dec. 31, 2016 USD ($)
Derivatives, Fair Value [Line Items]
Asset derivatives	$ 2
Liability derivatives	4
Foreign currency forward contracts [Member] \| Accounts and notes receivable - trade, net [Member]
Derivatives, Fair Value [Line Items]
Asset derivatives	2
Foreign currency forward contracts [Member] \| Other accrued liabilities [Member]
Derivatives, Fair Value [Line Items]
Liability derivatives	$ 4

Long-term Employee Benefits (Narrative) (Details) - USD ($) $ in Millions	6 Months Ended		12 Months Ended
	Dec. 31, 2015	Jun. 30, 2015	Dec. 31, 2017	Dec. 31, 2016
Defined Benefit Plan Disclosure [Line Items]
Employer contributions during period	$ 28		$ 45	$ 44
Minimum [Member]
Defined Benefit Plan Disclosure [Line Items]
Employer matching contribution percent of employees' gross pay	1.00%
Maximum [Member]
Defined Benefit Plan Disclosure [Line Items]
Employer matching contribution percent of employees' gross pay	7.00%
Parent Issuer [Member]
Defined Benefit Plan Disclosure [Line Items]
Employer matching contribution percent of match	100.00%
Employer matching contribution percent of employees' gross pay	6.00%
Employer contribution vesting period	3 years
Employer contributions during period		$ 26

Long-term Employee Benefits (Multiemployer Plan) (Details) $ in Millions	12 Months Ended
	Dec. 31, 2015 USD ($)
DuPont Pension and Retirement Plan (U.S.) [Member]
Multiemployer Plans [Line Items]
Pension and other postretirement benefit expense	$ 48
Other U.S. and non-U.S. Plans [Member]
Multiemployer Plans [Line Items]
Pension and other postretirement benefit expense	$ 5

Long-term Employee Benefits (Schedule of Net Periodic Pension Income and Amounts Recognized in Other Comprehensive Income (Loss)) (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Changes in plan assets and benefit obligations recognized in other comprehensive income (loss):
Net (gain) loss	$ (24)	$ 17	$ 11
Amortization of actuarial loss	(24)	(23)	(16)
Prior service credit	0	0	(24)
Amortization of prior service credit (cost)	2	1	(4)
Effect of foreign exchange rates	38	(15)	(33)
Benefit recognized in other comprehensive income (loss)	(8)	(23)	(66)
Pension Plan [Member] \| Foreign [Member]
Net periodic pension cost (income):
Service cost	16	14	16
Interest cost	16	19	19
Expected return on plan assets	(75)	(63)	(83)
Amortization of actuarial loss	22	23	16
Amortization of prior service (credit) cost	(2)	(1)	4
Curtailment gain		(2)
Settlement loss	1	5
Net periodic benefit cost	(22)	(5)	(28)
Changes in plan assets and benefit obligations recognized in other comprehensive income (loss):
Net (gain) loss	(24)	17	11
Amortization of actuarial loss	(24)	(28)	(16)
Prior service credit			(24)
Amortization of prior service credit (cost)	2	3	(4)
Effect of foreign exchange rates	38	(15)	(33)
Benefit recognized in other comprehensive income (loss)	(8)	(23)	(66)
Total net periodic pension income and benefit recognized in other comprehensive income (loss)	$ (30)	$ (28)	$ (94)

Long-term Employee Benefits (Amounts Recognized in Accumulated Other Comprehensive Loss) (Details) - Pension Plan [Member] - Foreign [Member] - USD ($) $ in Millions	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]
Net loss	$ 329	$ 336	$ 363
Prior service credit	(11)	(11)	(16)
Total amount recognized in accumulated other comprehensive loss	318	$ 325	$ 347
Estimated net loss to be amortized into net periodic pension cost (income) in the next fiscal year	14
Prior service credit to be amortized into net periodic pension cost (income) in the next fiscal year	$ 2

Long-term Employee Benefits (Change in Benefit Obligation and Plan Assets) (Details) - Pension Plan [Member] - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Defined Benefit Plan, Change in Fair Value of Plan Assets [Roll Forward]
Employer contributions	$ 38	$ 16
Foreign [Member]
Defined Benefit Plan, Change in Benefit Obligation [Roll Forward]
Benefit obligation at beginning of year	1,105	1,103
Service cost	16	14	$ 16
Interest cost	16	19	19
Plan participants’ contributions	2	2
Actuarial (gain) loss	(39)	69
Benefits paid	(53)	(36)
Plan Amendments	(1)
Curtailments		(3)
Settlements and transfers	(3)	(12)
Other events	(4)	(2)
Currency translation	138	(49)
Benefit obligation at end of year	1,177	1,105	1,103
Defined Benefit Plan, Change in Fair Value of Plan Assets [Roll Forward]
Fair value of plan assets at beginning of year	1,169	1,137
Actual return on plan assets	60	113
Employer contributions	38	16
Plan participants’ contributions	2	2
Benefits paid	(53)	(36)
Settlements and transfers	(3)	(12)
Other events	(3)
Currency translation	153	(51)
Fair value of plan assets at end of year	1,363	1,169	$ 1,137
Total funded status at end of year	$ 186	$ 64

Long-term Employee Benefits (Amounts Recognized in Balance Sheet) (Details) - USD ($) $ in Millions	Dec. 31, 2017	Dec. 31, 2016
Defined Benefit Plan Disclosure [Line Items]
Non-current assets	$ 260	$ 159
The accumulated benefit obligation for all pension plans	1,112	1,042
Pension Plan [Member] \| Foreign [Member]
Defined Benefit Plan Disclosure [Line Items]
Non-current assets	258	159
Current liabilities	(1)	(1)
Non-current liabilities	(71)	(94)
Total net amount recognized	$ 186	$ 64

Long-term Employee Benefits (Summary of Projected Benefit Obligations and Accumulated Benefit Obligations in Excess of Plan Assets) (Details) - Pension Plan [Member] - Foreign [Member] - USD ($) $ in Millions	Dec. 31, 2017	Dec. 31, 2016
Pension plans with projected benefit obligation in excess of plan assets
Projected benefit obligation	$ 178	$ 183
Accumulated benefit obligation	149	152
Fair value of plan assets	106	87
Pension plans with accumulated benefit obligation in excess of plan assets
Projected benefit obligation	178	179
Accumulated benefit obligation	149	151
Fair value of plan assets	$ 106	$ 84

Long-term Employee Benefits (Assumptions) (Details)	12 Months Ended
Long-term Employee Benefits (Assumptions) (Details)	Dec. 31, 2017	Dec. 31, 2016
Defined Benefit Plan, Weighted Average Assumptions Used in Calculating Benefit Obligation [Abstract]
Discount rate	1.90%	1.80%
Rate of compensation increase	2.50%	2.50%
Defined Benefit Plan, Weighted Average Assumptions Used in Calculating Net Periodic Benefit Cost [Abstract]
Discount rate	1.80%	2.40%
Rate of compensation increase	2.50%	2.50%
Expected return on plan assets	5.70%	5.70%

Long-term Employee Benefits (Plan Assets) (Details) - Pension Plan [Member] - Foreign Pension Plan [Member] - USD ($) $ in Millions	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Defined Benefit Plan Disclosure [Line Items]
Total weighted-average target allocation	100.00%	100.00%
Total pension assets before pension receivables/payables	$ 1,356	$ 1,174
Pension trust receivables, net (1)	7
Total pension assets	1,363	1,169	$ 1,137
Pension trust payables, net		(5)
Level 1 [Member]
Defined Benefit Plan Disclosure [Line Items]
Total pension assets	398	214
Level 2 [Member]
Defined Benefit Plan Disclosure [Line Items]
Total pension assets	$ 958	$ 960
Cash and Cash Equivalents [Member]
Defined Benefit Plan Disclosure [Line Items]
Total weighted-average target allocation	4.80%	2.50%
Total pension assets	$ 65	$ 77
Cash and Cash Equivalents [Member] \| Level 1 [Member]
Defined Benefit Plan Disclosure [Line Items]
Total pension assets	65	77
Cash and Cash Equivalents [Member] \| Level 2 [Member]
Defined Benefit Plan Disclosure [Line Items]
Total pension assets	$ 0	$ 0
Equity securities [Member]
Defined Benefit Plan Disclosure [Line Items]
Total weighted-average target allocation	42.60%	41.60%
Total pension assets	$ 581	$ 502
Equity securities [Member] \| Level 1 [Member]
Defined Benefit Plan Disclosure [Line Items]
Total pension assets	295	28
Equity securities [Member] \| Level 2 [Member]
Defined Benefit Plan Disclosure [Line Items]
Total pension assets	$ 286	$ 474
Fixed Income Securities [Member]
Defined Benefit Plan Disclosure [Line Items]
Total weighted-average target allocation	52.60%	55.90%
Fixed Income Securities [Member] \| Government Issued [Member]
Defined Benefit Plan Disclosure [Line Items]
Total pension assets	$ 505	$ 433
Fixed Income Securities [Member] \| Corporate Issued [Member]
Defined Benefit Plan Disclosure [Line Items]
Total pension assets	144	142
Fixed Income Securities [Member] \| Asset backed [Member]
Defined Benefit Plan Disclosure [Line Items]
Total pension assets	40	42
Fixed Income Securities [Member] \| Level 1 [Member] \| Government Issued [Member]
Defined Benefit Plan Disclosure [Line Items]
Total pension assets	1	8
Fixed Income Securities [Member] \| Level 1 [Member] \| Corporate Issued [Member]
Defined Benefit Plan Disclosure [Line Items]
Total pension assets	24	76
Fixed Income Securities [Member] \| Level 1 [Member] \| Asset backed [Member]
Defined Benefit Plan Disclosure [Line Items]
Total pension assets	0	25
Fixed Income Securities [Member] \| Level 2 [Member] \| Government Issued [Member]
Defined Benefit Plan Disclosure [Line Items]
Total pension assets	504	425
Fixed Income Securities [Member] \| Level 2 [Member] \| Corporate Issued [Member]
Defined Benefit Plan Disclosure [Line Items]
Total pension assets	120	66
Fixed Income Securities [Member] \| Level 2 [Member] \| Asset backed [Member]
Defined Benefit Plan Disclosure [Line Items]
Total pension assets	40	17
Derivatives - Asset Position[Member]
Defined Benefit Plan Disclosure [Line Items]
Total pension assets	8	3
Derivatives - Asset Position[Member] \| Level 1 [Member]
Defined Benefit Plan Disclosure [Line Items]
Total pension assets	2	0
Derivatives - Asset Position[Member] \| Level 2 [Member]
Defined Benefit Plan Disclosure [Line Items]
Total pension assets	6	3
Derivative Liability Position [Member]
Defined Benefit Plan Disclosure [Line Items]
Total pension assets	(1)	(32)
Derivative Liability Position [Member] \| Level 1 [Member]
Defined Benefit Plan Disclosure [Line Items]
Total pension assets	0	0
Derivative Liability Position [Member] \| Level 2 [Member]
Defined Benefit Plan Disclosure [Line Items]
Total pension assets	(1)	(32)
Other [Member]
Defined Benefit Plan Disclosure [Line Items]
Total pension assets	14	7
Other [Member] \| Level 1 [Member]
Defined Benefit Plan Disclosure [Line Items]
Total pension assets	11	0
Other [Member] \| Level 2 [Member]
Defined Benefit Plan Disclosure [Line Items]
Total pension assets	$ 3	$ 7

Long-term Employee Benefits (Cash Flows) (Details) - USD ($) $ in Millions	1 Months Ended	6 Months Ended		12 Months Ended
	Oct. 31, 2017	Dec. 31, 2015	Jun. 30, 2015	Dec. 31, 2017	Dec. 31, 2016
Defined Benefit Plan, Expected Future Benefit Payments, Fiscal Year Maturity [Abstract]
2018				$ 45
2019				47
2020				48
2021				47
2022				48
2023 to 2027				262
Pension Plan [Member]
Defined Benefit Plan Disclosure [Line Items]
Contributions by employer				38	$ 16
Estimated future employer contributions in next fiscal year				15
Pension Plan [Member] \| Parent Issuer [Member]
Defined Benefit Plan Disclosure [Line Items]
Contributions by employer		$ 8	$ 38
U.S. Pension Restoration Plan [Member]
Defined Benefit Plan Disclosure [Line Items]
Contributions by employer				$ 10
Cash payment to settle remaining liability	$ 10

Stock-based Compensation (Narrative) (Details) $ / shares in Units, $ in Millions		1 Months Ended		3 Months Ended	12 Months Ended
	Jan. 26, 2017 Period shares	Jan. 31, 2018 USD ($) shares	Jul. 31, 2015	Sep. 30, 2015 USD ($)	Dec. 31, 2017 USD ($) $ / shares shares	Dec. 31, 2016 USD ($) shares	Dec. 31, 2015 USD ($)	Apr. 26, 2017 shares	Jul. 01, 2015 USD ($) shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation cost \| $					$ 29	$ 20	$ 17
Employee Stock Purchase Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of common stock shares reserved for issuance	7,000,000
Consecutive offering periods	12 months
Number of purchase periods in offer period \| Period	4
Employee stock purchase plan initial offering period	Oct. 02, 2017
Percentage of common stock discount rate equal to the fair value	95.00%
Employee Stock Purchase Plan [Member] \| Subsequent Event [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock purchased under employee stock purchase plan, Value \| $		$ 1
Stock purchased under employee stock purchase plan, Shares		11,894
Stock Compensation Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Intrinsic value \| $									$ 18
Conversion of stock incremental cost \| $				$ 3
Stock Option [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expiration period			10 years		10 years	10 years
Stock-based compensation award vesting period					3 years	3 years
Total intrinsic value of options exercised \| $					$ 49	$ 9
Unrecognized compensation cost related to stock options \| $					$ 6
Unrecognized compensation cost period for recognition					2 years
Restricted Stock Units (RSUs) [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation award vesting period					3 years
Unrecognized compensation cost period for recognition					6 months 25 days
Shares issued upon conversion of equity award					1
Unrecognized compensation cost related to equity awards other than options \| $					$ 5
Weighted-average fair value at grant date (in dollars per share) \| $ / shares					$ 36.68
Performance Share Units [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation award vesting period					3 years
Shares issued upon conversion of equity award					1
Percentage of target award available for grant					100.00%
Weighted-average fair value at grant date (in dollars per share) \| $ / shares					$ 40.30
Number of additional shares to be awarded					700,000
Performance Share Units [Member] \| Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Percentage of target award available for grant					0.00%
Performance Share Units [Member] \| Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Percentage of target award available for grant					200.00%
Chemours Company Equity and Incentive Plan (the “Prior Plan”) [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares reserved for grants (in shares)						7,806,040			13,500,000
Shares issued upon conversion of equity stock option awards granted								1
Shares issued upon conversion of equity stock other than option awards granted								1.5
Chemours Company 2017 Equity and Incentive Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares reserved for grants (in shares)					17,677,641			0
Shares authorized for grants (in shares)								19,000,000
ASU 2016-09 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Income tax benefits from windfalls on share-based payments \| $					$ 22

Stock-based Compensation (Weighted Average Assumptions of Stock Option) (Details) - Stock Option [Member] - $ / shares	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Risk-free interest rate	2.14%	1.46%	1.50%
Expected term (years)	6 years	6 years	5 years 4 months 24 days
Volatility	44.49%	60.00%	42.00%
Dividend yield	0.35%	2.14%	6.90%
Fair value per stock option	$ 15.21	$ 3.41	$ 3.17

Stock-based Compensation (Stock Option Activity) (Details) - Stock Option [Member] - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]
Outstanding, beginning balance, shares	7,969
Granted, shares	878
Exercised, shares	(2,173)
Forfeited, shares	(47)
Expired, shares	(30)
Outstanding, ending balance, shares	6,597	7,969
Exercisable, shares	3,599
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]
Outstanding, weighted average exercise price, beginning balance (in dollars per share)	$ 13.72
Granted, weighted average exercise price (in dollars per share)	34.84
Exercised, weighted average exercise price (in dollars per share)	14.36
Forfeited, weighted average exercise price (in dollars per share)	20.55
Expired, weighted average exercise price (in dollars per share)	12.29
Outstanding, weighted average exercise price, ending balance (in dollars per share)	15.72	$ 13.72
Exercisable, weighted average exercise price (in dollars per share)	$ 14.00
Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]
Options outstanding, weighted average remaining contractual term	5 years 1 month 9 days	5 years 29 days
Options exercisable, weighted average remaining contractual term	3 years 5 months 15 days
Options outstanding, aggregate intrinsic value	$ 226,524	$ 66,668
Options exercisable, aggregate intrinsic value	$ 129,800

Stock-based Compensation (Restricted Stock Units Activity) (Details) - Restricted Stock Units (RSUs) [Member] shares in Thousands	12 Months Ended
	Dec. 31, 2017 $ / shares shares
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]
Non-vested, beginning balance, shares \| shares	2,316
Granted, shares \| shares	214
Vested, shares \| shares	(1,316)
Forfeited, shares \| shares	(49)
Non-vested, ending balance, shares \| shares	1,165
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]
Non-vested, weighted average grant date fair value, beginning balance (in dollars per share) \| $ / shares	$ 11.23
Granted, weighted average grant date fair value (in dollars per share) \| $ / shares	36.68
Vested, weighted average grant date fair value (in dollars per share) \| $ / shares	11.46
Forfeited, weighted average grant date fair value (in dollars per share) \| $ / shares	14.27
Non-vested, weighted average grant date fair value, ending balance (in dollars per share) \| $ / shares	$ 15.34

Stock-based Compensation (Performance Share Units Activity) (Details) - Performance Share Units [Member] shares in Thousands	12 Months Ended
	Dec. 31, 2017 $ / shares shares
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]
Non-vested, beginning balance, shares \| shares	803
Granted, shares \| shares	211
Vested, shares \| shares	0
Forfeited, shares \| shares	(27)
Non-vested, ending balance, shares \| shares	987
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]
Non-vested, weighted average grant date fair value, beginning balance (in dollars per share) \| $ / shares	$ 6.10
Granted, weighted average grant date fair value (in dollars per share) \| $ / shares	40.30
Vested, weighted average grant date fair value (in dollars per share) \| $ / shares	0
Forfeited, weighted average grant date fair value (in dollars per share) \| $ / shares	16.62
Non-vested, weighted average grant date fair value, ending balance (in dollars per share) \| $ / shares	$ 12.94

Geographic and Segment Information - Geographic Information (Details) $ in Millions	3 Months Ended								12 Months Ended
	Dec. 31, 2017 USD ($)	Sep. 30, 2017 USD ($)	Jun. 30, 2017 USD ($)	Mar. 31, 2017 USD ($)	Dec. 31, 2016 USD ($)	Sep. 30, 2016 USD ($)	Jun. 30, 2016 USD ($)	Mar. 31, 2016 USD ($)	Dec. 31, 2017 USD ($) segment	Dec. 31, 2016 USD ($)	Dec. 31, 2015 USD ($)
Revenues From External Customers And Long Lived Assets [Line Items]
Net Sales	$ 1,575	$ 1,584	$ 1,588	$ 1,437	$ 1,322	$ 1,398	$ 1,383	$ 1,297	$ 6,183	$ 5,400	$ 5,717
Property, Plant, and Equipment, Net	3,008				2,784				$ 3,008	2,784	3,177
Number of reportable segments \| segment									3
North America [Member]
Revenues From External Customers And Long Lived Assets [Line Items]
Net Sales									$ 2,255	2,288	2,570
Property, Plant, and Equipment, Net	2,018				1,861				2,018	1,861	2,184
Asia Pacific [Member]
Revenues From External Customers And Long Lived Assets [Line Items]
Net Sales									1,593	1,315	1,393
Property, Plant, and Equipment, Net	131				129				131	129	136
Europe, the Middle East, and Africa [Member]
Revenues From External Customers And Long Lived Assets [Line Items]
Net Sales									1,506	1,081	977
Property, Plant, and Equipment, Net	302				278				302	278	308
Latin America [Member]
Revenues From External Customers And Long Lived Assets [Line Items]
Net Sales									829	716	777
Property, Plant, and Equipment, Net	$ 557				$ 516				$ 557	$ 516	$ 549

Geographic and Segment Information - (Schedule of Segment Information) (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Segment Reporting Information [Line Items]
Net sales to external customers	$ 6,183	$ 5,400	$ 5,717
Adjusted EBITDA	1,422	822	573
Depreciation and amortization	273	284	267
Equity in earnings of affiliates	33	29	22
Net assets	865	104	130
Investments in affiliates	173	136	136
Purchases of property, plant, and equipment	411	338	519
Operating Segments [Member] \| Titanium Technologies [Member]
Segment Reporting Information [Line Items]
Net sales to external customers	2,958	2,364	2,392
Adjusted EBITDA	862	466	326
Depreciation and amortization	118	119	125
Net assets	1,785	1,513	1,659
Purchases of property, plant, and equipment	65	105	255
Operating Segments [Member] \| Fluoroproducts [Member]
Segment Reporting Information [Line Items]
Net sales to external customers	2,654	2,264	2,230
Adjusted EBITDA	669	445	300
Depreciation and amortization	109	101	88
Equity in earnings of affiliates	33	26	21
Net assets	1,842	1,400	1,567
Investments in affiliates	173	116	127
Purchases of property, plant, and equipment	249	120	142
Operating Segments [Member] \| Chemical Solutions [Member]
Segment Reporting Information [Line Items]
Net sales to external customers	571	772	1,095
Adjusted EBITDA	57	39	29
Depreciation and amortization	18	30	52
Net assets	460	292	839
Purchases of property, plant, and equipment	65	104	117
Corporate and Other [Member]
Segment Reporting Information [Line Items]
Adjusted EBITDA	(166)	(128)	(82)
Depreciation and amortization	28	34	2
Equity in earnings of affiliates		3	1
Net assets	(3,222)	(3,101)	(3,935)
Investments in affiliates		20	9
Purchases of property, plant, and equipment	$ 32	$ 9	$ 5

Geographic and Segment Information - (Reconciliation of EBITDA from Segments to Consolidated Net Income (Loss) Before Income Taxes) (Details) - USD ($)	1 Months Ended	3 Months Ended								12 Months Ended
	Dec. 31, 2016	Dec. 31, 2017	Sep. 30, 2017	Jun. 30, 2017	Mar. 31, 2017	Dec. 31, 2016	Sep. 30, 2016	Jun. 30, 2016	Mar. 31, 2016	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Segment Reporting Information [Line Items]
Income (loss) before income taxes		$ 264,000,000	$ 250,000,000	$ 225,000,000	$ 173,000,000	$ (273,000,000)	$ 234,000,000	$ (41,000,000)	$ 70,000,000	$ 912,000,000	$ (11,000,000)	$ (188,000,000)
Interest expense, net										215,000,000	213,000,000	132,000,000
Depreciation and amortization										273,000,000	284,000,000	267,000,000
Non-operating pension and other post-retirement employee benefit income										(34,000,000)	(20,000,000)	(3,000,000)
Exchange (gains) losses										(3,000,000)	57,000,000	(19,000,000)
Restructuring charges										57,000,000	51,000,000	285,000,000
Asset-related charges										3,000,000	124,000,000	73,000,000
(Gain) loss on sale of assets and businesses										(22,000,000)	(254,000,000)	9,000,000
Transaction costs										3,000,000	19,000,000	9,000,000
Legal and other charges										18,000,000	359,000,000	8,000,000
Adjusted EBITDA										1,422,000,000	822,000,000	573,000,000
Other assets, impairment charges	$ 13,000,000
Asset related charges										1,000,000	119,000,000	45,000,000
Goodwill impairment										0	0	25,000,000
PFOA MDL Settlement [Member]
Segment Reporting Information [Line Items]
Litigation accruals											335,000,000
Sulfur Business [Member]
Segment Reporting Information [Line Items]
Goodwill impairment												25,000,000
Disposed by Sale [Member] \| Sulfur Business [Member]
Segment Reporting Information [Line Items]
Asset related charges								$ 58,000,000			58,000,000
Headquarters Building Located in Wilmington, Delaware [Member] \| Disposed by Sale [Member]
Segment Reporting Information [Line Items]
Asset related charges											13,000,000
Aniline Facility [Member] \| Pascagoula, Mississippi [Member]
Segment Reporting Information [Line Items]
Other assets, impairment charges											48,000,000
Asset related charges											48,000,000
RMS Facility [Member] \| Niagara Falls, NY [Member] \| Operating Segments [Member]
Segment Reporting Information [Line Items]
Asset related charges												$ 45,000,000
Land [Member] \| Repauno New Jersey [Member]
Segment Reporting Information [Line Items]
Gain on sale of asset										13,000,000
Edge Moor Site [Member]
Segment Reporting Information [Line Items]
Gain on sale of asset										$ 12,000,000
Clean and Disinfect Product Line [Member]
Segment Reporting Information [Line Items]
Gain on sale of asset											169,000,000
Beaumont Site [Member]
Segment Reporting Information [Line Items]
Gain on sale of asset											$ 89,000,000

Geographic and Segment Information - (Schedule of Net Sales to External Customers by Product Group) (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Segment Reporting Information [Line Items]
Total net sales to external customers	$ 6,183	$ 5,400	$ 5,717
Divested Business [Member]
Segment Reporting Information [Line Items]
Total net sales to external customers	4	212	431
Titanium Dioxide [Member]
Segment Reporting Information [Line Items]
Total net sales to external customers	2,958	2,364	2,392
Fluoropolymers [member]
Segment Reporting Information [Line Items]
Total net sales to external customers	1,276	1,171	1,246
Fluorochemicals [Member]
Segment Reporting Information [Line Items]
Total net sales to external customers	1,378	1,093	984
Performance Chemicals and Intermediates [Member]
Segment Reporting Information [Line Items]
Total net sales to external customers	306	298	363
Mining Solution [Member]
Segment Reporting Information [Line Items]
Total net sales to external customers	$ 261	$ 262	$ 301

Accumulated Other Comprehensive Loss (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
AOCI Attributable to Parent, Net of Tax [Roll Forward]
Beginning Balance	$ 100
Assumption and establishment of pension plans, net	(3)	$ 18	$ 52
Ending Balance	860	100
Currency Translation Adjustment [Member]
AOCI Attributable to Parent, Net of Tax [Roll Forward]
Beginning Balance	(358)	(285)	19
Assumption and establishment of pension plans, net			0
Other comprehensive (loss) income	200	(73)	(304)
Ending Balance	(158)	(358)	(285)
Derivative Instruments [Member]
AOCI Attributable to Parent, Net of Tax [Roll Forward]
Beginning Balance	22	8	0
Assumption and establishment of pension plans, net			0
Other comprehensive (loss) income	(62)	14	8
Ending Balance	(40)	22	8
Employee Benefits [Member]
AOCI Attributable to Parent, Net of Tax [Roll Forward]
Beginning Balance	(241)	(259)	0
Assumption and establishment of pension plans, net			(311)
Other comprehensive (loss) income	(3)	18	52
Ending Balance	(244)	(241)	(259)
Accumulated Other Comprehensive Loss [Member]
AOCI Attributable to Parent, Net of Tax [Roll Forward]
Beginning Balance	(577)	(536)	19
Assumption and establishment of pension plans, net			(311)
Other comprehensive (loss) income	135	(41)	(244)
Ending Balance	$ (442)	$ (577)	$ (536)

Subsequent Event (Details) - USD ($) $ in Millions	Jan. 31, 2018	Dec. 31, 2017
Subsequent Event [Line Items]
Purchase of common stock value under the share repurchase program		$ 116
Common Stock [Member]
Subsequent Event [Line Items]
Purchase of common stock value under the share repurchase program		$ 116
Common Stock [Member] \| Subsequent Event [Member]
Subsequent Event [Line Items]
Purchase of common stock value under the share repurchase program	$ 34

Quarterly Financial Data (Unaudited) (Details) - USD ($) $ / shares in Units, $ in Millions	3 Months Ended								12 Months Ended
	Dec. 31, 2017	Sep. 30, 2017	Jun. 30, 2017	Mar. 31, 2017	Dec. 31, 2016	Sep. 30, 2016	Jun. 30, 2016	Mar. 31, 2016	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Quarterly Financial Information Disclosure [Abstract]
Net Sales	$ 1,575	$ 1,584	$ 1,588	$ 1,437	$ 1,322	$ 1,398	$ 1,383	$ 1,297	$ 6,183	$ 5,400	$ 5,717
Cost of goods sold	1,087	1,117	1,147	1,079	1,024	1,056	1,116	1,095	4,429	4,290	4,762
Income (loss) before income taxes	264	250	225	173	(273)	234	(41)	70	912	(11)	(188)
Net income (loss)	228	207	161	151	(230)	204	(18)	51	747	7	(90)
Net income (loss) attributable to Chemours	$ 228	$ 207	$ 161	$ 150	$ (230)	$ 204	$ (18)	$ 51	$ 746	$ 7	$ (90)
Basic earnings (loss) per share of common stock	$ 1.23	$ 1.12	$ 0.87	$ 0.82	$ (1.26)	$ 1.12	$ (0.10)	$ 0.28	$ 4.04	$ 0.04	$ (0.50)
Diluted earnings (loss) per share of common stock	$ 1.19	$ 1.08	$ 0.84	$ 0.79	$ (1.26)	$ 1.11	$ (0.10)	$ 0.28	$ 3.91	$ 0.04	$ (0.50)

Guarantor Condensed Consolidating Financial Information (Condensed Consolidating Statements of Comprehensive Income (Loss)) (Details) - USD ($)	3 Months Ended								12 Months Ended
	Dec. 31, 2017	Sep. 30, 2017	Jun. 30, 2017	Mar. 31, 2017	Dec. 31, 2016	Sep. 30, 2016	Jun. 30, 2016	Mar. 31, 2016	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Condensed Income Statements, Captions [Line Items]
Net sales	$ 1,575,000,000	$ 1,584,000,000	$ 1,588,000,000	$ 1,437,000,000	$ 1,322,000,000	$ 1,398,000,000	$ 1,383,000,000	$ 1,297,000,000	$ 6,183,000,000	$ 5,400,000,000	$ 5,717,000,000
Cost of goods sold	1,087,000,000	1,117,000,000	1,147,000,000	1,079,000,000	1,024,000,000	1,056,000,000	1,116,000,000	1,095,000,000	4,429,000,000	4,290,000,000	4,762,000,000
Gross profit									1,754,000,000	1,110,000,000	955,000,000
Selling, general, and administrative expense									602,000,000	934,000,000	632,000,000
Research and development expense									80,000,000	80,000,000	97,000,000
Restructuring and asset-related charges, net									57,000,000	170,000,000	333,000,000
Goodwill impairment									0	0	25,000,000
Total expenses									739,000,000	1,184,000,000	1,087,000,000
Equity in earnings of affiliates									33,000,000	29,000,000	22,000,000
Equity in earnings of subsidiaries										0	0
Interest (expense) income, net									(215,000,000)	(213,000,000)	(132,000,000)
Intercompany interest income (expense), net										0	0
Other income (expense), net									79,000,000	247,000,000	54,000,000
Income (loss) before income taxes	264,000,000	250,000,000	225,000,000	173,000,000	(273,000,000)	234,000,000	(41,000,000)	70,000,000	912,000,000	(11,000,000)	(188,000,000)
Provision (benefit) for income taxes									165,000,000	(18,000,000)	(98,000,000)
Net income (loss)	228,000,000	207,000,000	161,000,000	151,000,000	(230,000,000)	204,000,000	(18,000,000)	51,000,000	747,000,000	7,000,000	(90,000,000)
Less: Net income attributable to non-controlling interests									1,000,000	0	0
Net income (loss) attributable to Chemours	$ 228,000,000	$ 207,000,000	$ 161,000,000	$ 150,000,000	$ (230,000,000)	$ 204,000,000	$ (18,000,000)	$ 51,000,000	746,000,000	7,000,000	(90,000,000)
Comprehensive income attributable to Chemours									881,000,000	(34,000,000)	(334,000,000)
Eliminations and Adjustments [Member]
Condensed Income Statements, Captions [Line Items]
Net sales									(1,734,000,000)	(1,571,000,000)	(1,596,000,000)
Cost of goods sold									(1,691,000,000)	(1,543,000,000)	(1,596,000,000)
Gross profit									(43,000,000)	(28,000,000)	0
Selling, general, and administrative expense									(38,000,000)	(20,000,000)	(13,000,000)
Research and development expense										0	0
Restructuring and asset-related charges, net										0	0
Goodwill impairment											0
Total expenses									(38,000,000)	(20,000,000)	(13,000,000)
Equity in earnings of affiliates										0	0
Equity in earnings of subsidiaries									(849,000,000)	(100,000,000)	47,000,000
Interest (expense) income, net										0	0
Intercompany interest income (expense), net										0	0
Other income (expense), net									(34,000,000)	(20,000,000)	(20,000,000)
Income (loss) before income taxes									(888,000,000)	(128,000,000)	40,000,000
Provision (benefit) for income taxes									(4,000,000)	(7,000,000)	(3,000,000)
Net income (loss)									(884,000,000)	(121,000,000)	43,000,000
Less: Net income attributable to non-controlling interests										0	0
Net income (loss) attributable to Chemours									(884,000,000)	(121,000,000)	43,000,000
Comprehensive income attributable to Chemours									(1,081,000,000)	(66,000,000)	295,000,000
Parent Issuer [Member] \| Reportable Legal Entities [Member]
Condensed Income Statements, Captions [Line Items]
Net sales										0	0
Cost of goods sold										0	0
Gross profit										0	0
Selling, general, and administrative expense									36,000,000	21,000,000	15,000,000
Research and development expense										0	0
Restructuring and asset-related charges, net										0	0
Goodwill impairment											0
Total expenses									36,000,000	21,000,000	15,000,000
Equity in earnings of affiliates										0	0
Equity in earnings of subsidiaries									849,000,000	100,000,000	(47,000,000)
Interest (expense) income, net									(221,000,000)	(211,000,000)	(131,000,000)
Intercompany interest income (expense), net									64,000,000	60,000,000	44,000,000
Other income (expense), net									29,000,000	20,000,000	13,000,000
Income (loss) before income taxes									685,000,000	(52,000,000)	(136,000,000)
Provision (benefit) for income taxes									(62,000,000)	(59,000,000)	(46,000,000)
Net income (loss)									747,000,000	7,000,000	(90,000,000)
Less: Net income attributable to non-controlling interests										0	0
Net income (loss) attributable to Chemours									747,000,000	7,000,000	(90,000,000)
Comprehensive income attributable to Chemours									881,000,000	(34,000,000)	(334,000,000)
Guarantor Subsidiaries [Member] \| Reportable Legal Entities [Member]
Condensed Income Statements, Captions [Line Items]
Net sales									3,887,000,000	3,749,000,000	4,044,000,000
Cost of goods sold									3,084,000,000	3,218,000,000	3,708,000,000
Gross profit									803,000,000	531,000,000	336,000,000
Selling, general, and administrative expense									449,000,000	794,000,000	426,000,000
Research and development expense									74,000,000	77,000,000	95,000,000
Restructuring and asset-related charges, net									56,000,000	168,000,000	295,000,000
Goodwill impairment											25,000,000
Total expenses									579,000,000	1,039,000,000	841,000,000
Equity in earnings of affiliates										4,000,000	1,000,000
Equity in earnings of subsidiaries										0	0
Interest (expense) income, net									3,000,000	(3,000,000)	(1,000,000)
Intercompany interest income (expense), net										4,000,000	0
Other income (expense), net									139,000,000	193,000,000	92,000,000
Income (loss) before income taxes									366,000,000	(310,000,000)	(413,000,000)
Provision (benefit) for income taxes									117,000,000	(52,000,000)	(89,000,000)
Net income (loss)									249,000,000	(258,000,000)	(324,000,000)
Less: Net income attributable to non-controlling interests										0	0
Net income (loss) attributable to Chemours									249,000,000	(258,000,000)	(324,000,000)
Comprehensive income attributable to Chemours									253,000,000	(255,000,000)	(324,000,000)
Non-Guarantor Subsidiaries [Member] \| Reportable Legal Entities [Member]
Condensed Income Statements, Captions [Line Items]
Net sales									4,030,000,000	3,222,000,000	3,269,000,000
Cost of goods sold									3,036,000,000	2,615,000,000	2,650,000,000
Gross profit									994,000,000	607,000,000	619,000,000
Selling, general, and administrative expense									155,000,000	139,000,000	204,000,000
Research and development expense									6,000,000	3,000,000	2,000,000
Restructuring and asset-related charges, net									1,000,000	2,000,000	38,000,000
Goodwill impairment											0
Total expenses									162,000,000	144,000,000	244,000,000
Equity in earnings of affiliates									33,000,000	25,000,000	21,000,000
Equity in earnings of subsidiaries										0	0
Interest (expense) income, net									3,000,000	1,000,000	0
Intercompany interest income (expense), net									(64,000,000)	(64,000,000)	(44,000,000)
Other income (expense), net									(55,000,000)	54,000,000	(31,000,000)
Income (loss) before income taxes									749,000,000	479,000,000	321,000,000
Provision (benefit) for income taxes									114,000,000	100,000,000	40,000,000
Net income (loss)									635,000,000	379,000,000	281,000,000
Less: Net income attributable to non-controlling interests									1,000,000	0	0
Net income (loss) attributable to Chemours									634,000,000	379,000,000	281,000,000
Comprehensive income attributable to Chemours									$ 828,000,000	$ 321,000,000	$ 29,000,000

Guarantor Condensed Consolidating Financial Information (Condensed Consolidating Balance Sheets) (Details) - USD ($) $ in Millions	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Current assets:
Cash and cash equivalents	$ 1,556	$ 902	$ 366	$ 0
Accounts and notes receivable, net	919	807
Intercompany receivable		0
Inventories	935	767
Prepaid expenses and other	83	77
Total current assets	3,493	2,553
Property, plant, and equipment	8,511	7,997
Less: Accumulated depreciation	(5,503)	(5,213)
Property, plant, and equipment, net	3,008	2,784	3,177
Goodwill and other intangible assets, net	166	170
Investments in affiliates	173	136	136
Investment in subsidiaries		0
Intercompany notes receivable		0
Other assets	453	417
Total assets	7,293	6,060
Current liabilities:
Accounts payable	1,075	884
Current maturities of long-term debt	15	15
Intercompany payable		0
Other accrued liabilities	558	872
Total current liabilities	1,648	1,771
Long-term debt, net	4,097	3,529
Intercompany notes payable		0
Deferred income taxes	208	132
Other liabilities	475	524
Total liabilities	6,428	5,956
Commitments and contingent liabilities
Equity
Total Chemours stockholders’ equity	860	100
Non-controlling interests	5	4
Total equity	865	104	130	3,673
Total liabilities and equity	7,293	6,060
Eliminations and Adjustments [Member]
Current assets:
Cash and cash equivalents		0	0	0
Accounts and notes receivable, net		0
Intercompany receivable	(1,488)	(1,099)
Inventories	(90)	(50)
Prepaid expenses and other	11	7
Total current assets	(1,567)	(1,142)
Property, plant, and equipment		0
Less: Accumulated depreciation		0
Property, plant, and equipment, net		0
Goodwill and other intangible assets, net		0
Investments in affiliates		0
Investment in subsidiaries	(4,393)	(3,258)
Intercompany notes receivable	(1,150)	(1,150)
Other assets	(13)	0
Total assets	(7,123)	(5,550)
Current liabilities:
Accounts payable		0
Current maturities of long-term debt		0
Intercompany payable	(1,488)	(1,099)
Other accrued liabilities		0
Total current liabilities	(1,488)	(1,099)
Long-term debt, net		0
Intercompany notes payable	(1,150)	(1,150)
Deferred income taxes	(24)	0
Other liabilities		0
Total liabilities	(2,662)	(2,249)
Commitments and contingent liabilities
Equity
Total Chemours stockholders’ equity	(4,461)	(3,301)
Non-controlling interests		0
Total equity	(4,461)	(3,301)
Total liabilities and equity	(7,123)	(5,550)
Parent Issuer [Member] \| Reportable Legal Entities [Member]
Current assets:
Cash and cash equivalents		0	0	0
Accounts and notes receivable, net		0
Intercompany receivable	3	3
Inventories		0
Prepaid expenses and other		0
Total current assets	3	3
Property, plant, and equipment		0
Less: Accumulated depreciation		0
Property, plant, and equipment, net		0
Goodwill and other intangible assets, net		0
Investments in affiliates		0
Investment in subsidiaries	4,393	3,258
Intercompany notes receivable	1,150	1,150
Other assets	23	13
Total assets	5,569	4,424
Current liabilities:
Accounts payable	31	0
Current maturities of long-term debt	15	15
Intercompany payable	542	762
Other accrued liabilities	34	21
Total current liabilities	622	798
Long-term debt, net	4,087	3,526
Intercompany notes payable		0
Deferred income taxes		0
Other liabilities		0
Total liabilities	4,709	4,324
Commitments and contingent liabilities
Equity
Total Chemours stockholders’ equity	860	100
Non-controlling interests		0
Total equity	860	100
Total liabilities and equity	5,569	4,424
Guarantor Subsidiaries [Member] \| Reportable Legal Entities [Member]
Current assets:
Cash and cash equivalents	761	224	95	0
Accounts and notes receivable, net	308	299
Intercompany receivable	904	1,050
Inventories	394	341
Prepaid expenses and other	57	38
Total current assets	2,424	1,952
Property, plant, and equipment	6,449	6,136
Less: Accumulated depreciation	(4,438)	(4,285)
Property, plant, and equipment, net	2,011	1,851
Goodwill and other intangible assets, net	152	156
Investments in affiliates		0
Investment in subsidiaries		0
Intercompany notes receivable		0
Other assets	115	178
Total assets	4,702	4,137
Current liabilities:
Accounts payable	606	573
Current maturities of long-term debt		0
Intercompany payable	581	46
Other accrued liabilities	343	718
Total current liabilities	1,530	1,337
Long-term debt, net	10	3
Intercompany notes payable		0
Deferred income taxes	127	59
Other liabilities	388	428
Total liabilities	2,055	1,827
Commitments and contingent liabilities
Equity
Total Chemours stockholders’ equity	2,647	2,310
Non-controlling interests		0
Total equity	2,647	2,310
Total liabilities and equity	4,702	4,137
Non-Guarantor Subsidiaries [Member] \| Reportable Legal Entities [Member]
Current assets:
Cash and cash equivalents	795	678	$ 271	$ 0
Accounts and notes receivable, net	611	508
Intercompany receivable	581	46
Inventories	631	476
Prepaid expenses and other	15	32
Total current assets	2,633	1,740
Property, plant, and equipment	2,062	1,861
Less: Accumulated depreciation	(1,065)	(928)
Property, plant, and equipment, net	997	933
Goodwill and other intangible assets, net	14	14
Investments in affiliates	173	136
Investment in subsidiaries		0
Intercompany notes receivable		0
Other assets	328	226
Total assets	4,145	3,049
Current liabilities:
Accounts payable	438	311
Current maturities of long-term debt		0
Intercompany payable	365	291
Other accrued liabilities	181	133
Total current liabilities	984	735
Long-term debt, net		0
Intercompany notes payable	1,150	1,150
Deferred income taxes	105	73
Other liabilities	87	96
Total liabilities	2,326	2,054
Commitments and contingent liabilities
Equity
Total Chemours stockholders’ equity	1,814	991
Non-controlling interests	5	4
Total equity	1,819	995
Total liabilities and equity	$ 4,145	$ 3,049

Guarantor Condensed Consolidating Financial Information (Condensed Consolidating Statements of Cash Flows) (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Cash flows from operating activities
Cash (used for) provided by operating activities	$ 639	$ 594	$ 182
Cash flows from investing activities
Purchases of property, plant, and equipment	(411)	(338)	(519)
Proceeds from sales of assets and businesses, net	39	708	12
Intercompany investing activities		0	0
Investments in affiliates		(1)	(32)
Foreign exchange contract settlements, net	2	(12)	42
Cash (used for) provided by investing activities	(370)	357	(497)
Cash flows from financing activities
Proceeds from issuance of debt, net	495		3,491
Intercompany short-term borrowings repayments, net		0	0
Debt repayments	(27)	(381)	(10)
Payment of deferred financing fees	(6)	(4)	(79)
Purchases of treasury stock at cost	(106)
Proceeds from exercised stock options, net	31	11
Tax payments related to withholdings on vested restricted stock units	(12)
Payment of dividends	(22)	(22)	(105)
Cash provided at Separation by DuPont			247
Net transfers to DuPont			(2,857)
Cash provided by (used for) financing activities	353	(396)	687
Effect of exchange rate changes on cash and cash equivalents	32	(19)	(6)
Increase in cash and cash equivalents	654	536	366
Cash and cash equivalents at January 1,	902	366	0
Cash and cash equivalents at December 31,	1,556	902	366
Eliminations and Adjustments [Member]
Cash flows from operating activities
Cash (used for) provided by operating activities		0	9
Cash flows from investing activities
Purchases of property, plant, and equipment		0	0
Proceeds from sales of assets and businesses, net		0	0
Intercompany investing activities	(220)	560	202
Investments in affiliates		0	0
Foreign exchange contract settlements, net		0	0
Cash (used for) provided by investing activities	(220)	560	202
Cash flows from financing activities
Proceeds from issuance of debt, net			0
Intercompany short-term borrowings repayments, net	220	(560)	(202)
Debt repayments		0	0
Payment of deferred financing fees		0	0
Proceeds from exercised stock options, net		0
Payment of dividends		0	0
Cash provided at Separation by DuPont			0
Net transfers to DuPont			(9)
Cash provided by (used for) financing activities	220	(560)	(211)
Effect of exchange rate changes on cash and cash equivalents		0	0
Increase in cash and cash equivalents		0	0
Cash and cash equivalents at January 1,	0	0	0
Cash and cash equivalents at December 31,		0	0
Parent Issuer [Member] \| Reportable Legal Entities [Member]
Cash flows from operating activities
Cash (used for) provided by operating activities	(133)	(176)	(119)
Cash flows from investing activities
Purchases of property, plant, and equipment		0	0
Proceeds from sales of assets and businesses, net		0	0
Intercompany investing activities		0	0
Investments in affiliates		0	0
Foreign exchange contract settlements, net		0	0
Cash (used for) provided by investing activities		0	0
Cash flows from financing activities
Proceeds from issuance of debt, net	495		3,489
Intercompany short-term borrowings repayments, net	(220)	560	202
Debt repayments	(27)	(369)	(8)
Payment of deferred financing fees	(6)	(4)	(79)
Purchases of treasury stock at cost	(106)
Proceeds from exercised stock options, net	31	11
Tax payments related to withholdings on vested restricted stock units	(12)
Payment of dividends	(22)	(22)	(105)
Cash provided at Separation by DuPont			0
Net transfers to DuPont			(3,380)
Cash provided by (used for) financing activities	133	176	119
Effect of exchange rate changes on cash and cash equivalents		0	0
Increase in cash and cash equivalents		0	0
Cash and cash equivalents at January 1,	0	0	0
Cash and cash equivalents at December 31,		0	0
Guarantor Subsidiaries [Member] \| Reportable Legal Entities [Member]
Cash flows from operating activities
Cash (used for) provided by operating activities	603	355	171
Cash flows from investing activities
Purchases of property, plant, and equipment	(327)	(233)	(292)
Proceeds from sales of assets and businesses, net	39	591	6
Intercompany investing activities	220	(560)	(202)
Investments in affiliates		0	0
Foreign exchange contract settlements, net	2	(12)	42
Cash (used for) provided by investing activities	(66)	(214)	(446)
Cash flows from financing activities
Proceeds from issuance of debt, net			2
Intercompany short-term borrowings repayments, net		0	0
Debt repayments		(12)	(2)
Payment of deferred financing fees		0	0
Proceeds from exercised stock options, net		0
Payment of dividends		0	0
Cash provided at Separation by DuPont			87
Net transfers to DuPont			283
Cash provided by (used for) financing activities		(12)	370
Effect of exchange rate changes on cash and cash equivalents		0	0
Increase in cash and cash equivalents	537	129	95
Cash and cash equivalents at January 1,	224	95	0
Cash and cash equivalents at December 31,	761	224	95
Non-Guarantor Subsidiaries [Member] \| Reportable Legal Entities [Member]
Cash flows from operating activities
Cash (used for) provided by operating activities	169	415	121
Cash flows from investing activities
Purchases of property, plant, and equipment	(84)	(105)	(227)
Proceeds from sales of assets and businesses, net		117	6
Intercompany investing activities		0	0
Investments in affiliates		(1)	(32)
Foreign exchange contract settlements, net		0	0
Cash (used for) provided by investing activities	(84)	11	(253)
Cash flows from financing activities
Proceeds from issuance of debt, net			0
Intercompany short-term borrowings repayments, net		0	0
Debt repayments		0	0
Payment of deferred financing fees		0	0
Proceeds from exercised stock options, net		0
Payment of dividends		0	0
Cash provided at Separation by DuPont			160
Net transfers to DuPont			249
Cash provided by (used for) financing activities		0	409
Effect of exchange rate changes on cash and cash equivalents	32	(19)	(6)
Increase in cash and cash equivalents	117	407	271
Cash and cash equivalents at January 1,	678	271	0
Cash and cash equivalents at December 31,	$ 795	$ 678	$ 271

Label	Element	Value
Goodwill	us-gaap_Goodwill	$ 153,000,000
Operating Segments [Member] \| Chemical Solutions [Member]
Goodwill	us-gaap_Goodwill	55,000,000
Operating Segments [Member] \| Titanium Technologies [Member]
Goodwill	us-gaap_Goodwill	13,000,000
Operating Segments [Member] \| Fluroproducts [Member]
Goodwill	us-gaap_Goodwill	$ 85,000,000